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Prostaglandin E2 is a physiologically active lipid mediator. However, an upregulation of PGE2 is 
often seen within the tumour microenvironment of multiple cancer types, helping drive multiple 
aspects of tumour development. PGE2 has a versatile role in aiding tumour development and 
progression, including evasion of the immune system. Cytotoxic T cells play a key role in 
eliminating cancer cells, preventing tumour growth and development, through the specific 
recognition of tumour specific antigens and subsequent cytolytic function. Studies have shown 1uM 
PGE2 to suppress both the proliferation and effector function of naive cytotoxic T cells, preventing 
their cytotoxic function, in turn enabling cancer development. We aimed to determine the full 
extent of PGE2 induced immunosuppression of cytotoxic T cells(CTLs) in addition to the potential 
causative mechanism. Live cell microscopy imaging determined whether PGE2 affected the stability 
and maintenance of the immunological synapse, as a recently identified potential common 
mechanism of immune suppression. Flow cytometry analysis was used to investigate the effect of 
PGE2 on both proliferation and cytolytic action of CTLs. In addition, imaging-based kill assays were 
used to further confirm the effect of 1uM PGE2 on CTL cytolysis against Renca mCherry cells. 
Results showed PGE2 to have no significant effect on the stability of the immunological synapse 
between CTL and Renca targets. In contrast 1uM PGE2 was shown to induce significant decreases 
in both the proliferation and cytotoxicity of CD8+ T cells, in a non-dose dependant manner. Partial 
restoration of suppression was noted following the treatment of EP2 blocker TG4-155. However, 
the suppressive effect was completely abrogated through the addition of supplementary IL-2 into T 
cell culture. Overall, PGE2 was concluded to have a significant immunosuppressive effect against 
CTLs and therefore could potentially contribute to tumour mediated immunosuppression.  
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1. Introduction 
1.1 Cancer  
1.1.1 Overview 
Cancer is a term used to describe a group of over 200 individual diseases, characterised by 
uncontrolled and genetically unstable proliferation of cells, which have the potential to invade 
tissues and spread throughout the body. 
         Every year an additional 360,000 people are diagnosed with cancer in the UK alone(Cancer 
Research UK, 2012). With an increasing incidence, due to a combination of the ageing population 
and environmental factors, cancer will affect 1 in 2 people globally, at some point throughout their 
life time. Insight of this, cancer research has grown dramatically over the past 4 decades, with 
survival rates doubling to 50%(Cancer Research UK, 2012). The increased survival rate is primarily 
due to a vast improvement in diagnostics, the identification of prognostic markers and overall 
treatment methods. However as of 2016, cancer reached an annual death rate of 164,782 in the UK 
alone(Macmillan Caner). Cancer still proves to be one of the biggest killers in the world, accounting 
for 28% of deaths annually in the UK(Cancer Research UK, 2012). 
       Mitosis of eukaryotic cells is a vital process and is therefore controlled by many meticulous 
checkpoints to ensure that the DNA is replicated accurately to sustain equal genetic DNA in both 
daughter cells. However, a gradual accumulation of specific mutations can lead to the loss of one or 
more of these checkpoints and DNA damage repair mechanisms, otherwise known as tumour 
suppressor gene. Mutations also lead to the activation of sustained proliferation mechanisms, known 
as proto oncogenes(1) 
         Due to the novel genetic instability of the cancer cell genome, further mutations accumulate 
giving these transformed cells a survival or growth advantage. These additional mutations can give 
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rise to invasion and spread of cells throughout the body, in a process named metastasis. These cells 
would be classified as cancerous and possess a group of phenotypic properties or “hallmarks” that 
enable their development and progression, as seen in Figure 1(2). 
1.1.2 Hallmarks of cancer 
Malignancies develop due to the progressive evolution of multiple mutations leading to an unstable 
genome and the acquisition of a group of specific capabilities that enable the tumour pathogenesis. 
These attributes include:  
• Resistance to cell death: Cancer cell development must overcome many of the cellular 
mechanisms leading to apoptosis. In contrast to necrosis, apoptosis is an organised, ubiquitous 
Figure 1 : Hallmarks of cancer  
The select group of phenotypic attributes that allow the formation of a tumour. Each 
hallmark holds a vital role in tumour formation, therefore producing a potential set of 
therapeutic targets to overcome. Adapted from “The Hallmarks of Cancer: the next generation” - 
Hanahan D, Weinberg RA. 
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cellular suicide mechanism. Apoptosis can be induced in response to both the internal and 
external stimuli via intrinsic or extrinsic pathways, respectively(3). Environmental stresses such as 
DNA damage, hypoxia and signalling imbalances typically lead to induction of apoptosis to 
prevent loss of genetic integrity. However, cancer cells are under constant oncogenic stress, due to 
cell cycle arrest mechanisms attempting to contradict activated oncogene action, and therefore 
must develop mechanisms to prevent apoptosis, in particular the intrinsic pathway(4). Apoptosis is 
ultimately a multi-caspase driven mechanism, intrinsically mediated through the imbalance of 
apoptotic signalling molecules. Increased levels of pro-apoptotic protein signalling molecules, e.g. 
Bak and Bax, targeting the mitochondrial membrane induces apoptosis. Once bound to the 
membrane Bax molecules cluster inducing a pore that enables the release of cytochrome into the 
cytoplasm(5). In contrast, cancer cells common up regulate anti-apoptotic signalling molecules, 
such as BCL-2, to tip the balance in favour preventing apoptosis via competitive inhibition(6). 
 
• Induction of angiogenesis: Solid tumour formation leads to the production of an 3D mass of 
cells. Local circulation is sufficient to provide nutrients to a tumour up to 2mm in diameter 
however anything larger results in an outer shell of cells encasing a hypoxic core as the vital 
factors, such as oxygen, cannot reach the inner cells through simple diffusion(7). One mechanism 
a tumour overcomes the lack of sufficient oxygen is the development of novel blood vessels, 
through a process referred to as angiogenesis(8). Angiogenesis can lead to altered genetic profiles 
of the inner malignant cells. The up regulation of Hypoxia induced factor-1(HIF-1) expression is 
seen within cells facing hypoxic conditions(9). Increased levels of this gene promoter can lead to 
increased expression of Vascular endothelial growth factor(VEGF), resulting in angiogenesis 
throughout the tumour, enabling further growth(10). 
 
• Replication immortality: Cells within the body undergo varied levels of mitosis depending on 
their origin, cell type and purpose. However most eukaryotic cells have a limited number of 
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mitotic divisions, the exception being stem cells. Mitotic divisions are tightly controlled through 
multiple mechanisms including the DNA damage response and shortening of telomeres(11). 
Mutations in cellular mitotic checkpoint controls allows for the unlimited capability of cellular 
proliferation, in turn leading to tumour formation. Most eukaryotic cells reach a stage of senesce 
following a limited number of divisions. This is achieved through multiple intrinsic triggers. One 
mechanism used is the shortening of telomeres. Telomeres are repeated base pair sequences found 
at the end of chromosomes to protect the DNA. Each cellular division further shortens the cell’s 
telomeres as the initiating replication primer does not recognise the end of the telomere(12). Once 
the telomere reaches a critical length the DNA damage response recognises the telomere as 
exposed DNA damage triggering senescence. Many cancers overcome this through the 
modification and up regulation of telomerase enzymes that allow extension of the preexisting 
telomeres, preventing senescence(13). More commonly, mutations occur in the genes controlling 
the DNA damage response. P53, a key tumour suppressor gene, is named the guardian of the 
genome and is the most commonly suppressed protein due to mutation seen in cancer(14). P53 is 
activated in response to DNA damage, halting the cell cycle until the damage is resolved otherwise 
inducing apoptosis. The role of P53 in halting the cell cycle is completed to ensure correct and 
accurate DNA replication is completed, maintaining genetic integrity. “Loss of function” base pair 
mutations that lead to the partial or complete loss of protein function, are commonly seen in 
TP53, leading to the continuation of cellular proliferation despite DNA damage, allowing multiple 
mutations to occur due to the natural DNA polymerase error rate, as well as bypassing the 
apoptotic effect of critical length telomeres; driving further carcinogenesis(15). 
 
• Evasion of growth signals: Growth signals such as cytokines, chemokines and prostaglandins 
underpin the molecular signalling mechanisms of the cells within the body. They enable detection 
and transduction of external conditions within the cellular microenvironment, informing cells 
when to alter their metabolic rate, undergo mitosis and when to remain quiescent. Cancer cells 
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gain the ability to evade the necessity of these mediators allowing their growth and proliferation in 
all environments(16). One mechanism by which cancer cells achieve this is through genetic 
mutations causing the increased expression of growth factor receptors, such as the tyrosine kinase 
EGFR(17). By increasing the expression of growth factor receptors, the cells can activate pro-
replicative signalling cascades in even the lowest concentrations of growth factors(18). In addition, 
many neoplastic cells down regulate receptors of suppressive markers, inhibiting suppression of 
their cell growth(19).  
 
• Invasion and metastasis: A defining characteristic of cancer is its ability to spread throughout 
the body via two primary mechanisms: invasion and metastasis. Invasion defines the ability of the 
proliferating malignant cells to penetrate into neighbouring tissues(20). For invasion to occur the 
cancer cells must first overcome tight cell to cell interactions, predominantly ‘Tight Junctions’. 
Located on the apical membrane, tight junctions enforce adjacent cellular contacts that occlude 
the intercellular space, in turn, creating a barrier and preventing cell migration. This is completed 
through multiple protein interactions such as occludins. Studies have revealed that there is a 
significant down regulation of these proteins in cancer. One supporting study of 124 cancerous 
and 33 normal breast tissues found a significant down regulation of occludin proteins in metastatic 
disease(21). Once overcoming cellular adhesions, the transformed cells are seen to secrete 
paracrine enzymes that degrade basement membrane and extracellular matrix, enabling local 
spread of the tumour encompassing adjacent tissues and organs, named invasion. Metastasis is the 
ability of a cancer cell following invasion to enter circulation and migrate to a distant site initiating 
a secondary or even tertiary tumours(22). It occurs through a series of events, called the metastatic 
cascade. 
 
More recently it has been suggested that 4 additional ‘hallmarks’ substantially contribute towards 
development and pathogenesis of cancer. The 4 novel hallmarks consist of: Genome instability and 
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mutation, Deregulation of cellular metabolism, Tumour promoting inflammation and almost 
paradoxically evasion of the immune system(23). Evasion of the immune system, especially the 
directly cytotoxic cells such as NK cells and CD8+ T Cells, is essential in both primary tumour 
formation and metastasis(24). Cancer cells are typically highly immunogenic due to the multitude of 
mutations causing the expression and presentation of altered or even completely new proteins. The 
expression of adapted proteins allows for cancer cell recognition and elimination by the immune 
system, in a process called immunosurveillance(25). However, the immune elimination of cancer 
cells also acts as a selection pressure, driving further evolution of the transformed cells creating 
mechanisms that bypass recognition and elimination by the immune system. Immuno-edited 
malignant cells are then able to proliferate forming a tumour and ultimately cancer. 
 
1.2 The Immune system  
1.2.1 Introduction  
The immune system is a complex system comprised of multiple cell types, cooperatively functioning 
to protect the body against harmful pathogens as well as malignant cells(26). The advanced diversity 
of the immune system is enabled through multiple developmental rearrangement mechanisms that 
produce a wide variety of protein receptors combinations, capable of recognising and activating 
cytotoxic functions against foreign peptide fragments named antigens. In addition, the immune 
system can mount a memory response to previously detected antigens. Immune memory enforces a 
heightened, quicker and therefore more efficient response against re-occurring infections, known as 
immunity(27). The system includes multiple aspects including both a nonspecific and specific 
response, named Innate and Adaptive respectively. 
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1.2.2 Innate 
The innate immune response is the body’s nonspecific defence against antigens. This branch of 
immunity is not specific to any particular antigen but instead is an initial defense upon exposure to 
pathogens, allowing for a quick and broad prevention of infection. The innate system is comprised 
firstly of physical barriers, such as the skin, and chemical mediators, such as mucus and acid(28). 
The innate immune system is also composed of a cellular component, namely leukocytes. 
Leukocytes, also known as white blood cells, includes both phagocytic antigen-presenting cells e.g. 
Dendritic cells and macrophages, as well as cytotoxic cells e.g. NK cells. Recognition of foreign 
antigens, such as LPS, along with activating double molecules enforces a strong innate response 
against immunogenic pathogens. 
 
1.2.3 Adaptive  
The adaptive immune response is a specific, targeted response produced post-exposure to antigen. 
Consisting of two main branches, cellular and humoral, the adaptive immune system plays a role in 
detecting and eliminating, whilst remembering, pathogens that have breached outer epithelium. 
The adaptive immune system can be activated in multiple ways including antigen presentation by 
innate professional antigen presenting cells(APCs). APCs endocytose pathogens into their cytoplasm 
before degrading them into short peptides using the proteasome. Once degraded, 8-16 amino acid 
long peptides are then transported into the lumen of the endoplasmic reticulum via the TAP protein 
complex(29). Peptides that successfully bind to MHC1 or MHC2 complexes then leave the ER and 
are presented on the cell surface for interaction with naive lymphocytes in the local draining lymph 
node. 
        There are two classes of lymphocytes: B cells and T cells. B cells are both produced and 
developed within the bone marrow before migrating to the lymphatic system, either the spleen or 
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lymph nodes, where they reside until they are activated. Upon activation B cells can undergo two 
primary immune response. B cells can detect foreign antigens via specific membrane bound 
immunoglobulins, deemed B cell receptors. When exposed to an antigen a select group of B cells 
migrate out of the lymph nodes, into the circulation where they differentiate into short lived 
plasmablasts, enabling them to secrete antibodies to aid immune recognition, neutralisation of 
toxins and cytotoxicity towards pathogens(30). Alternatively, B cells reside in the lymph nodes 
forming germinal centres, where they are able to undergo both class switch recombination and 
somatic hypermutation to drive the immense diversity of antibody recognition. 
         T cells are produced in the bone marrow but develop in the thymus before entering 
circulation. During development all T Cells produce a unique T cell receptor(TCR) consisting of 2 
polypeptide chains, most commonly an alpha and beta chain(31). T Cells use their TCR to detect 
specific antigens presented by either a Class 1 or Class 2 Major Histocompatility Complex(MHC1) 
from the target cells. There are a variety of T cells, each playing a vital role in protecting the body. 
The three main classes being:  T helper cells, T regulatory cells and Cytotoxic T cells. T helper 
cells, also known as CD4+ T Cells, express the CD4 co-receptor to aid target cell interaction. 
CD4+ T cells are primarily involved in influencing the action of other immune cells, in either a 
positive or suppressive manner, through the release of cytokines(32). On the other hand, T 
regulatory cells predominant role is to down regulate immune responses, such as CD8+ T cells, and 
maintaining immune tolerance(33). Lastly CD8+ T cells are essential in the prevention of 
intracellular infection and tumour formation. 
 
1.3 Cancer Immunosurveillance 
1.3.1 Cancer Immunosurveillance 
The first description of the anti-tumour effects of the immune system was provided by William 
Coley in 1891, when he demonstrated that injecting attenuated pathogenic bacteria, Streptococcus 
UNIVERSITY OF BRISTOL  19 
pyogenes and Serratia marcescens, into a tumour lead to regression(34). This was thought to be due to a 
bystander effect of stimulation of the immune system. However due to the high risk associated with 
using pathogenic microorganisms as a treatment, the development of surgery as well as chemo and 
radiotherapy surpassed this hypothesis leaving little progression of the treatment, until the mid-20th 
century.  Thomas and Burnet first described the immuno-surveillance theory in 1957(35). Due to 
the multifaceted process of cancer development, the immune system holds many essential roles in 
the prevention of tumour formation.  
        One way in which the immune system prevents cancer development is the quick and efficient 
elimination of pathogens, preventing of inflammation and damage of host cells. Inflammation is a 
key process in the body’s recovery process following injury and infection however it has also been 
demonstrated to significantly contribute to tumour development. Chronic inflammation has been 
shown to increase the risk of tumour development(36). Inflammation can help drive carcinogenesis 
by inducing breaks in the DNA of transformed cells leading to an increased mutation rate(37). 
Additionally, it has been suggested that inflammation can aid tumour metastasis by degrading 
basement membranes and extracellular matrixes, allowing for intra/extravasion of metastatic 
cells(38). Therefore, the efficient regulation of inflammation following infection is essential in cancer 
prevention.  
         An additional process the immune system completes that prevents cancer development is the 
detection and elimination of viral infections. Viruses can contribute to the development of cancer in 
two main ways. The primary way in which viruses can induce and progress cancer development 
occurs through the mechanism of infection and inflammation previously described, such and HEP-
B(39). In addition to this, many viruses have been identified to directly cause cancer development 
such as HPV and EBV(40). This occurs through the insertion of oncogene encoding viral DNA into 
the host cells, resembling many of the naturally mutated oncoproteins seen in non-viral cancer(41). 
In both cases it is vital that the immune system can detect and eliminate all viruses that infect host 
cells in order to prevent the development of tumours.  
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         Lastly is the detection of naturally transformed cells. Mutations do occur within the cells of our 
body following proliferation, due to naturally occurring errors in replication polymerases(42). It is 
speculated that on average eukaryotic DNA polymerases create an error in 1 in every 105 bases, 
however the majority of these are corrected through the DNA damage response, ultimately leading 
to a spontaneous mutation rate of approximately 1010 per base pairs per replication cycle(43). Most 
mutations are missense and shall have little to no effect on our genome. However, transforming 
mutations can occur, leading to transformed and potentially cancerous cells. It is important that the 
immune system can detect any transformed cells in order to eliminate them before they have the 
opportunity to proliferate forming a tumour. This process is called cancer immunosurveillance and 
involves both the innate and adaptive branches of the immune response(44). There are 3 primary 
phases of immunosurveillance, as seen in figure 2. 
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Figure 2: The three E’s of immunoediting  
The three alternative relationships noted between cancer cells and the immune system. Primarily the 
immune system is able to detect and eliminate naturally transformed cells preventing tumour 
development. Cancer cells develop mechanisms to evade immune detection, however the main bulk of 
the tumour is still eliminated, leaving individual transformed cells, resulting in an equilibrium phase. An 
accumulation of additional mutations enables cancer cells to develop suppressive mechanisms, in turn, 
further evading the immune system until complete escape is complete and a tumour forms. Adapted from 
Strausberg, Genome Biol. (2005). 
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1.3.2 Elimination 
In the primary phase of immunosurveillance, transformed cells have not yet acquired sufficient 
mutations to outgrow the rate of elimination by the immune system. Many of the mutations that 
arise during or as part of the process of carcinogenesis also lead to the production of altered/novel 
proteins making the cells highly immunological. Alternatively, some cancer cells down regulate  
specific MHC complexes, making them susceptible to NK cell cytolysis(45).  Cytosolic novel and 
altered proteins are degraded by the proteasome into short peptides approximately 8-16 amino 
acids long. These peptides are transported into the Endoplasmic Reticulum(ER) via the TAP 
protein(46). Once in the ER the degraded peptides associate with an MHC1 complex. Is 
successfully associated the MHC1 and antigen complex are expressed on the cells surface. These 
peptides can be directly recognised by cytotoxic T cells in situ or indirectly recognised when 
presented by APCs, such as mDC cells, in the tumour draining lymph node, through cross 
presentation(47). Recognition by CTLs leads to elimination of the transformed cells. 
 
1.3.3 Equilibrium  
Equilibrium is an intermediate phase, which is accomplished when the genetic instability of the 
transformed tumour cells has lead to the development mechanisms enabling increased replication 
rates and/or a loss of immunogenicity, by down regulation of cell surface markers, preventing 
complete detection and elimination by the immune system(48). However, the cells have not 
developed enough evasive mechanisms to completely escape the immune system leading to a system 
in which the tumour cannot increase in size as it is being killed at the same rate it is proliferating, 
leaving a relatively low number of surviving transformed cells. This process shall continue to occur 
in a dynamic equilibrium, with the immune system acting as a selection pressure, until the 
transformed cells acquire additional mutations to further prevent elimination by the immune 
system, which in turn will lead to the “Escape” phase of immunoediting/evolution.  
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1.3.4 Escape 
Despite immunosurveillance mechanisms tumours are still able to develop due to an accumulation 
of further mutations reducing the immunogenicity of the cancerous cells and causing tumour 
mediated immune suppression. Cancer immune evasion is contributed to through many 
mechanisms such as decreasing their immunogenicity, antigenic modulation and tumour-induced 
immune suppression. For a cytotoxic T cell to kill a target cell it must first be able to recognise the 
class 1 major histocompatibility complex-bound antigen being presented, become stimulated 
through co-stimulation, and form a stable immune synapse through co-signalling molecules. 
Tumour cells exploit this mechanism by altering their cell surface expression to deter recognition 
and therefore elimination via immune cells(49). This has been shown to be done using three main 
strategies.  
         One mechanism cancer cells use to evade the immune system is the down regulation of MHC 
complexes. MHC1 expression is essential for the recognition of antigens and therefore cytolytic 
function of CD8 T cells. By down regulating the expression of MHC1, tumour cells evade 
recognition by the adaptive immune system preventing their death(50). However, NK cells exhibit a 
unique ability to be able to detect cells that express low or even undetectable levels of MHC1 
complexes(51). The mechanism behind NK recognition is still not fully understood however it is 
believed that NK cells express an inhibitory receptor that recognises MHC1 alleles, enabling their 
cytotoxic ability only when faced with a cell expressing low levels of MHC1.  
         Another mechanism of immune evasion by cancer cells is the loss of expression of co-signalling 
molecules, primarily CD80 and CD86 (52). Both these molecules are typically required for both the 
initial priming and activation of cytotoxic T cells. By losing CD80/CD86 expression the tumour is 
not only able to inhibit activation and therefore cytolytic action, but also induce anergy in CD8+ T 
cells. However, T cells can utilise adhesion molecules, specifically ICAM-1 and LFA-3, as a co-
stimulatory signal to undergo priming and activation.  CTLs express LFA-1, a cell adhesion 
molecule historically known to induce emigration of lymphocytes across blood vessel walls and into 
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tissues. More recently LFA-1 has also been associated with the activation and priming of CD8 T 
cells when bound to ICAM-1.  However, the loss of adhesion molecules, such as ICAM-1, in cancer 
cells has been noted decreasing migration of CTLs into the tumour as well as preventing activation. 
         An additional mechanism used my tumour cells to evade CTL or NK cell lysis is through 
endocytosis of molecules that many increase the cell surface immunogenicity(53). This is especially 
important in preventing antibody-dependant cellular cytotoxicity and complement. Both immunity 
mechanisms utilise the humoral aspects of the immune system to highlight target cells, making them 
more easily recognisable by cytotoxic cells of the immune system. To deter this, the tumour cells 
have been shown to endocytose and degrade the attached antibodies inhibiting them from activity 
cytotoxic cells. 
         Lastly, is the tumour ability to directly inhibit cytotoxic immune cells either by the up 
regulation of inhibitory cell surface proteins, such as PD-L1, or secretion of immune-suppressive 
factors, such as adenosine and PGE2, later described. 
 
1.4 CD8+ T cells 
1.4.1 CD8+ T cells 
Cytotoxic T Cells(CTL) express distinct T cell receptors that recognise a specific antigenic peptide 
bound to MHC1.  Additionally, CTLs express a dimeric CD8 co-receptor comprised of CD8α and 
CD8β polypeptide chain(54). MHC class 1 molecules are expressed on the surface of all nucleated 
cells of the body as well as platelets(55). They are used to present fragments of degraded 
intracellular peptides. This enables the immune system to detect any compromises in the internal 
cellular environment, such as viral infection or malignancy. CD8+ T cells have the intrinsic ability 
to directly induce cell death through multiple mechanisms upon recognition of a MHC1 bound 
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antigen and co-stimulation, making them essential in the prevention of cellular infection and 
tumour formation.  
 
1.4.2 T cell development 
T cell progenitors differentiate from haematopoetic stem cells, in the bone marrow before they 
localise, via the blood, to the cortex of the thymus. Once in the thymus they are classified as 
thymocytes. Thymocytes undergo a series of maturation steps to ensure the production of effective 




Figure 3: T cell development 
 The first step occurs in the cortex. At this stage the T cells lack both CD4 and CD8 co-stimulatory 
receptors and are therefore classified as “Double Negative”(56).  
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1.4.3 CD8+ T cell activation 
Stimulation of both the TCR and co-receptors results in a signalling cascade ultimately determining 
the fate of the T Cell, such as proliferation, survival, apoptosis or cytokine production. For 
         At this stage double-negative cells give rise to both γδ and αβ T cells(57). DN T cells must first 
generate a functioning TCR beta chain, through a process called VDJ recombination. VDJ recombination 
is the somatic genetic rearrangement within three distinct gene loci: the variable region, the diversity 
region, and the joining region(58). Rearrangement of these loci create the extensive diversity of TCR beta 
chains contributing to the specific recognition of an immense number of peptides. VDJ rearrangement is 
controlled by two Recombination Activating Gene enzymes, deemed RAG1 and RAG2(59). 
         Following VDJ rearrangement the resulting unique TCR beta chain is coupled with a surrogate TCR 
alpha chain forming the pre-TCR(60). Once formed the pre-TCR associates with a complex of peptides, 
named CD3. CD3 is a co-receptor made-up of four unique polypeptide chain, combined in 3 different 
ways, and is essential for proximal signal transduction(61). Formation of the TCR-CD3 complex allows for 
TCR signalling. If successful TCR signalling is transduced the T Cell is able to undergo proliferation, 
survival and further maturation. At this stage T cells with a non functioning TCR beta chain shall undergo 
apoptosis, ensuring only functioning TCR cells survive. The surviving cells undergo rearrangement of the 
TCR alpha chain via the same RAG driven VDJ mechanism, further increasing the diversity of specific 
TCRs. 
         Once a fully mature TCR has been established, additional genetic differentiation leads to the up 
regulation of both CD4 and CD8 co-receptors. The T Cells would now be considered “Double Positive”. 
Surviving T cells with a fully functioning αβ-TCR undergo positive selection. Positive selection entails the 
exposure of the T cell to a MHC1 bound self antigen to ensure a fully functioning αβ TCR has been 
produced. Cortical epithelial cells present a small array of self peptides bound to both MHC1 and MHC2 
complexes. For successful progression via survival signalling, TCRs must be able to adequately recognise 
these complexes. Studies have calculated that at this stage approximately 90% of DP T cells undergo death 
by neglect due to unsustained interaction with the peptide MHC complex(62).  
         Following successful recognition, lineage specific differentiation occurs causing the down regulation 
of either CD4+ or CD8+, generating a “Single Positive” T cell. T cells that solely express CD8+ co-
receptor are deemed Cytotoxic T Cells(CTLs). Single positive T cells migrate from the cortex to the 
thymus medulla to undergo negative selection. This process is named central tolerance and is necessary to 
eliminate any TCRs with a high affinity to self-peptides, in order to prevent autoimmune disease. 
Medullary thymic epithelial cells present a multitude of self-peptides, produced by the enzyme AIRE, on 
both MHC1 and MHC2 complexes(63). Any CTLs with a strong affinity to the self-peptide complexes are 
eliminated via apoptosis. T cells that are capable of recognising the self peptide with a lower affinity 
progress, exiting the thymus and entering circulation. Figure adapted from Germain, Ronald N. “T-cell 
development and the CD4–CD8 lineage decision.” Nature Reviews Immunology 2 (2002): 309-322. 
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activation to be successfully completed CTLs must receive both primary and co-stimulation(64). 
First, is the recognition of an MHC1 presented antigen by the generated specific TCR. If successful, 
TCRs within the cell surface membrane undergo clustering, leading to the formation of a complex 
structure containing TCRs, co-signalling molecules, and adhesion molecules. This structure is 
named the supramolecular adhesion complex(SMAC)(65).  
        
Figure 4 : T cell signalling 
The process of redistribution is controlled by modifications in the actin cytoskeleton, and 
creates the foundation for an intracellular signalling cascade that ultimately determines the 
fate of the T cell(66). Clustering of CD8 and CD28 co-signalling molecules to the TCR 
recruits the membrane bound tyrosine kinase Lck, away from the protein tyrosine 
phosphatase - CD45(67-68). High concentrations of CD45 dephosphorylates the stimulatory 
phosphorylation on Tyrosine 394, leaving phosphorylated Tyr505 and therefore a 
constitutively inhibited Lck. In contrast low levels of CD45 are capable of dephosphorylation 
of Y505 leading to the activation of Lck. Clustering enables the migration and 
compartmentalization of Lck from CD45, reducing its levels in turn enabling activation of Lck 
by transphosphorylation.(69) 
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           Recruitment of Lck to the SMAC, leads to the phosphorylation of the intracellular domain 
immuno-receptor tyrosine-based activation motifs(ITAMs) on CD3-ε chains. This phosphorylation 
attracts the recruitment of Zeta-chain associated protein kinase(ZAP-70) to both the CD3-ε and 
TCR-ζ, via Src homologous interaction(70). ZAP-70 is a 70kDa Syk family protein tyrosine kinase. 
ZAP-70 is able to activate the scaffold linker protein LAT, through phosphorylation of its multiple 
tyrosine residues. Activated LAT recruits and binds Slp76 via an adaptor protein, called Gads. 
Slp76, also known as lymphocyte cytosolic protein 2, is a vital signal transducing adaptor protein. 
This recruitment process is essential as it brings the Slp76 protein into close enough proximity to 
ZAP70 to be phosphorylated activating the LAT-Slp76 complex(71). This activated complex is 
responsible for recruiting and activating a variety of further signalling cascades, transducing the 
TCR activation signal throughout the T Cell.  
        Phospholipase C-γ is one of the most prominent signalling molecules to be activate. PLC-γ 
interacts with both LAT and Slp76 in the complex and progresses the signal through the hydrolysis 
of phosphatidylinositol bisphosphate(PIP2)(72). PIP2 is hydrolysed to produce diacylglycerol(DAG) 
and inositol triphosphate(IP3)(73). Both DAG and IP3 have an important role in downstream 
signalling.  
         DAG recruits and activates multiple proteins, the most important of which are Protein 
Kinase C-θ(PKC-θ) and Ras activating guanine nucleotide exchange factor(RasGRP)(74). 
RasGRP activates the Ras protein, therefore initiating the MAPK/ERK pathway. This pathway 
exerts many positive effects on the cell such as: stimulating proliferation through the activation of 
c-MYC and ELK-1; encouraging cell survival through the activation of RSK, which activates 
CREB whilst inhibiting BAD decreasing apoptosis; and inhibiting BIM further suppressing 
apoptosis(75). The signalling additionally promotes the transcription of NF-kB transcription factor. 
NF-kB controls multiple cellular processes overall inducing a cellular survival and proliferative 
response(76). 
          Alternatively, Ca2+ signalling is induced by IP3. IP3 causes the release of Ca2+ ions from 
the endoplasmic reticulum into the cytoplasm which stimulates the opening of calcium release-
activated cell Ca2+ channels within the cell surface membrane causing an influx of Ca2+ into the 
cell(77). The high concentration of Ca2+binds to calmodulin activating calcineurin(78). 
Calcineurin is a serine/threonine phosphatase that promotes the transcription of the IL-2 gene via 
nuclear factor of activated T cells(NFAT).  The up-regulation of IL-2 is able to further induce T 
cell growth and differentiation causing an expansion of the antigen specific cytotoxic T Cells 
enhancing the immune response. 
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1.4.4 Tumour specific T Cell Priming 
Developing tumours are often highly immunogenic due to the creation of novel and altered 
proteins. These proteins have the capacity to induce a specific immune response against the tumour. 
Experimental evidence, using EL4 cell line transduced with an NP366 epitope as a novel antigen, 
demonstrated that following inoculation there was a significantly high prevalence of NP366 specific 
CD8+ T cells detectable in both the peripheral blood and tumour draining lymph nodes within 6 
days, followed by the spleen in 9(79). Further patient studies have shown that it some cases of 
metastatic melanoma up to 10% of peripheral circulating CD8+ T cells are specific for a single 
tumour associated antigen(80).  
         The development of such a specific CD8+ immune response has been believed to occur due to 
antigen presentation within the lymph node by professional antigen resenting cells such as DCs. 
However, it is noted that often a strong tumour specific T cell response is only seen in the presence 
of metastatic infiltrates that have migrating into the lymph node, suggesting a role for the cancerous 
cells, themselves, in induction of a specific immune response(81). The observation of metastatic 
induction of CTL responses lead to the proposal of two alternative mechanisms of induction.  
         The classical pathway of tumour specific CD8+ T Cell induction involves professional antigen 
presenting cells, which an endocytose the whole cancer cell or tumour associated proteins. The 
cellular proteins are then degraded in the endosome before being bound to an MHC molecule and 
transported to the cell surface membrane, by a protein named TAP(82). The APCs then home to a 
secondary lymphoid organ, such as the lymph nodes, where they present the degraded peptide to 
naive T cells inducing activation and proliferation of a tumour antigen specific T cell response. This 
mechanism is referred to as cross-presentation, due to the requisition of an intermediate cell. 
However, experimental models have concluded that this is not the sole mechanism. 
         Genetically modified TAP deficient mouse models produce an experimental model that is 
unable to facilitate cross priming as the APCs are not capable of transporting the endocytosed 
peptide from the cytosol to the endoplasmic reticulum, inhibiting binding with the MHC complex 
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and therefore cell surface presentation. Naive NP366 specific monoclonal T cells were adoptively 
transferred into circulation before NP366-EL4 tumour inoculation. 2 days following inoculation the 
tumour draining lymph nodes clearly showed a high presence of tumour associated antigen specific 
CD8+T cells, confirming an alternative and direct pathway of immune induction by cancer cells in 
absence of efficient APCs.(79) It is therefore most likely that metastatic cells are able to migrate to 
the lymph nodes, directly priming and inducing tumour specific CD8+ immune responses.  
 
1.4.5 Alternative Co-stimulation 
The classical two signal model of naive CD8+ T cell activation involves cognate interaction of the 
TCR with MHC1 bound foreign antigen, proceeded by a secondary signal via a co-signalling 
receptor. TCR signalling alone leads to T cell anergy as well as sustained levels of p27, a cell cycle 
blocker(83). Priming of CTLs by professional antigen presenting cells is the primary mechanism of 
T cell stimulation. APCs express multiple cell surface molecules capable of providing the 
secondary(co-stimulation) signal for efficient T cell activation, the most studied of which are CD80 
and CD86. CD80/CD86  both interact with CD28 on the T cell surface, causing its co-localisation 
to the TCR(84). This clustering stimulates the formation of the cSMAC and pSMAC, creating a 
sustained immunological synapse and therefore initiating downstream T cell signalling(85). Many 
malignancies down regulate the expression of CD80/CD86 as an immunological evasion 
mechanism, resulting in what would deem a cold tumour. 
         However, many tumours can still provide two distinct T cell activation signals, in the absence 
of CD28(86). In the absence of CD28 the second stimulatory signal is achieved through the 
utilisation of alternative co-signalling molecules. Studies have described an array of alternative co-
signalling molecules, as seen in figure 4, capable of both initiating(co-stimulating) and 
suppressing(co-inhibiting) complete T cell signalling(87). It is these co-signalling receptors that 
determine the ultimate differentiation fate, proliferation and survival of the T Cell. ICAM-1 is a co-
signalling receptor of the immunoglobulin superfamily. Primarily identified for its role in leukocyte 
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arrest and extravasion, ICAM-1 binds to LFA-1 on leukocytes, halting them from their capillary 
rolling mechanism and enables extravasion from the blood into the surrounding tissues. Recent 
studies have further explored the multifaceted role of ICAM-1 and have determined a mechanism 
by which ICAM-1 can provide the secondary co-stimulation signal, through binding of LFA-1, in 
turn initiating T cell signalling(88). Binding of ICAM-1 to LFA-1 on T cell surface causes activation 
of PI3K, enabling T Cell proliferation, increased IL-2 secretion and rates of proliferation following 
co-stimulation are comparable with that following classical CD28 co-signaling(89). Paradoxically, 
the number of cells that undergo three or more divisions is seen to decrease 3-fold. In addition, 
LFA-1 co-stimulation has been shown to cause a significant decrease in p27, but that the remaining 
level was consistently slightly higher than with CD28 co-signaling(90). This suggests that LFA-1 
signalling can induce a significant T cell response however that the response may not be as efficient 
or sustained as that of classical CD28 signalling. In contrast, an alternative study discovered an 
increased percentage of cells undergoing proliferation post ICAM-1 co-stimulation(75%) compared 
to CD28 co-stimulation(55%) whiten 72hrs(91). Therefore, implying that the paths of co-stimulation 
may not cause a significant difference in cellular proliferation.  
         Experiments using the renal carcinoma cell line(Renca), have demonstrated that signalling via 
ICAM-1 LFA-1 interactions are able to of induce a tumour specific immune response. In vitro 
malignant renal carcinoma(Renca) cells, expressing the influenza virus(A/PR8/H1N1) 
haemagglutinin antigen(HA) as a neo-tumour specific antigen, demonstrated the ability to induce 
significant CD8+ T cell proliferation upon co culture with naive HA specific monoclonal T 
Cells(CL4)(92). Renca cells lack expression of the classical co-stimulatory molecules CD80/CD86, 
however do express ICAM-1. This in vitro study confirmed a possible mechanism for direct tumour 
cell T cell activation utilising alternative co-stimulatory mechanisms.  
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Figure 5: Cytotoxic T Cell Co-signalling molecules  
The balance of co-signalling molecules ultimately decide the fate of interacting CTLs. The classical two 
signal model of naive CD8+ T cell activation involves cognate interaction of the TCR with MHC1 
bound foreign antigen, proceeded by a secondary signal via a co-signalling receptor. Co-stimulatory 
CD86 and CD80 bind either CD28 inducing CTL co-stimulation or its competitive co-inhibitory 
receptor CTLA-4. More recently, co-stimulation via LFA-1:ICAM-1 interaction has been demonstrated 
to effectively stimulate T cell signalling. PD-L1 binds to the co-inhibitory receptor PD-1, suppressing T 
cell function. 
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1.4.6 CD8+ T cell cytotoxic function 
CD8+ T cells are key mediators in the adaptive immune system, with a primary role of eliminating 
compromised cells infected with intracellular pathogens such as bacteria and viruses. Additionally, 
they hold a vital role in eliminating transformed cells, therefore preventing the development of 
cancer. Cytotoxic CD8+ T cells have three main cytolytic mechanisms, all of which utilise the 
activation of apoptosis. These include: the release of cytokines, FAS induced apoptosis, and the 
release of cytolytic granules.  
          
 
  
Figure 6 : Mechanisms of  CD8+ T cell cytolysis 
The primary mechanisms of direct CD8+ cytotoxicity is by the polarisation and release of cytolytic granules 
containing perforin and granule-associated proteases collectively named granzymes. Perforin and granzymes are 
essential for efficient elimination of infected cells and are therefore stored into modified lysosomes forming lytic 
granules(93). This method of storage ensure they are inactive when inside the T cell preventing damage. Upon 
recognition of a MHC1 bound antigenic peptide, via the T Cell receptor, rearrangement of internal actin 
cytoskeleton occurs. Cytoskeletal rearrangements cause a migration of the microtubule organising 
center(MTOC) towards the forming immunological synapse(94). Binding between CD28 and CD86/CD80 
and/or LFA with ICAM-1 stabilise the immunological synapse to enable sufficient time for cytolytic activity.  
Succeeding the MTOC, the lytic granules subsequently polarise towards the cell surface membrane causing 
docking and release into the synapse by exocytosis(95). Formation of a stable immunological synapse preceding 
the release of granules is essential to ensure the perforin and granzyme are directed, in high concentration, 
solely at the target cell. 
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         Initial studies suggested perforin was believed to create pores in the target cell surface membrane enabling 
granzyme to efficiently diffuse into the cell inducing cell death. However, more recent studies have suggested that 
a more likely mechanism is the endocytosis of both molecules. Perforin is believed to then form pores in the 
endosome mediating the release of granzymes into the cytoplasm of the target cells, inducing cell death(96).  The 
two primary granzymes released by CD8+ T cells are: Granzyme A and Granzyme B. Some studies have 
suggested that as proteases it is possible that granzymes can act in both intra and extracellular fashion. In vitro 
studies have demonstrated their ability to cleave extracellular matrix proteins, such as fibronectin, inducing the 
release of cells and therefore death by anoikis. However, it is well established that their primary function occurs 
once they have reached the cytoplasm of target cells. Once in the cytoplasm, granzymes can initiate cell death 
through a variety of mechanisms. The proteases induce apoptosis of the target cell through caspase dependent 
and independent mechanisms.  
         Granzyme B induces apoptosis using two main mechanisms. The primary mechanism is the induction of 
mitochondrial pathway of apoptosis. Granzyme B cleaves Bid, a BH-3 homologous pro-apoptotic protein. 
Truncated Bid migrates to the mitochondria membrane where it binds to the trigger site of pro-apoptotic Bax, 
directly activating it, resulting in the release of cytochrome c(97). Cytochrome c binds to an APAP-1 monomer, 
inducing a conformational change that results in the oligomerisation and formation of the Apoptosome. The 
Apoptosome activates the initiator caspase 9 which, in turn, activates multiple effector caspases(98). Overall this 
mechanism induces the condensation of chromatin, laddering of DNA and membrane blebbing, otherwise known 
as apoptosis. Moreover, granzyme B is in-fact capable of directly activating the initiator caspase, caspase 8, as well 
as the effector caspase, caspase 3. 
         In contrast granzyme A’s primary cytotoxic mechanism is through the direct induction of DNA single 
strand breaks(99). An accumulation of single strand breaks can be extremely toxic to a eukaryotic cell especially a 
cancerous cell due to the potential loss of one or more aspects of the DNA damage response. In addition, 
granzyme A initiates the permeabilisation of mitochondrial membrane, in turn, causing the release of reactive 
oxygen species(ROS)(100). Reactive oxygen species are highly reactive oxygen atoms or molecules that are able to 
interact and damaging a multitude of proteins, resulting in loss of membrane integrity and cell death.  
         CTLs can also carry out cytolysis via alternative mechanisms such as utilising their expression of the Fas 
ligand, initiating the “Death receptor pathway”(101). CD8 T cells express the trimeric ligand, Fas, which can act 
on the Fas receptor(CD95/APO1) expressed by the majority of the cells in the body. The Fas receptor is made up 
of an extracellular Fas domain and an intracellular “death domain”. In the presence of the Fas ligand, Fas 
receptors trimerise leading to the recruitment of the Fas associated death domain. FADD is an adaptor molecule 
with homology to the intracellular death domain of the Fas ligand as well as to the death effector domain attached 
to Caspase 8 and 10 pro-enzymes(102). These pro-enzymes exhibit zymogen function. Due to the clustering of 
receptors and therefore caspase pro-enzymes, their intrinsic caspase activity enables cleavage of corresponding 
pro-enzymes releasing fully functioning caspases.   
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1.5 Immunological synapse 
1.5.1 Immunological synapse 
For efficient interactions between immune cells and their targets to be completed they must form a 
tight stable interface, described as the immunological synapse. The formation of a synapse is 
essential before the initiation of specific targeted interactions. CTLs play an essential role in 
eliminating cancer cells, primarily through the release of high toxic cytolytic granules. In order to 
achieve target specific killing, limiting co-lateral damage, an immunological synapse must form 
between the CTL and target before granule release. Upon recognition of a target, stimulation of the 
TCR induces a reorganisation of the cytoskeleton, as shown in figure 7.  
 
Caspase 8 is then able to exhibit two separate actions. Primarily it uses its caspase activity to activate the 
executioner caspase 3, inducing cellular apoptosis. In many cells, “Type 1”, this pathway is sufficient to kill the 
host cell. However, in some cells such as hepatocytes, named “type 2”, not enough caspase 3 is activated 
through the primary pathway therefore the active caspase 8 that is produced harnesses the mitochondrial 
pathway of apoptosis(103). Caspase 8 cleaves the Bid protein causing a conformational change truncating the 
protein. tBid is then able to initiate the mitochondrial pathway of apoptosis as previously described.  
         Another indirect mechanism in which CD8+ T cells eliminate intracellular pathogens is by the release of 
specific cytokines(104). Upon recognition of a foreign MHC1 bound peptide, CD8+ T cells release three key 
cytokines that enhance further elimination. IFN-y inhibits viral replication within the cell depleting the viral 
load, whilst also encourages and increased expression of MHC class 1 molecules. This, in turn, enhances the 
presentation of the viral peptides increasing the immunogenicity of the virus infected cells and enables more 
efficient recognition and killing by additional immune cells.  
         Furthermore IFN-y acts by activating and recruiting macrophages to the site of infection, increasing the 
chance in which the infected host cell will be recognised as a target and undergo cytolytic action(105). TNF-a 
and TNF-b both work alongside IFN-y to enhance the activation of local macrophages, increasing antigen 
presentation and cytotoxicity. In addition, TNF-a can act directly on a specific membrane bound receptor, 
TNFR, that can also induce cellular apoptosis by the Death receptor pathway. Therefore not only do these 
cytokines allow for increased local killing and enhance CD8+ effector function, but can also directly induce 
cell death. 
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Figure 7: The Immunological Synapse     
The eukaryotic cell cytoskeleton consists of tubulin, actin and intermediate filaments. Actin is a protein that 
can either occur singularly as globular actin(G-Actin) or as part of a polymer as filamentous actin(F-Actin) 
which plays a key role in the stabilisation of the immunological synapse by forming a peripheral ring 
structure to stabilise the contact. An accumulation of F-Actin is seen to accumulate at the center of the 
contact, proceeding cellular interaction. However, the accumulation of F-Actin is seen to quickly dissociate, 
through the enzymatic action of Cofilin, and instead form a distal ring surrounding the forming 
SMAC(105). The stable peripheral actin ring enables TCRs to undergo clustering at the center of the 
interface, alongside key co-signalling molecules, such as CD28, forming the cSMAC. Surrounding the 
cSMAC, adhesion molecules, such as LFA-1 and the adaptor protein Talin, form a tight ring further 
stabilising the immunological synapse(106). This structure is named the pSMAC and is tightly surrounded 
by the stable peripheral actin ring as well as additional proteins, overall forming what has been described as 
a bullseye configuration(107).  
         Once formed, the microtubule organisation center can relocate proximally from behind the nucleus 
towards the synapse(108). Studies have shown that migration of the MTOC holds a critical role, as one of 
the inner MTOC centrioles docks the cell membrane adjacent to the TCR micro-clusters(109). Stored lytic 
granules, containing perforin and granzymes, are found associated with the migrating MTOC. 
         Therefore, the cSMAC contact allows for an extremely concentration and directed release of lytic 
granules into the immunological synapse exhibiting a cytotoxic effect on solely the target cell through 
central sustained localisation of the MTOC and release of lytic granules. Additionally it is speculated to 
focus the admission of the FasL within the synapse further directing cytolytic effects(110). 
 
- 
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1.6 Immunotherapy 
1.6.1 Conventional vs Immunotherapy 
For many years cancer therapy has relied upon three treatments: Surgery, chemotherapy, and 
radiotherapy. Surgery is used to remove the main tumour mass, whereas chemotherapy and 
radiotherapy were used to kill cancer cells based on their ability to rapidly proliferate. These 
treatments have shown impressive results and are still regarded as the forefront of cancer treatment 
however not without cost. Agents eliminating rapidly dividing cells also dramatically affect other 
replicating tissues within the body, especially within then blood and immune system. One potential 
alternative or adjuvant therapy to assist combating cancer without significantly harming the patient 
is immunotherapy. 
         Immunotherapy is the enhancement of a patient’s own immune system in attempt to combat 
cancer. The two primary classes either attempt to overcome the immune evasion tactics used by 
tumours such as their immunosuppressive microenvironment, or generally amplify stimulation of 
immune system, enforcing a globally enhanced immune response towards the TAA causing specific 
tumour killing and regression but also potentially host cells. 
 
1.6.2 Non-specific Immunotherapy 
The first cytokine immunotherapy was officially approved by the FDA as a treatment against 
human metastatic melanoma and metastatic kidney cancer. IFN-α had undergone extensive murine 
pre-clinical trials to finally be sanctioned for its use against Hairy cell leukaemia, a rare form of B 
Cell leukaemia(111). IL-2 has since been approved for both metastatic renal carcinoma, in 1992, 
and advanced melanoma, in 1998(112). Cytokine treatment continues to prove great promise as an 
adjuvant cancer immunotherapy. Cytokines are soluble immune mediators that act both in 
paracrine and autocrine fashion. They are both produced and act on immune cells, controlling 
many active biological processes such as cell growth, proliferation and cell death. Cytokine therapy 
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aims to enhance the immune system in an attempt to drive anti tumour responses. Clinical trials 
using cytokine therapy against cancer have shown success, enhancing complete remission following 
treatments of either single agents, IFN-a, IFN-y, IL-2 and TNF-a, or even a mixed cocktail of 
multiple(113). However, as cytokines only act over a short distance, the intravenous concentration 
delivered for effective treatment is extremely high. This high concentration has been seen to have 
the potential to cause dramatic, life threatening side effects such as capillary leak syndrome and 
neutropenia(114). Due to these side effects and the high dose needed cytokines are not yet 
commonly used as monotherapy but instead as adjuvant to enhance the potential of tumour specific 
immunotherapies. 
 
1.6.3 Tumour specific immunotherapy  
The class of immunotherapies aimed at enhancing the tumour specific immune response consist of 
treatments that aim to overcome the decreased immunogenicity utilised by tumours to evade the 
immune system, in turn increasing specific tumour killing. CD8+ T cells capable of recognising 
tumour associated antigens are suppressed by numerous mechanisms found in the TME. Many 
treatments such as PD-1 blockades are currently being trialled and developed that target and inhibit 
these suppressive mechanisms(115). 
     Currently one approved active immunotherapy utilises dendritic cells(DC) as vaccines. DCs are 
essential for the priming of naive T cells. Circulating DC progenitors are isolated on their CD1c+ 
expression and eluted from a patient’s blood sample before being expanded ex vivo using cytokines 
and growth factors(116). Once an adequate number has been obtained, the DC are peptide loaded 
with tumour associated antigen and matured via additional maturation signals. Following 
maturation, the DCs are then reintroduced into the patient’s circulation. Introducing a high 
number of mature, TAA presenting DC cells into a patient’s circulation greatly enhances the cross 
priming of CD8+ T cells, in turn stimulating a greater tumour specific immune response. Dendreon 
has developed an effective vaccine, through the ex vivo expansion and enhancement of DC cells 
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presenting specific TAAs(117). Promising results has been seen, one trial showing a 2-fold increase 
in survival rate over 36 months (118). Currently a number of clinical trials are underway, however 
so far only one DC cell vaccine, Provenge®, has been officially licenced by the FDA for use in 
prostate cancer. 
           Further studies have investigated the possibility of using alternative cell based treatments. 
One study showing great promise being adoptive T cell transfer. Adoptive T cell therapy uses either 
peripheral T cells in circulation or isolated tumour infiltrating lymphocytes directly from patient 
tumour biopsies(119). Tumour infiltrating lymphocytes(TILs) have the innate ability to recognise 
tumour associated antigens. Tumour biopsies are fragmented and plated in the presence of IL-2, 
inducing TIL proliferation. TILs are assayed for their ability to recognise tumour-associated 
antigens, before being expanded ex vivo. Once expansion is complete TILs are reintroduced into 
circulation. Using IL-2 as an adjuvant has shown to significantly increase the in vivo persistence of 
TILs following infusion(120). The immense increase in CTLs capable of recognising tumour-
associated antigen exerts a significant specific cytolytic effect against tumours. However, even 
though this treatment enhances the immune system in a specific manner, some side effects are still 
seen such as vitiligo and uveitis(121). Currently, clinical trials utilising autologous TILs in adoptive 
T Cell transfer against metastatic melanoma have shown substantial clinical responses in 
approximately 40% to 72%  of patients(122). However, the primary limitation of TIL ACT is the 
necessity of a pre-existing population of TILs. To overcome this, many studies have been 
investigating the development of genetically engineered peripheral blood T cells. 
         T cells may be isolated from peripheral circulation and cultured, as previously described, 
before being genetically modified to recognise specific TAAs. Genetic modifications are most often 
completed using engineered replication incompetent y-retroviruses and lentiviruses(123). Viral 
infection incorporates specific genes into the host genome that enable expression of high affinity 
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TAA specific TCRs. Specific tumour associated antigens can be subdivided into several categories, 
seen in figure 8. 
The genetic modifications generate high numbers of tumour specific CTLs that may then be 
introduced into circulation. Impressive results have been noted in clinical trials combatting 
metastatic melanoma as well as oesophageal and synovial sarcomas(124). 
          Induction of tumour specific TCRs show great promise but is restricted by its ability to only 
interact with specific MHC1 haplotypes(125). In attempt to overcome the restriction, developments 
on this theory have evolved into creating further tumour specific CTLs that are able to act in an 
MHC-1 independant manner. MHC-1 independency has been achieved by the creation of a novel 
receptor type deemed chimeric antigen receptors(CARs). Currently three generations of Chimeric 
antigen receptors have been developed, each with an increasing level of complexity and cytoplasmic 
signalling domains. Chimeric antigen receptors each have an extracellular domain comprised of a 
single chain antibody or ligand specific for a receptor or protein expressed solely on cancer 
cells(126). The development of CARs allows for the unrestricted fabrication of genetically modified 
Figure 8: Classes of tumour associated antigens 
Different classes of tumour associated antigen along with reported examples. The identification of 
tumour specific antigens, enables targeted CTL responses against solely tumour cells, preventing local 
cell damage. Tumour specific molecules stem from either mutated proteins, due to genetic instability, 
which are therefore not expressed in normal tissues, or the aberrant expression of normal functioning 
proteins by alternative cells. 
Type of TAA: Example: 
Mutated Proteins(Point mutations/Gene 
rearrangements) 
BCR-ABL 
Cancer Testis Antigen (Aberrant expression of 
proteins usually only found in male germ cells ) 
MAGE, NY-ESSO-1 
Differentiation antigens   Melanin  
Overexpressed proteins  Her-2/Neu 
Abnormal post translational modifications Aberrantly N-acetylglucosamine modified 
proteins 
Novel proteins Point mutations/truncations 
Viral Oncogenes HPV 16 
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tumour specific CTLs, increasing the availability of adoptive T cell transfer cancer immunotherapy. 
Currently CAR therapy has seen impressive clinical success, with up to a 90% remission, against 
acute lymphocytic leukaemia(ALL) through targeting CD19 as well as against Neuroblastoma by 
targeting GD2(127). 
         Recent developments of soluble versions of genetically engineered high affinity TCRs are 
generated and bound to an anti-CD3 antibody fragment(128). Anti-CD3 antibodies are capable of 
cross linking CD3 molecules associated with peripheral CD8+ T cells inducing TCR signalling, 
named ImmTacs®. Therefore ImmTACs® are able to specifically attach to cancer cells enabling 
the activation of non-specific peripheral CD8+ T cells, inducing a cytolytic response. This novel 
technology is primarily still currently under development, however the first clinical trial is underway 
utilising PO-418 ImmTAC® molecules to target the HLA-A*0201/gp100 expressed on melanoma 
cells(129). 
         Despite the rapid development of tumour specific immunotherapies that are showing great 
promise in the clinic, there are numerous side effects have been identified. Impressive developments 
have been seen in detecting and generating responses against tumour specific antigens however the 
overwhelming multitude of immunosuppressive factors produced and expressed by the tumour 
microenvironment are still proving a problem to overcome. 
       
1.7 Tumour Microenvironment 
1.7.1 Tumour microenvironment 
Recent advancements in cancer research have led to the identification of a correlation between an 
increased number of lymphocytes within the tumour mass and a better prognosis following surgery 
or immunotherapy(130). Lymphocytes that have left the blood stream, migrating into a tumour 
mass can be identified in tumour biopsies and deemed “tumour infiltrating lymphocytes”. Both B 
and T lymphocytes are described to infiltrate into both the surrounding stroma and immersed 
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within tumour mass itself. It is known that tumours commonly down regulate cell surface molecules 
in attempt to decrease their immunogenicity yet the presence of these lymphocytes within the 
tumour implies that they have the unique ability to able to recognise a specific tumour associated 
antigen and therefore to eliminate specifically tumour cells. However, it has been discovered that 
TILs express a suppressed phenotype, decreasing their cytolytic capabilities(131). A vast amount of 
research has undergone to identify specific mechanism utilised by tumours to not only evade but 
actively suppress the immune system.  
 
1.7.2 Inhibitory receptors 
One immunosuppressive mechanism utilised by cancer cells is the up regulation of immune 
blockade ligands. Immune blockade receptors are expressed by active CTLs to modulate their effect 
function. CTL stimulation is controlled by the balance of co-stimulatory and co-inhibitory receptor 
signalling, ultimately determining the fate of the cell. This enables the tight regulation of CTL 
effector function, reducing the risk of unnecessary bystander effects or autoimmune disease. Upon 
reoccurring exposure to antigen CTLs face exhaustion and therefore up-regulate immune 
checkpoint receptors, predominantly Programmed Death Receptor-1(PD-1) and CTLA-4(132).  
        PD-1 is a co-inhibitory receptor, from the CD28 family, known to be expressed on a plethora 
of immune cells but it primarily recognised for its role in modulating active CTL effector function. 
Upon recognition of a target MHC1 complex CTLs release inflammatory cytokines, increasing the 
local expression of PD-L1 as a tolerance mechanism to prevent damage to local bystander cells(133). 
It is mainly activated through the recognition of the PD-1 Ligand(PD-L1), however reports have 
described a possible mechanism by which it is also stimulated through CD80, similarly to CTLA-
4(134). Upon binding PD-1 exerts an inhibitory effect, causing T cell suppression and dysfunction, 
the mechanism by which is still largely unknown. However, it has recently been proposed to disrupt 
the maintenance of the immunological synapse(135). 
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         Several cancers have been shown to exploit this mechanism by expressing high levels of PD-
L1 on their cell surface(136). Additionally, up regulation of PD-1 expression seen on tumour 
infiltrating lymphocytes suggests the TME has a role in driving this suppressed phenotype. 
However, identification of this has led to immense immunotherapy developments, with PD-1/PD-
L1 blocking antibodies showing impressive clinical success, as previously described.      
         CTLA-4 is also a co-inhibitory molecule, expressed by activated CTLs, that acts as an 
immune checkpoint protein(137). CTLA-4 competitively binds CD86/CD80 with an increased 
affinity to CD28 preventing co-stimulation, whilst additionally actively inducing inhibitory signals. 
The mechanism of CTLA-4 is still widely unknown, although it has been suggested that it 
implements a phosphatase action in the cSMAC deterring any induced TCR signalling(138). 
CTLA-4 is also found to be unregulated upon CTLS entry into the TME, demonstrating its 
potential for immuno-therapeutics(139). Ipilimumab has shown incredible clinical success especially 
in the fight against metastatic melanoma, but has also been approved for its use against multiple 
cancer types(140). 
         Recent advancements within the field of immunology has led to the discovery of one possible 
solution, Immune blockade receptor inhibitors. The 2018 noble prize in medicine was awarded for 
the discovery of two key immune blockade molecules PD-1 and CTLA-4 and their potential for 
inhibition(141). PD-1 and CTLA-4 are both co-inhibitory receptors expressed solely on activated 
CTLs. Modulation of T Cell function occurs through the ratio of co-stimulatory and co-inhibitory 
molecules.  Immune blockades primary function is to modulate immune reactions to prevent both 
over stimulation of CTLs limiting off site side effects, as well as autoimmune disease(142). However 
immune blockade ligands are found to be highly expressed on cancer cells, as a mechanism of 
immune evasion. To counteract this, research has developed monoclonal antibodies that target and 
block these inhibitory receptors preventing immune suppression. This treatment proves to be one of 
the most promising advancements in cancer therapy, showing clinical success for metastatic cancers 
with a previously very poor prognosis e.g. metastatic melanoma. Currently two treatments have 
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been approved by the FDA for use in clinic as cancer immunotherapies: inhibiting antibodies of 
either/both PD-1(Nivolumab) and PD-L1(Atezolizumab/Durvalumab), as well as blocking 
antibodies of CTLA-4(Ipilimumab). All of which have shown great clinical success and approval for 
the treatment of multiple cancer types. Further research is still underway to advance developments 
against alternative aspects of the tumour microenvironment.  
 
1.7.3 Soluble immunosuppressive factors 
Following the success of immune blockade receptor therapies, more and more research has been 
undertaken to investigate the immunosuppressive effects of the TME. One key category of identified 
factors are soluble suppressive molecules, including Adenosine and Prostaglandin E2. Adenosine is a 
naturally abundant purine nucleoside that has an important role in cellular metabolism and 
signalling(143). It binds to 4 independent G coupled receptors(A1,2a,2b,3), subclassed on their 
juxtaposed ability to either increase of decrease intracellular cAMP. Receptors A1 and A3 both 
inhibit the enzyme adenyl cyclase therefore suppressing intracellular levels of cAMP. In contrast, 
A2a and A2b both increase the activity of adenyl cyclase driving the up regulation of cAMP, which 
in turn has an extremely suppressive effect on immune cells(144). In the context of CTLS, increased 
cAMP is capable of suppressing TCR signalling, as well as down regulating the expression of key 
proliferative and survival transcription factor NF-kB(145). 
         Hypoxia is commonly associated with the growing tumour. As the transformed cells proliferate 
uncontrollably, they begin to outgrow the available blood supply leading to a necrotic core, of cells 
in which oxygen cannot reach through simple diffusion. These hypoxic conditions are believed to be 
a major driver of extracellular ATP. In addition to this Hypoxia induced factor-1(HIF-1), a 
transcription factor induces the expression of adenosine producing, ectoenzymes CD39 and CD73. 
Therefore, ATP is degraded via CD39 and CD73, creating high levels of adenosine in the 
TME(146). The increased level of adenosine seen in the TME has been demonstrated to prevent 
CTL proliferation and activation, whilst inducing T cell anergy function via a A2a dependent 
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mechanism(147). It is therefore believed that adenosine is a significant contributing factor towards 
tumour immune evasion. 
        This identification has led to research of adenosine receptor blockades as a potential adjuvant 
immunotherapy. However, to date, no therapeutics have made it past preclinical murine models. 
Instead adenosine producing ectoenzymes, CD39 and CD73 have been used as prognostic markers 
in multiple types of cancer, including but not limited to ovarian, gastric, colorectal and 
melanoma(148).  
 
1.7.4 Common immunosuppressive mechanism 
Several suppressive mechanisms are believed to operate within the TME, however how individual 
mechanisms occur, as well as the extent of their overall contribution in suppressing CTLs is still 
widely unknown. The diverse interactions of inhibitory molecules prove difficult to combat with a 
single immunotherapy. In addition, cancer itself is a collection of over 200 individual diseases, each 
with its own concoction of potentially suppressive mechanisms. Therefore, the discovery of a 
common immunosuppressive mechanism would hold great potential for an effective translational 
cancer immunotherapy. One possible common immunosuppressive mechanism is the loss of 
maintenance of the stable immunological synapse. Recent studies have demonstrated a link between 
the loss of cytolytic ability and the loss of a stable synapse(135). Following tumour infiltration it has 
been noted that TILs exhibit a decreased ability to maintain a stable immunological synapse.  
         Firstly, for effective cytolytic effector function the MTOC must localise to the immune synapse 
bringing with it associated granules for release. Studies have shown upon target cell interaction the 
MTOC localisation in TILs is significantly reduced(135). Further research demonstrated this to be 
coupled with an unstable cell couple maintenance. CTL:Target cell couples are well maintained for 
up to 12 minutes in a symmetrical synapse. However, TIL:Target couples were seen to lose 
symmetry merely 2 minutes after initial formation, suggesting an unstable interface(135). Coupled 
with this was the significant increase in off-site lamella formation(135). A CTL lamella is a small 
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membrane projection controlled by the actin cytoskeleton. They are often seen generated towards 
the immunological synapse for maintenance of the stable bond. However, TILs exerted a significant 
increase in off-site lamella, projecting away from the interface and believed to exemplify an unstable 
interface(135).  
    
      To further investigate the maintenance of the immunological synapse, studies aimed to 
determine whether the TME had any effect on the intracellular actin polarisation playing a pivotal 
role in the maintenance of the stable interface. CTLs and TILs were both assessed for their action 
patterning, as seen in figure 9, as well as the presence of cofilin. Cofilin is an actin binding protein, 
Figure 9: F-Actin Interface Patterning  
The immunological synapse is maintained through the formation and maintenance of a peripheral 
actin ring at the interface in order to stabilise the interaction. Studies have identified alternative actin 
accumulation patterns indicative of  impaired CTL synapse maintenance as an induced suppressed 
phenotype, following CTL infiltration into the tumour microenvironment. Adapted from Wuelfing et al, 
Early Signaling in Primary T Cells Activated by Antigen Presenting Cells Is Associated with a Deep and Transient 
Lamellal Actin Network, 2015. 
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that plays an essential role in actin polarisation through its ability of disassembling filamentous actin 
polymers. Upon host:target cell interactions, peripheral actin ring formations not seen to be 
significantly affected.  However, within 180 seconds a dramatic reduction in sustained peripheral 
actin ring was seen(135). This effect spanned over 420s with a significant reduction in the 
percentage of remaining peripheral actin rings(135). The combined data suggests defective 
intracellular polarisation as mechanism of CTL suppression following tumour infiltration.  
         To determine whether this phenotype affected the effector function of CTLs, additional 
research utilised Jasplakinlide treatment to simulate the dysfunction of actin dynamics following 
tumour infiltration. Jasplakinlide is a potent stimulant of actin polarisation(135). Following 
treatment, the CTLs showed a matched inability to maintain the peripheral actin ring alongside a 
significantly reduced cytolytic function. In conclusion this data suggests that dysregulation of actin 
dynamics and intracellular polarisation exerts an important role in TME suppression and could 
additionally show potential as a common mechanism of immunosuppression.(135) 
 
1.8 Prostaglandin E2 
1.8.1 Introduction 
Prostaglandins are lipid mediators involved in a wide variety of biological functions throughout the 
body. They are as part of the subclass of signalling molecules, the eicosanoids. They are produced 
by almost all nucleated cells in the body and are found in almost all tissues either constitutively for 
homeostasis or unregulated due to external stimuli such as trauma and inflammation, signalling 
molecules, and cellular signalling. All prostaglandins contain a 5-carbon ring and 20 carbon atoms 
however their structural differences give rise to a wide variety of physiological effects. In humans the 
most prevalent prostaglandin is Prostaglandin E2(149). PGE2 itself has been demonstrated to have 
an immensely diverse physiological effect depending on the tissue, cell type and receptor it binds 
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to(150). However ultimately its effects are focused around the stimulation of intracellular pathways 
that result in either the activation or inhibition of adenyl cyclase causing increased or decreased 
levels of intracellular calcium, respectively. 
 
1.8.2 PGE2 Production 
The synthesis of Prostaglandin E2 involves a multitude of enzymes in a primarily 3 step pathway 
starting with cell plasma membrane, as seen in Figure 10.          
Figure 10 : Prostaglandin E2 synthesis pathway 
The cell surface membrane is a bilayer made up of phospholipids. Phospholipids are typically made up of 
two hydrophilic fatty acid molecules bound to a hydrophilic phosphate group. These fatty acids can be 
liberated from the phospholipids, via hydrolysis by the enzyme phospholipase A2, in the form of 
Arachidonic acids(151). Arachidonic acids are comprised of a polyunsaturated 20 carbon chain and are 
primarily utilised as secondary signalling molecules. In addition to signalling AA is a key precursor in the 
synthesis of two key lipid signalling molecules: Leukotrienes and prostaglandins. AA are either metabolised 
by prostaglandin G/H syntheses, collectively named COX1-2, to syntheses prostaglandins or lipooygenases 
to produce leukotrienes. COX enzymes are bifunctional enzymes that can exert not only cyclooxygenase 
activity but also peroxidase, distinguishing as two isoforms COX 1 and 2(152). 
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The level of PGE2 production is controlled by the expression of COX1 and COX2. COX 1 is 
constitutively expressed in tissues, due to its involvement in tissue homeostasis. In contrast, COX2 is 
typically expressed at very low, even undetectable, levels but is seen to be unregulated in response to 
external stimuli such as inflammatory cytokines, as commonly seen in chronic inflammatory 
conditions, or due to carcinogenesis(154).  
 
1.8.3 PGE2 Receptors 
Part of the complexity of PGE2 signalling arises from the fact that there are 4 individual receptors 
and their varied levels expression patterning. Collectively termed EP1-4, EP receptors are 
serpentine transmembrane G couple receptors that bind PGE2 inducing distinct signal transduction 
pathways, as seen in figure 11(155). The pattern of expression of EP receptors widely varies 
throughout the body depending on the tissue and cell type, however their exact distribution is still 
largely unknown due to their typically low levels of expression(156).  
         Each EP receptor consists of a single polypeptide chain that spans the cell surface membrane 
seven times forming multiple helices, creating an overall barrel tertiary structure. Upon ligand 
binding the receptor structure undergoes cytoplasmic conformational changes enabling 
transduction of the intracellular signal via a G-protein coupling mechanism(157). Each EP receptor 
initiates an independant signalling cascade however their principle mechanisms all engage either the 
cAMP or PI3K pathways. EP subtypes primarily bind to PGE2 but each with a different 
affinity(158). Contradicting studies can be found describing alternative affinities of the EP receptors 
for PGE2 in both human and murine models, however most agree that in humans the order is seen 
to be EP3>EP4>EP2>EP1 contrasting to murine models in which EP3 is still believed to have the 
COX1-2 collectively oxygenate AAs resulting in the production of prostaglandin H2(PGH2). PGH2 can be 
further metabolised, into 4 key eicosanoids: PGD2, PGE2, PGI2 and TXA2. PGE2 is the most prevalent 
and well-studied of the eicosanoid family and is synthesised from PGH2 by the enzyme Prostaglandin E 
synthase(153). Once synthesised PGE2 can act in both paracrine and autocrine fashion until it is degraded 
by the enzyme 15-Prostaglandin Dehydrogenase(15-PGDH). Homeostatic turnover of PGE2 is typically 
very quick, ensuring low levels of PGE2.  
UNIVERSITY OF BRISTOL  50 
highest followed by EP4 however EP1>EP2(159). The altered expression and affinities between 
human and murine models further increase the complexity when attempting to investigate the EP 
receptors role using murine models.  
Figure 11:  PGE2 receptors 
The EP1 receptor is deemed a ‘contractile’ prostanoid receptor based to its ability to contract longitudinal 
smooth muscle(160). Upon ligand binding EP1 undergoes a conformational change causing mobilisation of 
its Gαq subunit inducing activation of both PLC-y and PI3-k, in turn, through phosphorylation. This 
action leads to an increase of cytosolic Ca2+ ions, initiating a further influx of Ca2+ via extracellular 
channels, causing contraction of the smooth muscle. In contrast EP2, EP3 and EP4 receptors exert their 
action through the inhibition or promotion of cAMP. 
         EP2 and EP4 share a common pathway through the induction of adenyl cyclase, increasing cytosolic 
cAMP and inducing Protein Kinase A(PKA), a kinase that can interacts with multiple downstream 
signalling molecules and transcription factors, such as CREB, altering a variety of gene expressions 
depending on the type of cell. Upon ligand binding, both receptors undergo an intracellular 
conformational change causing the dissociation of the Gαs-Gβγ complex. The distinguishing difference 
between EP2 and EP4 is the pathway leading to the induction of PKA.  
         EP2 acts primarily in a cAMP dependent manner, whereas EP4 also induces PI3-k additionally 
leading to PKA induction(161). In both EP2 and EP4 receptors Gαs mobilisation, following Gαs-Gβγ 
complex dissociation, activates adenyl cyclase causing increased intracellular cAMP and therefore PKA. In 
addition, EP4 receptors also induce the PI3k/AKT/mTOR and ERK pathways, as well as inducing 
Prostaglandin E receptor 4-associated protein(EPRAP), causing suppression of transcription factor NF-kB, 
an important regulator of inflammation, cellular proliferation and growth(162). The multiple pathways of 
EP4 contribute to PGE2’s multifaceted role in immuno-regulation. 
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1.8.4 PGE2 in cancer 
Altered levels of PGE2 have been widely noted in a broad spectrum of cancers implying a possible 
link with tumour development and survival. Studies have demonstrated a significant increase in 
COX2 expression in multiple tumour types, especially colorectal, renal, lung and mammary(165) 
Coupled with the increase in PGE2 synthesis, many tumours have been noted to exhibit suppressed 
levels of 15-PGDH, decreasing the rate of PGE2 hydrolysis therefore further increasing PGE2 levels. 
As PGE2 has an immense diversity of effects depending on the stimulated receptor and the cell type, 
it holds a multifaceted role within carcinogenesis. Multiple studies have linked PGE2 to all 6 of the 
original hallmarks of cancer(166). Experiments investigating colorectal cancer have demonstrated a 
synergistic mechanism of PGE2 and Wnt signalling(167). Binding of PGE2 to EP2/4 receptors has 
the ability inhibit the β-catenin destruction complex, via activation of the cAMP/PKA pathway, 
stimulating a self-replicative phenotype, further driving carcinogenesis(168). However, PGE2 does 
not solely affect tumour cells directly, it also exhibits substantial effects on immune system 
potentially helping tumour immune evasion. 
         These effects are especially paradoxical when it comes to the immune system. Typically 
stimulated by inflammation PGE2 surprisingly exhibits both pro and anti-inflammatory effects, 
making the identification of carcinogenic contribution extremely complex. The variation of effects 
seen on the cells of the immune system largely depend on their level of maturity, the concentration 
of prostaglandin and interaction with corresponding cells.  
         Studies discovered a pro inflammatory role for PGE2 as a potent chemoattractant for Mast 
cells. Both immature(2 week) and mature(10 week) bone marrow derived mast cells were seen to 
         EP3 receptors are deemed inhibitory due to their ability to suppress adenyl cyclase, counteracting 
both EP2 and EP4(163). Unique to EP3, it has 3 identified isoforms in mice, each comprising of 
different G protein subunits, that can all exhibit different signalling mechanisms(164). The 
predominant isoform, Gαi-Gβγ inhibits turn suppressing adenyl cyclase, in intracellular cAMP 
production upon ligand binding. Overall the sheer diversity of PGE2 receptor expression, tissue 
patterning and signalling pathways provides a complex obstacle to overcome when investigating 
the plethora of effects exerted by PGE2. 
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express EP3 and EP4 receptors. However, the migratory study, using specific EP3 and EP4 
antagonists, clearly demonstrated the chemoattractant mechanism was solely EP3 dependent(169). 
In addition to attracting mast cells to sites of inflammation, one study has described PGE2 to greatly 
enhance mast cell production of pro-angiogenic factors, in a dose dependent manner. Within 2 
hours of culture with PGE2 mast cells were seen to excrete up to 15-fold more monocyte 
chemoattractant protein-1(MCP-1), a key modulator of monocyte migration and infiltration, further 
driving inflammation(170).  
         Similarly, experiments have shown PGE2 to induce the expression of further chemotaxis 
mediators from colonic epithelial cells. PGE2 was seen to induce up regulation in the gene 
expression and stability of IL-8, a potent chemokine involved in the recruitment of Neutrophils and 
T Cells, in both a time and dose dependant manner(171). This also enhances local inflammation. 
Principally there are multiple pro-inflammatory effects of PGE2, hence its common description as a 
pro-inflammatory modulator, however in the context of cancer PGE2 is primarily mentioned for its 
immunosuppressive consequences. 
         Research has shown that NK exhibit suppressed cytolytic capabilities, in a dose dependent 
manner, when in the presence of PGE2. This is believed to be due to the significant increase in 
cellular cyclic AMP levels(172). Inhibition of cytolytic action by NK cells enables tumours to 
develop non-immunogenic phenotypes through down regulation of MHC1 complexes whilst 
preventing their elimination via NK cell lysis. In addition to a reduction in lytic unit production, a 
reduction in cytokine production as also seen when NK cells are cultured for 2 days in varied levels 
of PGE2(173). A significant reduction of IFN-y production has been noted, believed to be due to IL-
15 receptor down regulation again in a dose dependent manner(174). 
         Contradicting studies have been seen when describing the effect of PGE2 on FOX-P3 
expression in Treg cells. Some studies state that PGE2 increase the inhibitory function of T reg cells, 
inducing an enforced Treg phenotype on CD4+ CD25- T cells, as well as causing the up regulation 
of the FOXP3 transcription factor(175). In contrast, it has also been recorded that PGE2 signalling, 
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via the EP2 receptor, lead to stimulation of the cAMP and PKA pathways, negatively influencing 
the expression of FOXP3 and total Treg differentiation(176).  Further research believes to have 
identified a link between increased PGE2 expression and expansion of existing Tregs through the 
promotion of increased interactions with DCs(177). 
         B cell activation is essential to enforce a full set of functioning immunoglobulins. PGE2 has 
been reported to influence early regulatory events in B Cell activation, decreasing the ability to 
complete efficient immunoglobulin class switching. This is believed to the due to the ability of PGE2 
to effect intracellular cAMP signalling.(178) 
         Recent studies have demonstrated that the addition of 1uM PGE2 at the time of CD8+ T cell 
priming is sufficient to suppress both cellular divisions and IFN-y production. Monoclonal CTLs 
primed in vitro using Anti-CD3 and rICAM-1 stimulation, used to represent direct priming through 
lymph node metastases, was seen to be suppressed almost 3-fold by a significant reduction in CTLs 
reaching their last two divisions(from 75% vs 35%) following addition of 1um PGE2. Coupled with 
this was a large reduction in IFN-y production(21.8% vs 9.64%)(91). This phenomenon was seen to 
be CTL dependant through further investigations, inducing proliferation using irradiated murine 
renal carcinoma cells. Significant decreases in proliferation were only witnessed when 1um PGE2 
was added directly with the CTLs, in contrast to solely the Renca cells culture, therefore ensuring 
the PGE2 was affecting the CTLs directly rather than the Renca cells(179). The immunosuppressive 
effect was additionally examined and demonstrated to occur through classical co-stimulation. CTLs 
primed with Anti-CD3 and Anti-CD28 were also shown to exhibit suppressed proliferation upon 
the addition of 1uM PGE2, suggesting this suppression would be inclusive to cross presentation(91).  
This hypothesis was tested on varied levels of PGE2 to determine whether the response was dose 
dependant. At 1uM a strong immunosuppressive response was seen, as described, however at lower 
concentrations(10pM) PGE2 was seen to exhibit a pro-immune response, increasing the 
proliferation of CL4 when activated via irradiated tumour cells(179).  
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         Additionally, studies investigated whether the immunosuppressive effect of PGE2 was 
reversible once the stimuli was removed. Primary and secondary cultures were set up to determine 
whether the effect of PGE2 was sustained. The additional of PGE2 to primary culture induced a 
reduction in both IFN-y production ad proliferation. However once environmental PGE2 was 
removed for secondary culture, an increased number of proliferation and IFN-y producing CTLs 
was seen compared to conditions of sustained PGE2, therefore suggesting that the suppressive effects 
of PGE2 were reversible if the stimuli is removed(179). Lastly, cell lysates from the experiment 
showed a significant increase in intracellular cAMP levels in the PGE2 induced suppressed cells, 
suggesting that PGE2 immunosuppression acts through an cAMP dependent mechanism(179). 
         Overall the immunological effects of PGE2 vary vastly, depending on the cell type, the 
receptors stimulated and concentration achieved. However, studies would suggest that increased 
levels(1um) of PGE2, if sustained, induce an immunosuppressive response and could be, in part, 
responsible for the immunosuppressive TME. 
 
1.8.5 Renca Model 
CD8+ T Cells are a key mediator of tumour specific cytotoxicity. CTLs play an integral role in the 
suppression of tumour development and therefore must be overcome for tumour formation. Many 
tumour mediated cellular interactions, such as the expression of co-inhibitory receptors and 
suppressive soluble molecules, have been shown to CTL responses. To examine tumour specific 
CD8 T cells responses, our laboratory has developed and utilized a transgenic BALB/c murine 
renal carcinoma model,(Renca), model in which Renca cells are made to express the 
haemagglutinin(HA) protein from influenza virus A/PR/8(H1N1) as a neo-self-antigen and can be 
primed and killed by KdHA -specific TcR transgenic CL4 CD8 T cells.  Studies have showed that 
PGE2  is able to decrease proliferation of CL4 T cells in response to RencaKdHA , due to its ability 
to reduce IFN-y production which is required to upregulate ICAM-1 expression, which is essential 
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for priming of naïve CL4 T cells as they express do not express classical costimulatory co-
stimulatory molecules CD80 / CD86(91).   
 
1.9 Aims and Objectives 
1.9.1 Investigate tumour-mediated suppression by PGE2 
It is accepted that the tumour microenvironment(TME) plays a role in inducing suppressing the 
CTL activity of CD8+ tumour infiltrating lymphocytes(CTL).  Using the Renca / CL4 tumour 
model, the study aims to determine whether or not PGE2 is capable of suppressing the effector 
function of activated CTLs. 
 
Hypotheses: 
• PGE2 inhibits stable maintenance of the immune synapse. 
• PGE2 affects TCR signalling 
• PGE2 suppresses cytolytic function of activated CTLs. 
• PGE2 suppresses the proliferation of CTLs 
 
The study aims to identify any alternations to the stability immune synapse as well as the actin 
patterning, post exposure to PGE2 for 24hrs, as this time length is representative to the time CTLs 
spend in the in vitro spheroid model and within the tumour microenvironment when utilised in an 
adoptive transfer model. The immune synapse studies shall be complete this using confocal 
microscopy of retrovirally transduced CL4 T cells following PEG2 exposure. In addition, 
investigations shall aim to determine whether PGE2 effects TCR signalling. Calcium signalling shall 
be analysed using widefield microscopy of Fura-2 dyed CL4 following 24hr PGE2 exposure. 
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         In order to determine the effect of PGE2 on the function of CTLs both kill and proliferation 
assays shall be completed using CTLs cultured with/without the presence of 1um PGE2 from 
priming. 
 
1.9.2 Develop novel tumour model 
Much of the work in our lab has focused on the interactions of CL4 CD8 T cells with the Renca  
cells.  To determine whether there are common or unique processes regarding tumour mediated 
immune suppression associated with the Renca and other tumour cell types we wish to develop new 
BALB/c models of tumour derived from other tissue origins. CT26 cell line consists of fibroblasts 
derived from a colorectal carcinoma(180). 4T1 cell line is an epithelial line originating from a 
mammary carcinoma; and is highly metastatic(181).  Studies are aimed at characterizing the cell 
surface molecular phenotype of the 4T1 and CT26 cells by flow cytometry, as this will enable us to 
ascertain their ability, when pulsed with KdHA; or later stably transfected with an HA-expressing 
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2. Methods and materials 





Title Components Use 
Complete 
Media  
RPMI 1640 plus L-glutamine(Gibco), supplemented with 10% 
FBS(Sigma), 100uM Penicillin Streptomycin(Gibco) and 50uM 
mecarptoethanol(Gibco). 
Cancer cell line culture 
T cell Media  
RPMI 1640 plus L-glutamine(Gibco), supplemented with 10% 
FBS(Sigma), 100uM Penicillin streptomycin (Gibco) and 20uM 
mecarptoethanol(Gibco).  
T Cell culture in the 
absence of IL-2 
IL-2 Media  
RPMI 1640 plus L-glutamine(Gibco), supplemented with 10% 
FBS(HyClone), 100uM Penicillin streptomycin(Gibco) and 20uM 
mecarptoethanol(Gibco), supplemented with 50ul/ml IL-
2(NIH/NCI BRB Preclinical Repository) 
T Cell culture 
Incomplete 
Media 
DMEM(Gibco) supplemented with 10% FBS(HyClone), 100uM 
Penicillin streptomycin (Gibco) and 100uM Non-essential amino 
acids(Gibco). 
Phoenix cell culture 
FACs Buffer 
Dulbecco’s PBS(Gibco) supplemented with 0.5% BSA(Sigma 
Aldrich). Flow Cytometry staining 
MACs Buffer 
FACs buffer as described above, supplemented with 2mM 




Dulbecco’s PBS(Gibco), supplemented with 10% 
FBS(HyClone) and 100uM MgCL2 and CaCl2. 
Live confocal microscopy, 
wide-field microscopy and 
Flow cytometry sorting 
Chloroquine 
Saline 
Chloroquine diphosphate dissolved in dH2O at 4.1mg/ml(1M) Retroviral production 
Fluorobrite 
Medium 
Fluorobrite DMEM(Gibco), with 10% FBS(Sigma), 100uM 
Penicillin/Streptomycin(Gibco), and 50uM mecarptoethanol, 
supplemented with 100uM L-Glutamine 
Incucyte imaging-based 
killing assay 
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2.2 Mouse breeding and maintenance 
2.2.1 Mice 
All mice used throughout the project were Thy1.1+/+ BALB/c. Both transgenic CL4+/- mice, 
expressing monoclonal TCR CD8+ T cells, and CL4 -/- mice were used for immunological studies. 
All mice were bred and housed at the University of Bristol Animal Services Unit in pathogen free 
conditions. Any experiments utilising mice were conducted in accordance with U.K Home Office 
guidelines.  
 
2.2.2 Clone 4 Genotyping 
Genotyping was used to determine which bred mice exhibited the CL4 monoclonal CD8+ T Cell 
phenotype. Blood was extracted through the tail vein of each mouse and diluted using FACS buffer. 
Samples were centrifuged(1400rpm, 5min) and supernatant discarded. The pellet was resuspended 
in Ack Lysis buffer(Thermo Fisher Scientific), a solution causing erythrocyte lysis.  Cells were 
washed using FACS buffer and extracellularly antibody stained for CD8b(APC) and Vb8.1(FITC) 
for 30 minutes before being washed twice to remove any superfluous antibody. Samples were run 
on a Novocyte 3000 Flow Cytometry analyser. Results were analysed using a gating strategy, found 
in appendix, identifying the ratio of CD8+ T cells expressing a Vb8.1 TCR allowing positive 
selection of CL4 mice. 
 
2.3 Tumour Cell Lines 
2.3.1 Renca  
The adherent Renca cell line stems from a murine renal carcinoma. Throughout the project 2 
additional transfected variants of the Renca cell line were used. Renca cells transfected to present 
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endogenous KdHA allowing for recognition by CL4 CTLs, deemed Renca HA. In order to 
maintain a HA presenting population, 100ug/mL geneticin(G418; Sigma-Aldrich) was added to 
culture media as a selective antibiotic.  In addition, Renca wild type cells transfected to emit 
mCherry red cytoplasmic fluorescence, named Renca mCherry. 250ug/mL hygromycin 
B(Invitrogen, Carlsbad, USA) was supplemented to the culture media, ensuring all surviving cells 
emitted mCherry red fluorescence. All Renca derivatives were split at a 1 in 9 ratio every 3 days or 
once they had reached 60-80% confluence, or 1 in 12 for the weekend.   
 
2.3.2 4T1 
The 4T1 cell line was a novel cancer cell line in the Morgan Lab. It is a highly tumorigenic and 
metastatic, mammary epithelial cancer cell line(181). The cells were subcultured using the same 
protocol as with Renca Cells however were split at a higher dilution, 1 in 15,  every 3 days due to 
their increased rate of proliferation. It became apparent that any cultures proceeding to grow to 
100% confluence resulted in mass cell death.  The 4T1 cell line had additionally been transfected to 
express the luciferase enzyme(Luc), allowing detection during in vivo models(182). 
 
2.3.3 CT26 
The CT26 cell line was new to the Morgan Lab. It is a fibroblastic colorectal cancer cell line, 
reported to metastasis in murine models(180). The fibroblastic origin of the cell line enable varied 
studies and investigations into the collaboration of types of cells within the tumour 
microenvironment. CT26 cells were split at the same ratios as Renca cells(1:9 and 1:12). Upon 
reaching 100% confluence CT26 cells were capable of growing upon one and other, inducing the 
formation of a tight fibroblastic mesh. 
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2.3.4 Subculture of Tumour cells 
The Renca cell line was maintained in either a T25cm2 or T75cm2 filter ventilated flasks(Corning, 
NY, USA). Cultures were stored in a humidified incubator, with 5% CO2 at 37oC. 
When splitting, culture media was discarded, and flask rinsed in 3-5ml of PBS(Gibco) to remove any 
excess protein. 0.5/1mL Trypsin-EDTA 0.05%(Sigma Aldrich) was added to the flask and returned 
to the incubator. Every 2-3 minutes the flask was visually examined under a microscope to detect 
detached cells. Flasks were gently tapped to aid detachment. After all cells had detached the trypsin 
was quenched using ~3 times the amount complete media and pipetted into a 15ml falcon tube. 
The suspension was centrifuged at 1200 RPM for 3 minutes. The supernatant was discarded leaving 
only the pellet of cells, which was then resuspended in fresh media at the required dilution. 
 
2.4 Liquid nitrogen storage 
2.4.1 Freeze down 
In order to store cancer cell lines for extended periods of time cells were conserved in Liquid 
nitrogen stores at -196oC. Cells were first detached from flasks using Trypsin-EDTA 0.05%(Sigma 
Aldrich). Once detached cells were counted and resuspended at 1-2x106 cells/mL in Freeze buffer. 
Freeze buffer was formed of 90% FBS(Gibco) and 10% DMSO. Once resuspended the solution was 
quickly aliquoted into Liquid Nitrogen flasks. The aliquots were placed in a ‘Mr frosty’ followed by 
a -80oC freezer for 24hrs, up to 3 months. For extended periods of time the aliquots were 
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2.4.2 Thaw 
Cells were thawed rapidly in hand/37oC waterbath, gentled pipetted into 9ml complete medium 
using a pasteur pipette and centrifuged at 1000rpm for 5 minutes. Supernatant was discarded, cells 
resuspended in 5ml complete medium and plated into a T25 cell culture flask before being 
incubated at 37oC. 
 
2.5 Cell Counting 
2.5.1 Haemocytometer 
10uL of cellular suspension was extracted and mixed with 10ul Trypan-Blue. 10uL of the 
cellular/trypan-blue solution was extracted, pipetted onto a Haemocytometer and viewed under a 
microscope. The 4 outer edge square of the haemocytometer were counted and totalled. From the 
count, the overall total cell count was calculated using the equation: 
 
 
2.5.2 FACS sorting of CL4 CTLs 
Florescence activated cell sorting was used to ensure correct cell numbers were utilised in sensitive 
experiments. Cells were resuspended in imaging buffer(10% FBS) and sorted for a variety of factors 
depending on the cell type and experiment. For kill assays, CTLs were gated on their size, for single 
cells, and for alive cells using Drax7(Pacific Blue). In addition, CTLs previously transduced to 
express GFP F-Tractin for imaging studies were sorted on a one long increase in GFP fluorescence 
to ensure sufficient emission was apparent for actin imaging. 
 
 
Total cell count ——————4 x 2 x 10
4  = cells/mL 
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2.6 T Cell Culture 
2.6.1 IL-2 supplemented CD8+ T Cell Culture 
CL4 +/- mice were killed in a humane manner, by either cervical dislocation or CO2 chamber, in 
accordance to Schedule 1 protocol and spleen surgically removed. The spleen was dissected, 
pulverised and washed with RPMI, through a 40um filter, leaving a splenocyte rich solution. The 
solution was then centrifuged,(1400rpm,5 minutes) and supernatant discarded. The cellular pellet 
was resuspended in 1mL Ack Lysis solution(Thermo Fisher Scientific) for 3 minutes, whilst 
continually shaken, to eliminate all erythrocytes. 50mL 0.5% Protein Media was used to quench the 
lysis buffer and the samples re-centrifuged. Once the supernatant had been discarded, the cellular 
pellet was resuspended in 5mL T cell media, and counted using a haemocytometer. Any clumps of 
fat were removed using a pipette tip. Once counted the cells were resuspended at 5x106 cells/mL in 
T cell media. 1mL of the splenocyte solution was loaded into individual wells of a 24 well plate 
along with 1ul KdHA and left overnight, allowing for a mixed lymphocyte reaction. The following 
morning, all wells were collected into corresponding conditioned falcon tubes and 
centrifuged(1400rpm, 5 minutes). Supernatant was discarded and cells washed 3 times in RPMI to 
remove any exogenous KdHA peptide. Cells were resuspended at 2.5x106 cells/mL in IL-2 media 
and 2mL plated into individual wells of a 24 well plate. IL-2 media was replenished bi-daily over the 
following two days by gently extracting and discarding 1mL media, replacing it with fresh IL-2 
media before re-suspending. If the cells were confluent, each well was split into two by re-
suspending the wells before extracting 1mL and moving it to a neighbouring well. 1mL IL-2 media 
was then added to each corresponding well. 
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2.6.2 Newly Developed CD8+ T Cell Culture 
A CL4-/- mouse were killed in a humane manner, by either cervical dislocation or CO2 chamber, 
in accordance to Schedule 1 protocol and spleen surgically removed. The CL4-/- spleen was 
dissected and pulverised through a 40uM filter, washed with RPMI. The resulting suspension was 
centrifuged and supernatant discarded. 1mL Ack Lysis buffer was used to resuspend the cellular 
pellet and shaken for 3 minutes, to eliminate all erythrocytes. The solution was quenched using 
39mL of 0.5% protein media and centrifuged. Supernatant was discarded and pellet resuspended in 
30mL T Cell media. The splenocyte solution was then irradiated for 42 minutes at a distance of 
27cm from the gamma irradiation source(Irradiator), exposing splenocytes to 3000 Rads.  
         Following irradiation, splenocytes were centrifuged, washed once, and resuspended in 1ml T 
cell media, along with 5ul KdHA peptide. The peptide loaded solution was incubated for 1hr at 
37oC. A CL4+/- mouse was killed in a humane manner, by either cervical dislocation or CO2 
chamber, in accordance to Schedule 1 protocol, and spleen prepped as previously described. Post 
Ack Lysis buffer the cells were washed 3 times until being resuspended at 5x105 cells/mL. Once the 
hour was complete the CL4-/- splenocytes were washed 3 times, counted using a haemocytometer, 
and resuspended at 5x106 cells/mL. Both solutions were then plated in a 24 well plate, with 1mL of 
each solution per well, resulting in a 1:10 ratio of CL4+/- to CL4-/- cells respectively. The culture 
was placed in the humidified incubator 37oC for 96 hours, until needed.  
 
2.7 Retroviral transduction of CL4 T cells 
2.7.1 Plasmid Mini-prep 
Plasmids been previously stored in a bacteria glycerol stock, or as eluted DNA. Competent NEB 5a 
E.coli were heat shocked inducing the uptake of pre-existing eluted DNA. The competent E.coli was 
thawed on ice. Once thawed ~1-5ul eluted DNA was added to the cells, and kept on ice for 20-30 
minutes. The DNA and cell solution was placed from ice into a 42oC waterbath for 30-60 seconds, 
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before being returned to ice for an additional 2-3 minutes. 250ul LB broth was added to the solution 
and sewn onto a supplemented agar plate to be grown over night at 37oC. In glycerol stocks, 
extraction of the plasmid entailed sewing the bacteria onto an Agar plate supplemented with 1% 
Ampicillin and grown over night. Individual colonies were extracted using a sterile inoculation loop, 
and used to inoculate 3ml of LB broth, before being placed in a shaking incubator for 16 hours, 
with the lids ajar. Bacterial overnight culture was centrifuged at 8000rpm for 3 minutes to form a 
pellet. Supernatant was discarded and pellet resuspended in 250ul Buffer P1(Qiagen) before being 
transferred into a micro centrifuge tube. 250ul Buffer P2(Qiagen) was added and the tube inverted 
4-6 times until the solution becomes clear, as lysis occurs. Within 5 minus 350ul Buffer N3(Qiagen) 
was added and mixed thoroughly. The solution was centrifuged at 13000 rpm for 10 minutes. 800ul 
supernatant was then pipetted into a QIAprep 2.0 spin column, centrifuged for 30-60 seconds and 
flow-through discarded. The wash was repeated using 750ul Buffer PE for 1 minute to discard 
residual buffer. The spin column was transferred into a sterile 1.5ml eppendorf tube. 50ul Buffer EB 
or autoclaved deionised water was added to the center of the QIAprep 2.0 spin column, let to rest 
for 1 minute and centrifuged for 1 minute at 13000rpm to elute the DNA. DNA samples were 
quantified using a Nanodrop spectrophotometer(Thermo Fisher Scientific, Karlsruhe, Germany) 
 
2.7.2 Plasmid Digest 
To ensure the plasmid acquired contained the correct gene a plasmid digest was completed. 3ul of 
eluted plasmid DNA was combined with the restriction enzymes: NDE1 and STU, and incubated 
for 1hr at 37c. A control of 3ul of the undigested of DNA was diluted in ddH20.  Agarose powder 
and ddH2O was mixed and the resulting solution gently warmed until all agarose had fully 
dissolved. Once clear, the solution was poured into a gel template and wells created using a pronged 
comb. When solid, the gel was slid onto an electrophoresis unit and submerged in 1% TAE(Tris 
base, acetic acid and EDTA). All samples were mixed with loading dye and pipetted into their 
corresponding wells, at the negative end of unit. 1Kb molecular weight ladders were loaded either 
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sides of the samples to enable the calculation of their sizes. The current was turned on and gel run 
for 1 hour. Upon completion the gel was removed from the unit and photographed using a 
Transilluminator for imaging and analysis. 
 
2.7.3 Phoenix Cells 
Phoenix cells are a mammalian retroviral producing cell line used to generate retroviruses for 
transfection. Phoenix cells are cultured in 3ml incomplete media. 1ml of 0.02% of EDTA(Thermo 
Fisher Scientific) was used to detach phoenix cells from them plate. Once detached, cells were 
extracted and centrifuged at 1200rpm for 3 minutes and supernatant discarded. The cells were 
resuspended in 6ml fresh Incomplete media, before being split and re-plated in a cell culture 
dish(Corning). 
 
2.7.4 Retroviral production 
In order to transfect Phoenix cells, 25ul Chloroquine was added drop-wise to Phoenix cell culture to 
prevent intracellular lysosome degradation of plasmid DNA.  2X HBS and 2ul NaOH were 
combined in a 50ml falcon tube(Corning), deemed Tube A.  500ul ddH2O and 62ul 2M CaCl2 was 
used to dilute 10ul of desired plasmid DNA, before being added drop wise into Tube A, whilst air is 
bubbled through the pre-existing solution. The resulting 1mL of precipitate was added drop-wise, 
onto the Phoenix cell culture. 
 
2.7.5 Transduction of Clone 4 CTLs 
Splenocytes were extracted from the spleen and stimulated with the KdHA peptide for ~18hrs, as 
previously described. Following stimulation the splenocytes were centrifuged(1400rpm, 5 min) and 
washed 5 times in RPMI. Before the final centrifuge Phoenix cell media, containing the retrovirus, 
was drawn from their plates and centrifuged (1200rpm, 3min) in a 15ml falcon tube alongside the 
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splenocytes. Once complete, the splenocyte media was discarded whilst 6ml of the Phoenix cell 
media was extracted leaving both pellets undisturbed at the base of the falcon tube. The pellet of 
splenocytes was resuspended in the retrovirus containing media and plated into 3 wells of a 6 well 
plate. This was then placed in a centrifuge(2hr, 1200rpm, 37c) initiating spinduction. Following 
spinduction the media was extracted, ensuring to not disturb the cells which were then resuspended 
in IL-2 media and cultured for 72hrs.  
 
2.8 Live cell imaging of CTLs 
2.8.1 KdHA pulsing 
Renca mCherry cells were used as APCs for imaging experiments. Renca mCherry cells were 
detached from their flask using Trypsin-EDTA(0.05%)(Thermo Fisher Scientific). Once detached 
cells, were quenched using complete media and extracted into a 15mL falcon tube. Samples were 
centrifuged(1200rpm, 3min), and resuspended in 1mL of complete media. The cells were counted 
and resuspended to make 1x106 cells/mL. 2ul/mL KdHA peptide was then added into the 
suspension and incubated for 60 minutes. Following incubation the suspension was centrifuged and 
washed twice using complete media. once washed the cells were resuspended at 5x105 cells in 
225uL.  
 
2.8.2 Live cell microscopy 
Renca-HA cells are counted and resuspended at 1x106 cells/mL. 1ml of cells is extracted and 2uL 
KdHA peptide added for 60mins. 6x104 conditioned CD8 T cells are sorted into an eppendorf 
containing 2X conditioned imaging buffer. Once peptide loading is complete, the Renca-HA cells 
are centrifuged and washed 3 times. Once washed, the 1x106 cells are resuspended in 450uL 
imaging buffer. CL4 CTLs were centrifuged in a microfuge. Imaging buffer was discarded, and cells 
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resuspended in 15uL of 2X conditioned imaging buffer. 50uL of imaging buffer was added into one 
well of a 384 well glass bottom plate, followed by 5uL of CL4 CTLs. Once all settled, the glass 
bottomed plate was placed onto of an oiled confocal or widefield microscope, and focused ensuring 
no air bubbles formed between the plate and lens. When in focus, 5uL of Renca-HA cells were 
added directly onto of the CTLs. As soon as Renca-HA cells fell into range, microscopy images 
were recorded.  
 
2.8.3 Fura Staining  
1uL Fura-2 dye was added to the CTLs, samples vortexed and incubated, 30 minutes RT. Peptide 
pulsed Renca cells were washed and resuspended to 3x105 cells/mL in imaging buffer. Once 
incubation was complete CTLs were washed and resuspended in 200uL 2uM PGE2 imaging buffer. 
The widefield microscopy images were taken through a 384 well glass bottomed plate. 5uL CTLs 
were added to wells containing 50uL imaging buffer ensuring no bubbles were formed and placed 
onto the inverted 40x oil-immersion lense. Once settled 4uL pulsed Renca cells were gently pipetted 
directly onto on the CTLs and widefield imaging started. DIC, 340nm and 380nm excitation 
images were taken every 10 seconds for 10 minutes. 
 
2.9 Proliferation assay 
2.9.1 CTV Proliferation assay 
Each aliquot of CTV dye was thawed at room temperature and dissolved in 20ul DMSO. Resulting 
solutions were stored at -20oC. CL4 splenocytes were extracted from the spleen and prepared, as 
previously described. Before priming CL4 cells were washed in PBS and counted. CTV dye was 
diluted 1uL in 1000uL PBS, per 4x106 CL4 splenocytes. If staining cell lines, the described dilution 
can be used up to 1x106 cancer cells. Once counted the CL4 splenocytes were resuspended in the 
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diluted CTV stain and incubated in the dark for 20 minutes at 37oC. Following incubation, the 
samples were quenched using 5 times, 0.5% protein media, and left in the dark for an additional 15 
minutes, RT. Once quenched samples were centrifuged and washed twice in T cell media. Stained 
CL4 splenocytes were resuspended to 5x105cells/mL in T cell media and plated using either of the 
culture methods previously described. If utilising tumour cells to prime, CD8+ T cells were first 
isolated using MACs before being stained. Following the required culture period, the samples were 
resuspended and cells Live/Dead stained, in addition to CD8+ stained before being run on a 
Novocyte Flow Cytometer system. 
 
2.9.2 Irradiation of Tumour cells 
A T25(cm3) flask of tumour cells was detached using 1ml Trypsin-EDTA 0.05%. Once detached the 
flask was washed using 3mL complete media and suspension collected in a 15mL falcon tube. The 
cells were centrifuged, and supernatant discarded leaving only the cellular pellet. The pellet was 
resuspended in 10mL complete media and transferred into a 50mL falcon tube. The flacon tube 
was then placed 33cm from the irradiation source and exposed for 9780 seconds, resulting in 9200 
Rads irradiation. Once complete the samples were centrifuged, supernatant discarded, and cells 
resuspended for counting. Cells were washed once and resuspended at 1x10^6 cells/mL. 100uL of 
the resulting suspension was added to individual wells of a 96 well plate along with the addition of 
MACs separated CL4 CD8+ T cells. 
 
2.9.3 MACs separation of CD8+ T cells 
A CL4 spleen was extracted and prepared as previously described. The CL4 suspension was washed 
twice in MACs buffer(1400rpm, 5min), resuspended in 600uL MACs buffer in addition to 50uL 
anti-CD8 MACs beads, and incubated for 30 minutes at 4oC. An LS column was placed in a 
midiMACs magnet, above an open 50mL falcon tube, and wetted using MACs buffer. Once 
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incubation was complete, cells were washed twice and resuspended in 5ml MACs buffer. The 
suspension was applied to the LS column(Miltenyi Biotec Ltd). Following the sample, 5mL MACs 
buffer was used to wash the LS column. Once complete, 5mL MACs buffer was added to the LS 
column whilst it was removed from the midiMACs magnet. A sterile plunger was used to forcefully 
push the solution through the column into a 50ml falcon tube, resulting in a CD8+ rich population 
of cells. Upon collection the CD8+ cells were washed using T cell media, counted and resuspended 
at 1x106 cells/mL in T cell media. 
 
2.10 Kill Assay 
2.10.1 IncuCyte imaging-based kill assay  
CTLs were cultured for 96 hours using either the IL-2 supplemented or novel culture method 
previously described. mCherry-Renca cells were detached from their flask, counted and centrifuged. 
Supernatant was discarded and the remaining cellular pellet resuspended at 3x105cells/mL. 50uL of 
mCherry-Renca were plated into individual wells of a glass bottomed 384 well plate and incubated 
until adherence(~3-4 hours). Once mCherry had adhered the cultured CTLs were harvested and 
sorted for live cells using fluorescence-activated cell sorting(FACs). 1.5x104 cells were sorted per well 
of Renca-mCherry cells, to ensure equal numbers of live CTLs would be added to each condition. 
CTLs were centrifuged on a microfuge and supernatant discarded. CTLs were resuspended to 
3x105cells/mL. 50uL of CTLs were added onto of the wells containing adhered mCherry-Renca 
cells at a 1:1 ratio, before being placed in the Incucyte incubated microscope. The plate was then 
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2.10.2 Novocyte flow cytometry-based kill assay  
CL4 splenocytes were extracted and cultured, using one of the previously described method. 
Tumour cells were stained with CTV, using the previously described method. Stained tumour cells 
were counted and resuspended to 1x106 cells/mL in complete media. 1mL cancer cells was 
transferred into an 15mL falcon tube along with the addition of 2uL KdHA peptide. All samples 
were incubated for 60mins at 37oC. Once complete, peptide loaded cancer cells were washed and 
resuspended to 1x106 cells/mL in complete media. CTLs were harvested, washed and resuspended 
at 1x106 cells/mL in complete media. 100uL of peptide cancer cells were plated in individual wells 
of a 96 well plate, in rows of repeats. One row of un-pulsed cancer cells was plated to ensure any 
effect seen is due to specific recognition of the HA peptide. 100uL CTLs were added to each well, 
resulting in a 1:1 target to effector ratio. 2 rows of 100ul pulsed cancer cells only were plated, along 
with 100uL additional complete media, to use as a growth and positive controls. The plate was 
incubated for 17 hours at 37oC. Upon completion the plate was centrifuged(1400rpm, 5min) and 
supernatant flicked off. PI was diluted 1:400 in accutase. All wells were resuspended in 150uL PI-
accutase solution for 10 minutes, to detach any surviving cells. 1 row of cancer cell only wells was 
collected into a 1.5mL eppendorf tube and placed in a heat block at 90oC to induce cell death and 
use as a control. When ready, the positive control was returned to a new sterile row on the plate, 
and the plate run on the Novocyte flow cytometer system. 
 
2.11 Antibody staining and flow cytometry 
2.11.1 Live/Dead Stain 
To determine live/dead cells Propidium iodide(PI) and Zombie NIR live/dead fixable dead cell 
staining kit(Biolegend) were used. PI staining enabled flow cytometry of samples with no need to fix. 
PI was diluted 1 in 400 in FACs buffer to form a staining solution. Samples were centrifuged and 
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supernatant discarded, before being resuspended in the PI solution. Resuspended samples were run 
instantly, and live cells detected through the lack of PI fluorescence.  
         Each aliquot of Zombie NIR dye was thawed at RT and dissolved in 100ul DMSO, with 
resulting solutions being stored at -20oC. Samples were washed in PBS, to remove any exogenous 
protein that may aberrantly interact with the dye. Zmb NIR was diluted in PBS to a 1:100 ratio. 
Cells were counted using a haemocytometer. Up to 1x106 cells were resuspended per 20uL diluted 
Zmb NIR solution, and left in the dark at room temperature for 15 minutes. Samples were washed 
twice using FACs buffer, before either being further stained or fixed using 1% PFA. 
 
2.11.2 Extracellular staining 
Extracellular flow cytometry staining was used to identify the expression of cell surface molecules on 
both tumour cells and CTLs. Live/Dead stained cells were washed twice in FACs buffer to remove 
any superfluous cell dye. Fc block(Invitrogen) was diluted 1uL in 50uL PBS, and used to prevent 
aberrant binding of targeted antibodies. 20uL diluted Fc Block was added and samples incubated 
for 15 minuets at 4oC. Fluorochromes used throughout the project include: Allophycocyanin(APC), 
Allophycocyanin -Cy7(APC-Cy7), Brilliant Violet 605(BV605), Brilliant Violet 655(BV655), 
Brilliant Violet 785(BV785), Fluorescein isothiocyanate(FITC), Phycoerythrin(PE), Peridinin 
Chrlorophyll Protein-Cy5(PerCP-Cy5), and Peridinin Chrlorophyll Protein-Cy7(PerCP-Cy7). 
Stains were diluted in either FACs buffer or PBS, as shown in Antibody Table. 50ul diluted 
antibody stain was added, for up to 1x106 cells and incubated at 4oC for 30 minutes before being 
quenched and washed. Experiments in which cells were stained with multiple fluorochromes also 
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2.11.3 Intracellular Staining  
Cells were counted and resuspended to 1x106 cells/mL in PBS. Resulting solutions were aliquoted 
to 250uL in single FACs tubes per condition tested. A control sample was prepared by adding 
250uL pervanadate solution to one sample for 5 minutes at 37oC. All samples were washed in 1mL 
PBS. Zmb NIR dilution was made 1uL per 100uL PBS, staining samples centrifuged and 
resuspended in 100uL of the Zmb NIR solution. Samples were incubated in the dark for 15 minutes 
at RT, before being washed in 1mL FACs buffer. Staining samples were centrifuged,(1400rpm, 
5mins) and resuspended in extracellular stains CD8+ and Thy1.1+. Staining occurred for 30 
minutes at 4oC. Samples were washed with 1mL FACs buffer and supernatant removed. Cells 
undergoing intracellular staining were fixed in 100uL phosflow cytofix(BD Bioscience), vortexed 
and left to incubate for 15 minutes at 4oC. Samples were washed twice, in 1mL FACs buffer, and 
supernatant discarded. 1mL permeable buffer(BD Biosciences) was added to each sample, vortexed 
and kept on ice in the dark for 30mins. Cells washed twice in 1mL FACs buffer and supernatant 
discarded. Intracellular antibody stains were prepared in permeable buffer. Each sample was 
resuspended in 50uL staining perm buffer solution and incubated at room temperature, 60mins. 
Samples were washed using 3mL FACs buffer before being fixed in 200uL 1% PFA, and analysed 
within 1 week.  
2.11.4 Statistics 
Data was analysed for significance, p<0.05, using GraphPad Prism.v7 software. Parametric data 
sets were compared using either a two tailed Student’s T Test or a one-way Anova with Tukey’s 
multiple comparison test. Un-parametric data was analysed using Kruskal-Wallis tests with 
Dunn’s multiple comparison test. When data sets were paired, a RM one-way Anova with 
Tukey’s multiple comparison test or a Friedman test with Dunn’s multiple comparison test was 
used for parametric and un-parametric data sets respectively.  
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3. Results and Discussion 
3.1 PGE2 mediated suppression of T cell signaling   
3.1.1 Introduction 
Naive T cells are primed, both directly and through cross presentation, within the lymph nodes. 
Priming occurs through stable interactions between CTLs and cells presenting MHC1/2 bound 
peptides that are recognised by specific TCR. Specific recognition and interactions occur through 
the formation of a stable synapse, deemed the immunological synapse(64). The immunological 
synapse is comprised of an accumulation of TCRs and specific co-signaling receptors, named 
supramolecular activation clusters(SMACs)(66). Stable SMAC formations induce the intracellular 
transmission of T cell signaling. It is vital that the immunological synapse is sustained for effective T 
Cell signaling and therefore for priming, proliferation, and effector function to occur(68).  
         Previous studies have proposed that one common mechanism of tumour mediated immune 
suppression is the inhibition of cellular polarisation and maintenance of the immunological 
synapse(135). An inability to sustain stable immunological synapses has been demonstrated in 
lymphocytes following tumour infiltration and is believed to be induced through multiple 
mechanisms within the tumour microenvironment(135). Recent studies have demonstrated the 
ability of Programmed death receptor-1(PD-1) to induce a polarisation impaired state, in turn 
disabling the immune synapse, leading to decreased cytolytic capabilities(135). Many soluble 
molecules have also been identified as potential candidates for inducing a suppressed immunological 
synapse phenotype, including adenosine and PGE2. Suppression of T Cell signaling can be 
identified through a collection of phenotypic attributes such as morphology, actin polarisation and 
subdued intracellular secondary signaling molecules.  
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3.1.2 Aims 
I. To assess the effect of PGE2 on the stability of the immunological synapse. 
II. To determine whether PGE2 effects intracellular actin dynamics of CTLs. 
III. To assess the effect of PGE2 on TCR signaling. 
 
3.1.3 Does PGE2 effect the stability of the immunological synapse? 
3.1.3.1 Morphology studies  
Previous studies have identified the loss of maintenance of a stabile immunological synapse as a 
potential common immunosuppressive mechanism. Following adoptive transfer, primed CL4 
CD8+ T cells were seen to exhibit an inability to maintain a stable immunological synapse, leading 
to loss of effector function and proliferation upon infiltration into the tumour 
microenvironment(135). Multiple immunosuppressive molecules are under investigation to 
determine whether they also induce an unstable immunological synapse as a mechanism of 
suppression. PGE2 has been suggested to play a role in tumour mediated immunosuppression and 
has previously been described to inhibit both CTL proliferation and effector function(91). 
         To determine whether PGE2 has an effect on the maintenance of a stable immune synapse, 
inducing an immunosuppressive effect, a variety of imaging-based assays were completed. CL4 
CD8+ T cells were primed using a mixed lymphocyte reaction and cultured for 96hrs. 1uM PGE2 
was added for the final 24 hours to represent potential time spent of CTLs within the tumour 
microenvironment. Once culture was completed, CL4 CD8+T cells were co-cultured with KdHA 
peptide loaded Renca mCherry cells. Interactions between CTLs and the Renca target cells were 
analysed using spinning disk confocal microscopy.  
          Morphological attributes were monitored over 15 minutes to determine whether the 
immunological synapse formed between CTLs and target cells was stable and sustained. CTLs often 
project lamella towards the target interface, increasing their stability. However, lamella projecting 
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away from the synapse, named off-site lamella, are indicative of an unstable immunological synapse. 
The percentage of cells exhibiting off-site lamella formation was recorded and presented in figure 
12. Following 24hr culture in 1uM PGE2, 25.8% percent of CL4 CTLs were seen to form off-site 
lamella throughout the assay. When compared to untreated CL4 CTLs(24.2%), no significant 
difference was seen in the percentage of cells producing off site lamella. In comparison, both 
untreated CTLs and CTLs cultured in 1uM PGE2 had a significantly lower percentage of off-site 
lamella formation than lymphocytes isolated from within the tumour 
microenvironment(TILs)(50.4%). The results suggests that PGE2 within the tumour 
microenvironment has little/no involvement in up-regulating off site lamella formation as seen in 
CTLs following tumour infiltration. 
         Further phenotypic investigation used differential interference contrast images, from live 
spinning disk confocal microscopy, to analyse the average interface diameters between CTLs and 
HA presenting Renca target cells. Shortening of the synapse diameter following initial interaction, 
was used to identify loss of stable interactions between CD8+ T Cells and their targets. The 
interface diameters of 50 cell couples were analysed, originating from the initial interaction and 
spanning 540 seconds, results presented in figure 13. A high level of variation was noted between 
cell couple interface diameter however no significant decrease in the diameter of the immunological 
synapse was detected at any point throughout the experiment, suggesting the maintenance of stable 
synapse interactions. The result therefore suggests that 1um PGE2 alone is not sufficient to induce 
the inhibition of the stable formation and maintenance of the immunological synapse, noted in TIL. 
However, the previously stated investigations only observed external morphological attributes of the 
cultured CTLs therefore further investigations were carried out to examine the internal cytoskeletal 
environment. 
 






















Figure 12: Off site lamella formation 
 Naive CL4+/- splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. Once primed splenocytes were resuspended to 2.5x106 cells/mL in IL-2 
media, and 2mL plated into individual wells of a 24 well plate. Resulting cells were cultured for an 
additional 72 hours. 1uM PGE2 was supplemented for the final 24 hours of CTL culture.  When culture 
was complete, 1x106 Renca mCherry cells were peptide pulsed with 2uL KdHA, for 1hr. Cultured CTLs 
were harvested, washed and sorted in 1uM PGE2 imaging buffer, using a BD influx sorter(BD bioscience) 
for x105 live cells. Resulting CTLs were centrifuged, supernatant gently extracted and resuspended in 
200uL 2uM PGE2 imaging buffer. Once peptide pulsed, Renca cells were washed and resuspended to 
3x105 cells/mL in imaging buffer. The microscopy images were taken through a 384 well glass bottomed 
plate. 5uL CTLs were then added to wells containing 50uL imaging buffer ensuring no bubbles were 
formed and placed onto the inverted 40x oil-immersion lense. Once settled 4uL pulsed Renca cells were 
gently pipetted directly onto on the CTLs and imaging started. DIC images were captured every 20 
seconds for 15 minutes. Resulting images were analysed for off site lamella formation, using Metamorph 
computational software. No significant increase in off site lamella formation following 24hr treated with 
1uM PGE2 was detected when compared to the untreated CL4 control(n=50). CL4 control and Tumour 
infiltrating lymphocytes were provided by Dr Rachel Ambler(135) and were recorded over many biological 
repeats to ensure accurate representative results. 




































Figure 13: CTL Interface diameter 
Naive CL4+/- splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. Once primed splenocytes were resuspended to 2.5x106 cells/mL in IL-2 
media, and 2mL plated into individual wells of a 24 well plate. Resulting cells were cultured for an additional 
72 hours. 1uM PGE2 was supplemented for the final 24 hours of CTL culture.  When culture was complete, 
1x106 Renca mCherry cells were peptide pulsed with 2uL KdHA, for 1hr. Cultured CTLs were harvested, 
washed and sorted in 1uM PGE2 imaging buffer, using a BD influx sorter(BD bioscience) for x105 live cells. 
Resulting CTLs were centrifuged, supernatant gently extracted and resuspended in 200uL 2uM PGE2 
imaging buffer. Once peptide pulsed, Renca cells were washed and resuspended to 3x105 cells/mL in imaging 
buffer. The microscopy images were taken through a 384 well glass bottomed plate. 5uL CTLs were then 
added to wells containing 50uL imaging buffer ensuring no bubbles were formed and placed onto the inverted 
40x oil-immersion lense. Once settled 4uL pulsed Renca cells were gently pipetted directly onto on the CTLs 
and imaging started. DIC images were captured every 20 seconds for 15 minutes. Resulting images were 
analysed, and interface diameters measured, using Metamorph computational software. No 
significant changes in the interface diameter were detected across the duration of the assay.(n=50) 
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3.1.3.2 Does PGE2 effect the actin dynamics of the immunological synapse? 
In order for cytotoxic T cells to complete their effector function against target cells, including cancer 
cells, they must produce a stable immunological synapse, following recognition. The immunological 
synapse comprises a tight, cell coupling, interface that enables the release of cytolytic granules, 
containing both perforin and granzymes, in a specific targeted manner, preventing adjacent cell 
damage(183). The immunological synapse is maintained through the formation and maintenance of 
a peripheral actin ring at the interface, stabilising the interaction(184). Studies have identified 
impaired CTL synapse maintenance as an induced suppressed phenotype, following CTL 
infiltration into the tumour microenvironment(135). Suppression was partially rendered through the 
loss of a sustained actin presence at the immunological synapse, resulting in the destabilisation of 
peripheral actin ring formations, and therefore synapse function(135). PD-1was identified to have a 
key role in inducing the polarisation impaired state seen in tumour infiltrating lymphocytes(135). 
PD-1 is but one mechanism unregulated within the tumour microenvironment to aid immune 
evasion. PGE2 is commonly unregulated within multiple cancer types and is believed to utilised as 
an immuno-suppressive mechanism by cancer cells(186).  
         In order to determine whether or not PGE2 contributes towards inducing the impaired 
maintenance of CTL immunological synapses,  the pattern of interface actin accumulation of CTLs 
following 1uM PGE2 treatment were investigated. F-tractin-GFP transduced CL4 CD8+ T cells 
were co-cultured with KdHA presenting Renca mCherry cells as targets. The culture was examined 
using epifluorescent live spinning disk confocal microscopy over 15 minutes, with GFP Fluorescence 
and DIC images taken every 20 seconds. CTL:Target cell conjugates were detected and actin 
dynamics analysed, 40 seconds before and 480 seconds after initial synapse formation. Resulting 
data was compared against both CTL controls and TIL data(collected by Dr Rachel Ambler).  
         Total actin accumulation levels depict the ability of CTLs to effectively polarise their 
intracellular cytoskeleton. 24 hours treatment with1uM PGE2 was not shown to induce any 
disabling phenotypic changes in CTL interface actin dynamics. As shown in figure 14, the level of 
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total actin accumulation saw no significant changes throughout the time course, following 1uM 
PGE2 exposure. TIL data prototypically demonstrates a reduction in actin dynamics, experiencing 
significantly decreased total actin accumulations at multiple time points across the assay. 
         Further investigations examined the level of CTL peripheral actin ring formation. Upon first 
glance the level of peripheral actin ring formation and maintenance in CTLs treated with1uM 
PGE2 does appear to be lower across the majority of the assay, placing its time course curve almost 
midway between CTL and suppressed TILs however when tested the results showed no significant 
alterations in the overall level and trend in peripheral actin formation and maintenance. At 180 
seconds, PGE2 treated CTLs were seen to have a significantly decreased peripheral actin expression. 
However, by the following time point, re-sustained levels of peripheral actin ring formation were 
noted to exceed the untreated control, therefore deeming the overall change non-suppressive. 
Examination of TIL data clearly demonstrates their inability to form and maintain peripheral actin 
rings structures, overall suggesting 1uM PGE2 to not have any significant immunosuppressive effect 
on intracellular actin dynamics. 
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Figure 14: Actin interface patterning.  
Naive CL4 splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with KdHA, as 
described in methods. 15x10^6 primed splenocytes were harvested, washed and resuspended in 6ml retroviral rich 
phoenix cell supernatant. 2mL cellular suspension was plated into single wells of 24 well plate, supplemented with 
2uL protamine sulphate, and centrifuged for 2hr at 200xg, 32oC. Following spinduction, the phoenix cell media 
was carefully discarded and each well of cells resuspended in 2mL IL-2 media. Resulting cells were cultured for an 
additional 72 hours. 1uM PGE2 was supplemented for the final 24 hours of CTL culture.  When culture was 
complete, 1x106 Renca mCherry cells were peptide pulsed with 2uL KdHA, for 1hr. Transduced CTLs were 
harvested and sorted in imaging buffer, using a BD influx sorter(BD bioscience) for live cells exerting a 1 log 
increase in GFP emission. Once peptide pulsed, Renca cells were washed and resuspended in imaging buffer. The 
microscopy images were taken through a 384 well glass bottomed plate. 5uL CTLs were then added to wells 
containing 50uL imaging buffer ensuring no bubbles were formed and placed onto the inverted 40x oil-immersion 
lense. Once settled 4uL pulsed Renca cells were gently pipetted directly onto on the CTLs and imaging started. 21 
z-stack images were captured every 20 seconds along with a single DIC reference image, for 15 minutes. GFP 
images were analysed using Metaphorph computational software.(n=48) 
A. Total interface actin accumulation - 1uM PGE2 treated cells(Green) showed no significant difference in 
total actin accumulation when compared with untreated CL4(Red) and TILs(Black). 
B. Peripheral actin accumulation - 1uM PGE2 treated cells(Green) showed no significant difference in 
peripheral actin maintenance compared with untreated CL4(Red). TILs(Black) demonstrate the 
destabilisation of peripheral actin formation, indicative of an unstable immune synapse. 
C. Summary actin patterning of 1uM treated CL4 - High levels of total interface actin accumulation, 
coupled with efficient maintenance of peripheral actin patterning suggest dully functioning actin polarisation 
and stable immunological synapse formation. 
A B 
C 
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3.1.2 Does PGE2 effect T cell signaling? 
3.1.2.1 Lck signaling 
Formation of the immunological synapse is controlled by multiple molecular interactions between 
the CD8+ T Cell and its target(105). TCR recognition of a specific MHC1 bound peptide enables 
clustering of both TCRs and co-signaling molecules(106). The formation of these SMACs ultimately 
leads to the induction of multiple intracellular signaling cascades. When key co-signaling molecules 
CD8 migrates towards the central SMAC(cSMAC) it brings with it lymphocyte specific protein 
tyrosine kinase(Lck), bound to its intracellular tail(68). Lck is a crucial kinase that transmits T cell 
signaling through phosphorylation of multiple downstream signaling complexes. Lck activity is 
primarily controlled through 2 independent phosphorylations of both Y505 and Y394. 
Phosphorylation at Y505 is an inhibitory phosphorylation, causing an inactive protein 
conformation, whereas phosphorylation at Y394 is stimulatory driving kinase activity(67). Migration 
of Lck towards the peripheral SMAC induces the dephosphorylation of the inhibitory Y505 
phosphate group, enabling transphosphorylation and in turn increased Lck activity(69). 
Phosphorylation has also been reported to occur simultaneously at both sites and is considered 
active(187). The mechanistic control of Lck activity enables it to be utilised as an indicator of active 
T Cell signaling.  
     Therefore, to assess whether intracellular T cell receptor signaling was affected by the presence 
of PGE2, Lck phosphorylation status of the T cells was investigated following culture in the 
presence of 1uM PGE2. Cells were primed and cultured in the absence of IL-2 for 24hrs, before the 
addition of 1uM PGE2. In addition, a group of cells were treated with TG4-155, an EP2 specific 
blocker, and further samples treated with both PGE2 and TG4-155. Following a 72hr culture 
period, the T cells were intracellularly flourescently stained for phosphorylation at Y505, Y394 in 
addition to total Lck phosphorylation and analysed using flow cytometry. Pervanadate induces 
phosphorylation of all intracellular proteins and therefore was used as a positive control.  
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         Results, depicted in figure 15, show a decreased percentage(30.1%) of cells exhibiting 
phosphorylation at both Y505 and Y394(Double positives) following 1uM PGE2 culture compared 
to the untreated CTL control(48.9%). In contrast, the results demonstrate an increase in the 
percentage of cells with solely Y394 phosphorylation(54.2% vs 43.2%) possibly indicating clustering 
of Lck. However little change in the overall concentration of activate Lck was noted. Nonetheless, 
an increased percentage of the PGE2 treated cells were seen to lack phosphorylation of both Y505 
and Y418(double negative)(15.0%), associated with the inactive conformation Lck, therefore 
implying a potential decrease T cell signaling efficiency and therefore the possibility of a suppressed 
phenotype induced via 1uM PGE2. Simultaneous to the potential suppression via PGE2, the results 
show a substantial increase in the active conformation of sole phosphorylation at Y394 following 
CTL treatment with TG4-155(73.8%), potentially denoting increased Lck clustering and 
enhancement of T cell signaling. An increase in T cell signaling following EP2 blockade could imply 
a role of PGE2 in suppressing SMAC formation and therefore T cell signaling. Yet the overall 
changes in percentage of phosphorylations were not seen to be significant deeming the test 
inconclusive.  
         The lack of significant identification of altered Lck phosphorylation was believed to be due to 
the inability to isolate cells undergoing cell coupling at the time of analysis. Meanwhile recent 
studies have developed an imaging-based flow cytometry method that should overcome the issue by 
enabling isolation of solely coupled cells for analysing in order to detect Lck phosphorylation(189). 
Therefore instead, further exploration focused on utilising intracellular calcium signaling as 










































Figure 15: Phosphorylation status of Lck following 1uM PGE2 treatment. 
Naive CL4+/- splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. Once primed splenocytes were resuspended to 2.5x106 cells/mL in T cell 
media, and 2mL plated into individual wells of a 24 well plate. Resulting cells were cultured for an 
additional 48 hours in the presence of 1uM PGE2. Cells were counted, washed twice and resuspended to 
1x106 cells/mL in PBS. 250uL was extracted into 5 FACs tube samples, in addition to necessary USC and 
FMO controls. One sample was treated with 250uL pervanadate for 5mins at 37oC. All samples were 
washed in 1mL PBS, and Live/Dead stained using Zmb NIR, using method described. A Zmb only 
control was fixed in 1% PFA, and remaining samples treated with 50uL Fc Block(diluted 1ul:100uL) for 
15 mins, at 4oC. Cells were washed once, and extracellularly stained, along with FMOs, in 50uL diluted 
antibody for Thy1.1 and CD8b, to identify CL4 CD8+ cells. After 30mins, at 4oC samples were washed in 
1mL FACs buffer, fixed in preheated 37oC 100uL phosphlow cytofix, vortexed and incubated for 15mins, 
4oC. Samples were washed and resuspended in 1mL perm buffer and kept on ice for 30 mins. Following 
one additional wash, intracellular staining was completed, as described in methods, using 50uL antibody 
stain for 60 mins at room temperature. FMOs were made. Intracellular stains targeted: Lck Total, Lck 
505 and Lck 418. Anti-Lck 418 antibody was used as a proxy measure as it is only able to bind when 
Y394 is phosphorylated resulting in active conformation. Samples were washed and fixed in 200uL 1% 
PFA and run within 1 week. No significant changes in Lck Phosphorylation were noted(n=1). 
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3.1.2.2 Calcium Signaling 
Calcium ions(Ca2+) act as an intracellular secondary messenger, transducing extracellular signals to 
the internal environment(78). As calcium ions hold a positive charge they are unable to freely move 
across both the cell surface membrane and the membrane barrier of the endoplasmic reticulum, 
allowing for their regulation via specific membrane channel proteins, making them extremely useful 
in signal transduction. Upon T cell:target interaction a path of phosphorylations transmits the initial 
signal from cell surface receptors to a multitude of the intracellular signaling domain, ultimately 
inducing the hydrolysis of PIP2 into DAG and Inositol triphosphate(IP3)(73). IP3  is a signaling 
molecule that, when produced, induces the release of intracellular Ca2+ ions from endoplasmic 
reticulum into the cytoplasm(77). The increase in cytoplasmic Ca2+ induces the opening of calcium 
release-activated cell Ca2+ channels within the cell surface membrane causing a further influx of 
Ca2+ into the cell. The process of intracellular Ca2+ influx is a key step in the transmission of T 
cell signaling and therefore allows detection of successful T Cell signaling. 
         To analyse intracellular calcium signaling CTLs were primed, via an MLR, and cultured in 
IL-2 media for 96hrs. 1uM PGE2 was added for the final 24hrs in attempt to mimic the potential 
time spent within the tumour microenvironment/spheroid model. Following culture, the CTLs 
were stained using FURA-2 dye. FURA-2 dye is a fluorescent dye that binds to intracellular calcium 
that enables detection in changes of calcium levels. The membrane permeant ester nature of 
FURA-2 allows the dye to freely diffuse into the cytoplasm where it is cleaved by cellular proteases 
leaving a polarized form of the dye trapped within the cell(190). Once dyed the cells are co-cultured 
with target Renca cells and examined using UV-widefield microscopy. FURA-2 excites at 
wavelengths 340 and 380 outputting emissions in a ratio-metric fashion, allowing the calculation of 
intracellular calcium levels. The average intensity of the emission ratio per cell was recorded, 
starting 60 seconds before immunological synapse formation and for 8 minutes post, as presented on 
figure 13.  
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         The graph, figure 16, shows untreated CTLs and those treated with 1uM PGE2 to exert an 
initial influx of intracellular calcium throughout synapse formation. Untreated CTLs show the peak 
of their intracellular calcium levels following 1 interval(10 seconds) after initial synapse formation, 
whereas PGE2 treated CTLs are seen to continually increase for an additional 60 seconds, however 
the difference seen is not deemed significant implying the occurrence of efficient T cell signaling. In 
contrast both TILs and spheroid infiltrating lymphocytes(SILs) show little/no significant increase in 
calcium levels throughout the formation of the immunological synapse spanning the whole 540 
second assay, clearly demonstrating evident T cell signalling suppression. Following synapse 
formation PGE2 treated CTLs show sustained high levels of Ca2+, comparable to that seen in 
untreated CTLs, showing evidence for continual T Cell signaling and therefore no notable 
suppression. The results seen, further support that 1uM PGE2 is not sufficient to induce comparable 
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Figure 16: The effects of 1uM PGE2 on intracellular Ca2+ signalling as a measure 
of T Cell signalling. 
 Naive CL4+/- splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. Once primed splenocytes were resuspended to 2.5x106 cells/mL in IL-2 
media, and 2mL plated into individual wells of a 24 well plate. Resulting cells were cultured for an 
additional 72 hours. 1uM PGE2 was supplemented for the final 24 hours of CTL culture.  When culture 
was complete, 1x106 Renca mCherry cells were peptide pulsed with 2uL KdHA, for 1hr. Cultured CTLs 
were harvested, washed, resuspended in imagine buffer and sorted into 200ul 2uM PGE2 imaging buffer, 
using a BD influx sorter(BD bioscience) for 1.5x105 live cells. Resulting CTLs were centrifuged, 
supernatant gently extracted and resuspended in 500ul 1uM PGE2 imaging buffer. 1uL Fura-2 dye was 
added to the CTLs, and the sample vortexed and incubated for 30 minutes. Once peptide pulsed, Renca 
cells were washed and resuspended to 3x105 cells/mL in imaging buffer. Once incubation was complete 
the CTLs were washed and resuspended in 200uL 2uM PGE2 imaging buffer. The widefield microscopy 
images were taken through a 384 well glass bottomed plate. 5uL CTLs were added to wells containing 
50uL imaging buffer ensuring no bubbles were formed and placed onto the inverted 40x oil-immersion 
lense. Once settled 4uL pulsed Renca cells were gently pipetted directly onto on the CTLs and widefield 
imaging started. DIC, 340nm and 380nm excitation images were taken every 10 seconds for 10 minutes. 
Results show sustained levels of Ca2+  signalling in 1uM PGE2  treated CTLs throughout the duration of 
the assay. 
Low Ca2+ concentration High Ca2+ concentration 
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3.2 PGE2 suppression of cytotoxic T cells 
3.2.1 Introduction  
CD8+ Cytotoxic T cells play a vital role in tumour elimination through immunosurveillance. One 
immune evasion method utilised by tumours is the up-regulation and secretion of soluble 
immunosuppressive molecules, a key example being Prostaglandin E2(PGE2). PGE2 exposure has 
been demonstrated to induce immunosuppressive phenotypes in a plethora of immune cells. 
         Studies have demonstrated that 1uM PGE2 is capable of significantly inhibiting activation and 
proliferation of naive CD8+ T cells(91). The study shows, the 48hr culture of CTLs in 1um PGE2 is 
sufficient to cause both a decreased percentage of CD8+ T cells reaching the last 2 division, in 
addition to a 4-fold reduction in the production of IFN-y, identifying PGE2 as a potential immune- 
suppressive mechanism of direct priming following tumour metastasis(91). This effect was seen to be 
reversible, with no significant effect seen succeeding secondary culture without consistent 1uM 
PGE2 supplementation(179).  
          Inhibition of direct priming of CD8+ T cells is believed to contribute towards tumour 
growth(Ref). However, in addition CTLs are primed within the lymph node through cross 
presentation by profession antigen presenting cells(APCs). Antigen bound MHC 1 and 2 complexes 
are presented on the surface of APCs to naive CTLs along with sufficient co-stimulation through co-
signaling molecules CD86/CD80(191). CTLs are activated, via cross presentation, to target a 
tumour associated antigens and thus infiltrate into the tumour. Following tumour infiltration, 
activated lymphocytes are seen to exhibit a suppressed phenotype. This is due to a multitude of 
mechanisms employed by cancer cells that contribute to the tumour immunosuppressive 
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3.2.2 Aims 
I. To assess the effect of PGE2 on the priming of naive CTLs. 
II. To assess the effect of PGE2 on the cytolytic effect of CTLs. 
III. To determine whether the addition of exogenous IL-2 prevents suppression of CTLs by IL-2. 
 
3.2.3 Does PGE2 suppress priming and proliferation of CTLs? 
Previous studies have demonstrated 1uM PGE2 to exhibit a suppressive effect on the priming and 
proliferation of CD8+ T cells. Naive CD8+ T cells primed using either anti-CD3 + anti-CD28 or 
anti-CD3 + rICAM-1 in the presence of 1uM PGE2 were seen to exhibit significantly suppressed 
proliferative and effector function, determined through the decrease in percentage of cells reaching 
the final two divisions and decreased IFN-y production(91). Further studies confirmed increased 
levels(1uM) of PGE2 to exhibit suppression in direct priming of CTLs by Renca tumour cells(91). 
To investigate the effect of PGE2 on proliferation of naive T cells was also seen when priming by 
cross-presentation via APCs, proliferation assays were completed.  
           CL4 splenocytes were isolated and stained with Cell Trace Violet(CTV). CTV is a 
cytoplasmic stain that not only enables detection of specific cells but also depicts the number  of 
cellular divisions. As cells undergo proliferation, they divide into two daughter cells, therefore 
splitting their intracellular cytoplasmic environment, including CTV, into two. Staining cells with 
CTV allow for identification of numbers of divisions, represented as loss of CTV fluorescence when 
analysed using flow cytometry. The stained splenocytes were HA peptide loaded for 17 hours 
allowing for a mixed lymphocyte reaction(MLR), with or without the addition of varied 
concentrations of exogenous PGE2(0.1uM/1uM/10uM). MLR induces priming of naive CD8+ T 
Cells through cross presentation of the HA peptide through endogenous population of antigen 
presenting cells with the spleen. As only the monoclonal CL4 CD8+ T cell population is specific for 
the HA peptide, the CTLs undergo extensive priming and proliferation, outgrowing the alternate 
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splenocytes. Following 17hrs the cells were washed, removing any remaining exogenous HA 
peptide, and resuspended in splenocyte media supplemented with 50units/uM IL-2(+/- PGE2), and 
cultured for a further 72hrs. Throughout the culture the media was replenished twice daily to not 
only ensure sufficient nutrients but also a consistent concentration of PGE2.     
         Once CL4 CTLs had been identified using the gating strategy, shown in figure 17, the levels 
of CL4 CTL CTV emission were analysed using FlowJo software, and the percentage of cells 
reaching a minimum of 4 divisions compared, results presented in figure 18. 
         In the absence of PGE2 percentage of CTLs to reach at least 5 divisions, was seen to be 
59.76%, matching similarly to CTLs treated with 1uM PGE2 at 58.03%. CTLs treated with 0.1uM  
saw a slight decrease, 53.08%, in the number of CTLs reaching equal levels of proliferation. 
However, CTLs treated with 10uM PGE2 saw a substantial decrease, with only 41.2% of cells 
reaching the at least 5 divisions. As not all conditions passed Shapiro-wilk normality test, a Kruskal-
Wallis test was used to confirm the significant difference in levels of proliferation. The test 
confirmed a significant difference in the levels of proliferation following CTL treatment with 10uM 
PGE2(0.0132, p<0.05) when compared to the untreated control. In addition, further significance 
was also detected when comparing CTLs treated with 1uM and 10uM PGE2(0.0067 p<0.05). The 
results suggest that suppression of CTL proliferation is only seen following treatment with 10uM 
PGE2.  
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Figure 17: Proliferation assay gating strategy:  
Cultured CTV stained CTLs were centrifuged(1400rpm, 5min) and supernatant discarded. Cells 
were washed twice in PBS. Zmb NIR stain was diluted 1ul in 1000ul PBS. Samples were 
centrifuged, supernatant discarded, and resuspended in 20uL diluted stain for 15 minutes at room 
temperature. Live/Dead stained samples were washed twice and resuspended in 200uL FACs 
buffer.(A) Lymphocytes were determined based on cell size and granularity(FSC-H/SSC-H).         
(B) Single cells were detected from the lymphocyte population using FSC-H/FSC-A. (C) Zmb NIR 
Live dead staining allowed detection of alive cells due to the decreased APC-CY7 emission.           
(D) CTLs were identified through their CTV fluorescence and proliferation determined through 











Figure 18: Effect of PGE2 on the proliferation of CTLs.  
Naive CL4 splenocytes were harvested, counted and washed twice in PBS. CTV stain was diluted 1uL in 1000uL 
PBS. 1uL CTV was used per 4x106 cells. Splenocytes were centrifuged, supernatant discarded and resuspended 
in diluted CTV stain. CTV Staining was completed at 37oC for 15 minutes, followed by a 5x quench in 0.5% 
protein rich media and an additional 15 minute, dark incubation at room temperature. When complete, cells 
were washed 3 times in RPMI, re-counted and primed overnight using a mixed lymphocyte reaction with KdHA, 
as described in methods. PGE2 conditions(0uM/0.1uM/1uM/10uM) were added into separate wells at time of 
priming. 5x106 primed splenocytes per condition were harvested, washed and resuspended in 2ml IL-2 media 
supplemented with their corresponding PGE2 conditions. The cellular suspensions were plated into separate wells 
of a 24 well plate and cultured for 72 hours. Following culture, 1mL cells was extracted from each conditioned 
well and transferred into individual FACs tubes. Samples were washed twice in PBS and Live/Dead stained using 
Zmb NIR, as described in methods. Once stained, samples were extracellularly stained for both CD8(APC) and 
Thy1.1(FITC). Samples were fixed in 1% PFA and run on the Novocyte flow cytometer within 1 week. Analysis 
utilised a gating strategy, shown in figure 13, to identify alive CL4 CTLs. CTV emission was analysed and 
percentage of cells in the last two divisions calculated. Kruskall-wallis results show a significant difference(n=2, 
p=0.0036) between the group means. Individual comparative statistical tests identified a significant reduction in 
proliferation in CTLs treated with 10uM PGE2(p=0.0132). No significant difference was noted in cells treated 
with 0.1uM/1uM PGE2. 
<————— CTV 
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With previous studies demonstrating inhibition of CTL suppression at 1uM PGE2, the results seen 
were unexpected. Suppressed proliferation was only significantly demonstrated following a 10-fold 
increase in the concentration of PGE2 than previously reported. Further investigations into the 
matter, resulted in the belief that the culture method of CTLs was inhibiting the level of suppression 
seen. The current CTL culture method utilises 50units/ul IL-2 to supplement the culture media. 
Activated CTLs naturally produce IL-2 to further drive proliferation and differentiation in an 
autocrine and paracrine fashion. However, the increased levels of IL-2 are considered to be 
unphysiological and therefore potentially inhibit the level of suppression witnessed in the completed 
proliferation assays that utilise it in the culture method.  
         To test this theory additional proliferation assays were completed using the same method on 
the exception that no exogenous IL-2 was supplemented. In order to determine whether 1uM 
would be sufficient to induce a suppressed level of proliferation, the cultures were treated with either 
solely 1uM of PGE2 or PGE2 and TG4-155. TG4-155 is a specific EP2 receptor blockade. By 
treating cells with both PGE2 and TG4-155 we were able to identify whether it was specifically 
PGE2 inducing any effects seen. In addition, a group of cells were treated with solely TG4-155 for 
use as a control. The culture of CTLs in the absence of supplemented Il-2 required the proliferation 
assay to be completed after 72 hours, in contrast to 96 hours, as this was when the CTLs appeared 
most prevalent and healthy. Levels of proliferation were compared following FlowJo analysis, using 
the percentage of cells reaching their final 2 divisions, as seen in figure 19. 
         Results show a significant difference in proliferation following treatment of 1uM PGE2. 
42.43% of cells were seen to reach their final two divisions following treatment with 1uM PGE2, 
compared to 64.37% in untreated cells. Following the additional treatment of TG4-155 to 1uM 
pGE2 cultured cells the decrease in proliferation was seen to be partially restored, yet not 
completely, with 50.6% of cells reaching the final 2 divisions. The only partial restoration post EP2 
blockade implies the involvement of additional PGE2 receptors in inducing suppression of CTLs. 
EP2 and EP4 receptors primarily act in a similar function, both resulting in an increase of 
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intracellular cAMP. The remaining suppression may, therefore, be a result of EP4 stimulation by 
PGE2. TG4-155 treatment alone was not seen to affect the level of proliferation(62.4%), ensuring 
that any effect witnessed was PGE2 dependent. 
         The results were analysed pairwise, between biological repeats, to account for the high level of 
variability between murine CTLs. The pattern of proliferation suppression, as seen in figure 15, was 
consistent across all repeats further suggesting that suppression was being witnessed. A parametric 
one-way Anova statistical test confirmed the difference seen between groups was significant, with 
the 1uM PGE2 conditioned cells having a significant reduction in proliferation compared to the 
alternative conditions. 
          The results suggest that the up regulation of exogenous PGE2 reported within tumour 
microenvironment may be capable of inducing a suppressed phenotype in CTLS, decreasing 
proliferation of infiltrating lymphocytes and therefore suppressing their population. However, it is 
evident that the suppressive effect of 1uM PGE2 is only seen in the absence of supplementary IL-2. 
Comparisons between the two alternative proliferation assays would suggest that IL-2 acts to oppose 
immunosuppression induced by PGE2, in turn requiring increased levels of suppressive molecules to 
induce a suppressed proliferative phenotype. Moreover, the counteractive effect of IL-2 on immune 
suppression has been demonstrated to have an effect on proliferation yet further investigations must 
be completed to determine whether the effect is also evidence in cytotoxic capabilities. 
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Figure 19: Effect of 1uM PGE2 on the proliferation of CL4 CD8+ T cells when 
cultured in the absence of IL-2.  
Naive CL4 splenocytes were harvested, counted and washed twice in PBS. CTV stain was diluted 1uL in 
1000uL PBS. 1uL CTV was used per 4x106 CTLs. Splenocytes were centrifuged, supernatant discarded 
and resuspended in diluted CTV stain. CTV Staining was completed at 37oC for 15 minutes, followed by a 
5x quench in 0.5% protein rich media and an additional 15 minute, dark incubation at room temperature. 
When complete, cells were washed 3 times in RPMI, re-counted and primed overnight using a mixed 
lymphocyte reaction with KdHA, as described in methods. Experimental conditions(1uM PGE2/1uM 
PGE2 + 1uM TG4-155/1uM TG4-155) were added into separate wells at time of priming. 5x106 primed 
splenocytes per condition were harvested, washed and resuspended in 2ml T cell media with their 
corresponding conditions. The cellular suspensions were plated into separate wells of a 24 well plate and 
cultured for 48 hours. Following culture, 1mL cells was extracted from each conditioned well and 
transferred into individual FACs tubes. Samples were washed twice in PBS and Live/Dead stained using 
Zmb NIR, as described in methods. Once stained, samples were extracellularly stained for both CD8(APC) 
and Thy1.1(FITC). Samples were fixed in 1% PFA and run on the Novocyte flow cytometer within 1 week. 
Analysis utilised a gating strategy, shown in appendix, to identify alive CL4 CTLs. CTV emission was 
analysed and percentage of cells in the last two divisions calculated. An RM one-way Anova statistical test 
confirmed a significant difference(n=2, p<0.0001) between the group means. Individual comparisons 
confirmed a significant reduction(p<0.0001) in proliferation following 1uM PGE2  treatment. Suppression 




P + T 
TG4-155 
<————— CTV 
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3.2.4 Does PGE2 suppress cytotoxic function of CTLs? 
The key role of CTLs in immunosurveillance is the elimination of transforming/transformed cancer 
cells, thereby preventing tumour growth(26). CTLs capable of deterring tumour growth recognise 
cancer specific antigens presented bound to class 1 MHC complexes inducing infiltration into the 
tumour microenvironment, deeming the CTLs as tumour infiltrating lymphocytes(TILs). Upon 
recognition CTLs induce cytolysis of cancer cells via three primary mechanism: The release of 
cytotoxic granules, presentation of the Fas ligand, and the secretion of inflammatory cytokines. The 
cytolytic action of CTLs acts as a selection pressure within the tumour, leading to the evolution of 
multiple immunosuppressive mechanisms within the tumour microenvironment.  
         Many of the investigated immunosuppressive mechanisms, including up regulation of PD-1 
and CTLA-4, have demonstrated the induction of impaired cytolytic abilities, presenting a 
suppressed phenotype of CTLs (192). An additional proposed suppressive mechanism is the up 
regulation of COX-2 within tumour cells, consequently leading to increased concentrations of 
PGE2 within the TME (150). 1uM PGE2 has been demonstrated to suppress CTL priming and 
proliferation via both direct and cross presentation(91). However, the suppressive effects of 1uM 
PGE2 on proliferation were only witnessed in the absence of IL-2, where10uM was needed for 
suppression to be seen. To investigate whether PGE2 induced a suppressed cytolytic phenotype in 
CTLs, a newly developed  and optimised flow cytometry-based killing assay was completed.  
         A flow cytometry-based killing assay was developed utilising Cell Trace Violet(CTV+) 
cytoplasmic staining to detect target cells and allow quantification of levels of killing. CL4 
splenocytes were extracted from a mouse and cultured, in the presence of PGE2 for 72 hours post 
priming. Untreated CTLs cultured in the absence of IL-2 were used as a control comparison. Renca 
cells endogenously expressing the HA antigen(Renca HA) were used as target cells. Renca HA were 
stained using CTV before being peptide pulsed to ensure sufficient levels of HA antigen were 
presented to induce CTL recognition and cytolysis. Once peptide loaded, target cells and CTLs 
were co-cultured in a 96 well plate at a 1:1 ratio. Optimisation of the assay,(See appendix)  
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determined that a 1:1 ratio being the most effective and accurate for detecting a separation between 
live and dead populations in flow cytometry analysis. The plate was incubated for 17 hours allowing 
sufficient cytolytic effects to be detected, before being analysed using a NovoCyte flow cytometer 
system. The resulting data was analysed using the gating strategy seen below, in figure 20.  
         To determine whether PGE2 had a significant effect on the cytolytic ability of CTLs, the 
percentage of detected Dead cells were calculated and compared across the culture conditions. 
Results show an increase in cytolysis of target cells by CTLs when cultured in PGE2 . A Kruskal-
Wallis Anova confirmed a significant difference(p=0.0144) between the means of culture conditions 
demonstrating PGE2 to have an effect of cytolysis. Further multiple comparisons noted significant 
difference between the CL4 CTL control and all individual culture conditions containing 
PGE2(0.1uM <0.0001, 1uM =0.0286, 10uM=0.0022). However, no difference was noted between 
the PGE2 culture concentrations thereby determining the effect to be non-dose dependent. The 
killing assay results suggest PGE2 to aid CTLs in the elimination of tumour cells contrary to pre-
existing beliefs.    
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Figure 20: Investigating the effect of PGE2 on CTL specific cytotoxicity 
Naive CL4 splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. PGE2 conditions(0.1uM PGE2/1uM PGE2/10uM PGE2) were added into 
separate wells at time of priming. 5x106 primed splenocytes per condition were harvested, washed and 
resuspended in 2ml IL-2 media with their corresponding conditions. The cellular suspensions were plated 
into separate wells of a 24 well plate and cultured for 96 hours. 60-80% confluent Renca HA cells were 
detached from a T25 flask using 1mL Trypsin-EDTA. Detached cells were quenched in 4mL complete 
media, collected into a 15mL falcon tube and centrifuged. Renca HA cells were resuspended in 1mL 
complete media and counted. Additional complete media was added until 1x106 cells/mL was achieved. 
2uL KdHA was added to the suspension, and incubated for 60 minutes, at 37oC. Once complete cells were 
centrifuged(1200rpm, 3min), supernatant discarded and the cells washed twice in PBS. CTV stain was 
diluted 1uL in 1000uL PBS. 1uL CTV was used per 1x106 cancer cells. Renca HA cells were counted, 
centrifuged, supernatant discarded and resuspended in diluted CTV stain. CTV Staining was completed at 
37oC for 15 minutes, followed by a 5x quench in 0.5% protein rich media and an additional 15 minute, 
dark incubation at room temperature. When complete, cells were washed twice in complete media, re-
counted and resuspended to 1x106 cells/mL in complete media.  All cultured CTLs were harvested into 
separate 15mL falcon tubes corresponding to their culture conditions. All CTLs were washed in RPMI, 
and counted. CTLs were further washed and resuspended to 1x106 cells/mL in complete media. 100ul of 
both cancer cells and CTLs were co-cultured in repeated wells of a 96 well plate. 4 repeats were plated per 
condition, in addition to 4 wells of Renca HA only and 4 wells for a positive killed control. The plate was 
incubated at 37oC for 17 hours. When complete, media from the positive control wells was carefully 
extracted ensuring not to disturb the adherent cells. 150ul accutase was added to the positive control wells 
and incubated for 10 minutes at room temperature. Positive control wells were resuspended and collected 
into a 1.5mL eppendorf. The eppendorf was heated to 90oC for 10 minutes in a heat plate.  
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  The newly developed flow cytometry kill assay provides sustained comparable results to investigate 
the cytolytic ability of CTLs following the addition of PGE2 however one limitation may be the 
inability to detect a population post apoptotic target cells due to their size and the loss of CTV 
following cytolysis. To ensure the results being obtained were both accurate and reliable, an 
additional imaging-based kill assay was completed.  
         For the IncuCyte imaging-based assay to work, target cells must emit either green or red 
wavelength cytoplasmic fluorescence to allow detection. Therefore, Renca mCherry cells were used 
as target cells. Renca mCherry is a Renca cell line that has been transfected with a plasmid to 
induce cytoplasmic emission of red fluorescence.  Renca mCherry were plated into a glass bottomed 
384 well plate and incubated until adherence to the plate occurred. Once the mCherry cells had 
adhered cultured CTLs were harvested and sorted for live cells using fluorescence-activated cell 
sorting(FACs). Sorting ensured that equal numbers of live CTLs would be co-cultured. The CTLs 
were able to be sorted solely on live cells as over 90% of the remaining alive cells following 96 hours 
of culture were CL4 CD8+ cells, demonstrated previously. Once sorted, equal numbers of CTLs 
were added onto of the wells containing adhered mCherry Renca cells at a 1:1 ratio. The plate was 
then incubated for 18 hours in a IncuCyte live cell analysis system(Essenbioscience). 
         In order to quantify the level of cytolytic activity exerted by CTLs following the addition of 
PGE2. The total surface area of target cells, measured by the area of fluorescence(um2/well), was 
calculated and averaged across 4 repeat wells. The average at each timepoint was normalised in 
relation to the first time point to calculate the difference seen over time. Rolling averages were then 
The remaining plate was centrifuged at 1400rpm 5 mins, and supernatant discarded. PI was diluted 
1uL:400uL in accutase. 150uL PI solution was added to each remaining well, incubated for 10 minutes at 
room temperature and run within the hour. PI was added to the heated cell accutase at a 1uL:400uL ratio. 
150uL kill positive cells were pipetted into a new row of wells in the 96 well plate. All wells were 
resuspended and run on the Novocyte. Gating strategy seen in figure 16 was used to identify target cells 
including their live/dead populations. Percentage of dead target cells was determined and specific 
cytotoxicity calculated using the formula, noted in methods. A Kruskal Wallis anova confirmed significant 
differences between population means(n=4, p=0.0144). Multiple comparison tests deemed significant 
differences between CL4 CTL controls and all PGE2 treated groups(0.1uM, p<0.0001 / 1uM, p<0.0001 
/10uM, p<0.0003) . No significant difference was noted between the PGE2 treated groups.(n=4) 
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calculated at each time point to reduce short term fluctuations and instead emphasise the overall 
trend. The resulting rolling averages are plotted to allow identification of cytolysis, depicted by the 
decrease in target surface area, results shown in figure 21.  
         The results show a clear significant reduction in target cell surface area due to the CL4 CTL 
cytolysis. However, no significant difference is noted in CL4 treated with 1uM PGE2. Contrary to 
the previous test, the imaging-based assay concludes that 1uM PGE2 does not have an effect on the 
cytotoxic ability of CTLs. This is further depicted, in figure 22, by the gradient of the decrease in 
target cell surface area, as indicative of the rate of cytolysis. No significant effect following the 
addition of 1uM PGE2 was seen. As the imaging-based kill assay is well established assay and allows 
the identification of any confounding results through the acquisition of intervallic images, it is 
believed to be more accurate and reliable than the novel flow cytometry based kill assay, thereby 
confirming that PGE2 does not induce any significant effect in CTL cytolytic ability.  
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CL4 
Figure 21: Imaging based kill assay to determine the effect of 1uM PGE2 on CTL 
cytotoxic abilities  
Naive CL4 splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. PGE2 conditions(0uM PGE2/1uM PGE2) were added into separate wells 
at time of priming. 5x106 primed splenocytes per condition were harvested, washed and resuspended in 
2ml IL-2 media with their corresponding conditions. The cellular suspensions were plated into separate 
wells of a 24 well plate and cultured for 96 hours. 60-80% confluent Renca mCherry cells were detached 
from a T25 flask using 500uL Trypsin-EDTA. Detached cells were quenched in 4mL complete media, 
collected into a 15mL falcon tube and centrifuged. Renca mCherry cells were resuspended in 1mL 
complete media and counted. Additional complete media was added until 1x106 cells/mL was 
achieved. 2uL KdHA was added to the suspension, and incubated for 60 minutes, at 37oC. Cells 
were centrifuged, supernatant discarded and washed twice using 10mL RPMI. Once washed, 
Renca mCherry cells were re-counted, and resuspended to 3x105 cells/mL in Fluorobrite media. 
50uL Renca mCherry cells were plated in individual wells of a glass bottomed 384 well plate, and 
incubated until cellular adherence, at 37oC. 4 repeats per condition were plated. All cultured CTLs 
were harvested into separate 15mL falcon tubes corresponding to their culture conditions. All CTLs were 
washed in PBS, and resuspended in 1mL conditioned imaging buffer. 1.5mL eppendorf were prepared 
containing 200uL 2X conditioned imaging buffer, for each experimental condition. 
Renca only control  
(+/- 1uM PGE2) 
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Figure 22: Rate of CTL induced target cytolysis 
The gradient of each kill assay time curve was calculated by division of the change in surface area by time. The 
gradient of the increase in surface area demonstrated by the renca only control, was detracted from the resulting 
cytolytic gradients to account for the full change in surface are and therefore cytolysis over the time course. The 
results gradients were plotted on a bar chart to represent the rate of cytolysis. No significant difference in the rate 
of cytolysis was noted. 
CTLs were sorted using FACs for 60,000 alive cells per condition into their corresponding eppendorf, 
taking into account an un-pulsed control group. Sorted CTLs were centrifuged, 4000xg 4minutes, using a 
microfuge, and supernatant carefully extracted ensuring no disturbance to the cellular pellet. All CTLs 
were resuspended to 3x105 cells/mL in 2X conditioned Fluorobrite media. 50uL CTLs were added to 
corresponding target wells containing adhered Renca mCherry, immediately before the plate was placed in 
the IncuCyte imaging system for 18 hours. Total target cell surface area(um2/well) was measuring using 
red fluorescence masking, over the duration of the assay. The mean of 4 repeats was calculated per 
timepoint for each condition. Results were normalised, and rolling averages produce. Renca only controls(-
1uM PGE2 seen in yellow/+1uM PGE2 seen in light green) were used to demonstrate cell growth over the 
duration of the assay. The decrease in target cell surface area was indicative of target cell death via CTL 
cytolysis. No significant difference was detected between the rate of killing of 1uM PGE2 treated CL4(dark 
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3.2.5 Discussion 
The contribution of PGE2 on tumour development has been widely investigated. Primarily noted 
for its up regulation within the tumour microenvironment and its contributing role in Wnt signalling 
towards the development of colorectal cancer, studies have more recently begun to focus on the 
effect of PGE2 on the immune system following the increasing interest and development of 
immunotherapies(186). Historically known as a pro-inflammatory molecule, PGE2 has a 
multifaceted role in immune-regulation depending on the cell type, maturity and 
concentration(193). CD8+T cell play a key role in immunosurveillance of cancers and have been 
shown to exhibit suppressed phenotypes due to multiple up-regulated suppressive mediators within 
the tumour microenvironment, such as PD-1, CTLA-4 and PGE2(135). Previous studies 
demonstrated 1uM PGE2 to suppress CD8+ T cell proliferation when primed using classical co-
stimulation(91). In addition, 1uM PGE2 was also demonstrated to significantly decrease the level of 
IFN-y production inferring a decrease in effector function, suggesting a contributing role of PGE2 
in tumour mediated immunosuppression(91).  
         Our study further investigated the immunological effect of PGE2 on CD8+ T Cells, focusing 
on signalling, proliferation and cytotoxic ability. Live confocal microscopy enabled the evaluation of 
the stability of the immune synapse. CTLs have been demonstrated to exhibit suppressed 
phenotypes following infiltration into the tumour microenvironment. Tumour infiltrating 
lymphocytes were seen to be defective in their ability to polarise their internal cytoskeletal leading to 
a polarisation in-paired phenotype, in turn suppressing their ability to maintain immunological 
synapses. The inability to maintain a stable cell couple, depicted by increased off site lamella 
formation, actin dynamics and an unstable interface, was demonstrated to be induced by the 
tumour microenvironment. Multiple suppressive mechanisms are known to be utilised by cancer 
cells to produce a suppressive tumour micro environment. Commonly up-regulated molecules 
within the tumour microenvironment, such as PD-1 and CTLA-4, were shown to play a key role in 
the induction of the suppressed phenotype(135). However, when investigated, PGE2 was not seen to 
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increase the rate of off-site lamella formation. The maintenance in number of off-site lamella 
formation was coupled with stable synapse formation depicted by maintained interface diameter 
throughout the 480 second assay. Therefore, the ability to maintain stable immunological synapses 
following 24hr culture in 1uM PGE2, was clearly witnessed at comparable levels to the untreated 
CTL control. The findings would suggest that PGE2 is not capable of inducing a polarisation 
impaired state, implying that PGE2 was not contributing towards the suppressed phenotype seen 
within the tumour microenvironment.    
         PD-1 has been proven to play a key role in the induction of defective intracellular actin 
depolarisation, leading to the inhibition of successful immunological synapse maintenance and 
therefore the suppression of CTL cytotoxic ability(135). Defective actin polarisation and synapse 
maintenance has since been suggested as a common path of tumour induced immunosuppression. 
When investigating whether the up-regulation of PGE2(1uM) seen within the tumour 
microenvironment played a contributing role in the induction of the defective actin interface seen in 
TILs, it was demonstrated that 1uM PGE2 was not capable of significantly effecting CTL actin 
dynamics. Sustained levels of total actin accumulation were seen, confirming no witnessed defects in 
accent polarisation. Furthermore, no significant changes were noted in the CTLs ability to maintain 
a peripheral actin ring formation, further supporting the off-site lamella and interface diameter 
studies, in that stable immunological synapses were maintained. Deeper inspection of the data 
revealed an in-significant, yet consistent, slight decrease in the level of peripheral actin ring 
formation potentially suggesting the a contributing role in the decrease in stability was been noted 
however insignificant. Previous studies have shown 1uM PGE2 to induce CTL suppression in 
proliferation and effector function, however confounding factors such as IL-2 supplemented culture 
method used in the actin imaging study may have led to decreased levels of suppression being 
witnessed, thereby requiring higher concentrations of PGE2 for suppression to be deemed 
significant. However due to insignificant results, the study cannot conclude that unregulated PGE2 
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within the tumour microenvironment contributes towards the induction of defective actin 
polarisation seen in TILs. 
         Analysis of T Cell signalling, further supported the study by confirming equal levels of TCR 
signalling were occurring in CTLs following exposure to 1uM PGE2. Investigations into calcium 
signalling as an indicator  of T cell signalling showed tumour infiltrating lymphocytes to have a 
significantly decreased ability to amount efficient T Cell signalling following interaction with 
tumour cells. The significant decrease in signalling is clearly shown in tumour infiltrating 
lymphocytes and explains their defective cytolysis mechanism and suppressed phenotype. CTLs 
treated with 1uM PGE2 were not seen to exhibit any significant defect in their signalling ability. 
Overall it was therefore concluded that 1uM PGE2 exerted no suppressive effect on CTL signalling 
or the formation and maintenance on the immunological synapse. However, previous studies clearly 
demonstrated CTL proliferation suppression following treatment with 1uM PGE2, therefore further 
studies were carried out to determine whether the lack of witnessed suppression was due to 
confounding factors such as the the priming and culture method used within the lab.  
          Previous studies have demonstrated, suppression of proliferation following exposure to 1uM 
PGE2 in CTLs primed both via tumour cells directly or plate bound anti-CD3 and anti-
CD28/anti-ICAM antibodies(91). However, when investigated using our current culture method no 
suppression of proliferation was witnessed. Contrary to previous studies, further exploration lead to 
the discovery that suppression in proliferation was only seen when a 10-fold higher concentration of 
PGE2(10uM) was used. Furthermore, investigations into the effect of 1uM PGE2 on CTL cytotoxic 
abilities, demonstrated no significant effects with very high levels of cytolysis still occurring. The 
requirement of 10uM PGE2 for suppression was unphysiological and unexpected,  as previous 
studies noted 1uM as their highest concentration utilised. Therefore, it was hypothesised that the 
need for an increased concentration of PGE2 was down to the priming and culture conditions 
utilised within the lab.  
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         Currently our lab utilises a mixed lymphocyte reaction in which endogenous antigen 
presenting cells present the HA peptide to naive CD8+ T cells. The cells are then cultured for 96 
hours, in which culture media is replenished twice a day. The media used in the culture method is 
supplemented with very high levels of IL-2(50units/ul) in order to encourage effector CD8+ T cell 
development and proliferation. However, it is believed that the supplementary IL-2 added to the 
culture media was also the cause for the lack of witnessed suppression. Further tests into PG2 
induced suppression, confirmed this theory showing that when cultured in the absence of IL-2, 
proliferation of CTLs was significantly inhibited in the presence of 1uM PGE2, suggesting a 
suppressive role of PGE2. The suppression seen was also partially reverted upon the addition of 
1uM TG4-155, a specific EP-2 blocker. Resolution of suppression following the addition of TG4-
155, clearly indicates the suppressed effect to be induced by PGE2 specifically, supporting current 
literature and demonstrating a clear potential immunosuppressive role of PGE2 within the tumour 
microenvironment. PGE2 is capable of binding 4 individual receptors, EP1-4. Activation of both 
EP2 and EP4 result in increased levels of intracellular cAMP, capable of inducing suppression(194). 
As TG4-155 blocks solely EP2, it is believed that the partial resolution is due to the stimulation of 
the alternative EP receptors, namely EP4, however further investigations must be completed to 
confirm whether this is correct.  
         Along with suppressed proliferation, previous studies have established the ability of 1uM 
PGE2 to decrease IFN-y production, indicating a suppressed effector function, however the 
cytolytic action was not fully investigated(91). Original kill assays showed no significant effect to the 
cytolytic ability of CTLs following PGE2 exposure. The lack of effect was also believed to be due to 
the culture and priming method previously described. IL-2 encourages the formation of IFN-y as 
well as key cytolytic effector molecules such as perforin and granzyme, therefore the high levels of 
IL-2 within the culture process is believed to inhibit PGE2 suppression(195). Culturing CTLs using 
the current culture method without supplementary IL-2 proved troublesome as CTLs would begin 
to die post 72 hours in culture. Timing of cultures and limited resources made attempting kill assays 
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using cultures in the absence of IL-2 un-resourceful and inhumane. Therefore, for further 
investigations into the effect of PGE2 on CTLs, a new culture and priming method was developed 
to enable more physiological and representative results of the workings within the tumour 
microenvironment. 
         Overall the studies would suggest that PGE2 has an immunosuppressive effect on Cytotoxic T 
cells and therefore could potentially be a contributing mechanism of suppression within the tumour 
microenvironment. However supplementing IL-2 into CTL culture, as commonly done in adoptive 
T cell therapy, subverts the suppression seen and dramatically increases the concentration of PGE2 
needed for significant suppression to be noted. Additionally, IL-2 notably increases the level of CTL 
proliferation and effector function, potentially deeming the resulting cells unphysiologically active 
and effective. Therefore for further,more reliable investigations to occur into the tumour 
microenvironment, new culture methods should be developed that more accurately represent the 
internal lymph node environment for analysis and identification of suppressive mechanisms of the 
tumour microenvironment. In addition, previous experiments using high levels of IL-2 in CTL 
culture as a control may need to be revisited to determine whether the extent of suppression seen 
was due to the tested mechanism or due to having enhanced effector CTLs as a compared control. 
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3.3 Development of novel T cell culture method 
3.3.1 Introduction 
Current T cell culture method utilises complete cell media supplemented with IL-2(50units/ul) to 
enhance proliferation and survival of CTLs, in order to sustain growth over the weekend resulting 
in enough CTLs for the whole lab. A minimum of one CL4 mouse is culled weekly and its spleen 
harvested. The erythrocytes are eliminated using a lysing agent(Ack Lysis buffer) and the 
splenocytes isolated. CL4 splenocytes are then primed through a mixed lymphocyte reaction. MLR 
utilises the endogenous antigen presenting cells within the spleen by loading them with the HA 
influenza(A/PR/8/H1N1) peptide.  The loaded APCs are capable of priming naive CL4 
splenocytes through specific TCR signaling. In order to ensure a high yield of CD8+ T cells, 
following activation the cells are washed and cultured in splenocyte media supplemented with 
50units/ul Il-2. Furthermore, culture media is replenished twice daily spanning the weekend to 
ensure sufficient nutrients for the CTLs, but consequently making CTL culture a demanding 
process. Using IL-2 in T cell culture provides increased survival, proliferation and effector function 
of CTLs at 96hrs, and is therefore extremely useful. However, the level of IL-2 utilised is 
unphysiological and previous results have suggested it holds a role in inhibiting multiple suppressive 
mechanisms witnessed in the tumour microenvironment, hence its use as an anti-tumour cytokine 
therapy. The inhibition of T cell suppression has its uses; however, it may also hinder the 
identification of tumour mediated suppression mechanisms. Therefore, in order to fully investigate 
the immunological effects of PGE2 a new, more physiological, and overall simplistic CTL culture 
method was developed. 
          The new culture method required the use of two mice, one CL4 +/- and one CL4 -/-. The 
spleen of a CL4 -/- mouse was harvested and the splenocytes extracted.  Once extracted the 
splenocytes were irradiated at 3000 Rads(RX30/55M Irradiator).  Following irradiation, the 
splenocytes were then peptide loaded enabling the endogenous APC population to present the HA 
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peptide bound to an MHC1. Once peptide loading has begun, a CL4 +/- spleen is harvested and 
splenocytes extracted as previously described. Succeeding peptide pulsing, both CL4+/- and CL4-
/- splenocytes are resresuspended in culture media and plated in a 24 well plate at a 1:100 ratio. 
The culture can then be left for 96 hours to allow for priming and proliferation, resulting in a simple 
and effective CTL culture method.  
 
3.3.2 Aims 
I. To determine whether the new culture of CTLs enables sufficient proliferation. 
II. To optimise and characterise the new culture method. 
III. To assess the cytotoxic ability of CTLs following new culture. 
IV. To assess the suppressive effect of PGE2 on CTL proliferation in the absence of additional Il-2. 
 
3.3.3 Are CTLs able to effectively proliferate when cultured in the 
absence of IL-2? 
The primary function of CTL culture is to induce and sustain the priming and proliferation of 
effective CTLs. Therefore, the proliferation of CTLs cultured using the new method was assessed. 
CTV proliferation assays were completed to detect the percentage of surviving cells, the number of 
divisions over 96 hours, and the percentage of CTLs reaching the final two divisions. Following 96-
hour culture samples were taken from individual wells and analysed using flow cytometry. Live cells 
were detected through the use of Propidium Iodide(PI). PI is a DNA-binding dye that is actively 
pumped out by living cells therefore allowing identification of dead/dying cells by the increased PI 
fluorescence. The percentage of living cells was analysed using FlowJo software and gating strategy 
and results shown in figure 19. 
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First lymphocytes were identified through detection of the correct population of cells through 
forward scatter and side scatter gating. Forward scatter relates to the overall size of the cell, whereas 
side scatter corresponds to the granularity. As T Cells are both small and typically simplistic with 
few granules, the main population can originally be identified. Following lymphocyte gating, the 
cells are gated as single cells.  When analysing flow cytometry, it is important to only analyse single 
cells, as the fluorescence emitted from multiple adhered cells can collaborate inducing flash positive 
readings. Therefore, single cells are detected on the time and size of cells that pass through the 
detection laser. Once single cells have been isolated, they can be further analysed to interpret the 
percentage of remaining live cells. The results, shown in figure 23, demonstrate 87.6% of 
lymphocytes remaining alive, following 96-hour culture. The  post culture results suggest that the 
culture method is able to sustain enough nutrients whilst providing stimulation over the 96-hour 
period without the need for media replenishment reducing the workload demand required whilst 
still producing substantial levels of alive cells. 
         Using the alive cell gate as previously described, it is possible to examine the proliferation 
undergone by the CTLs over the culture period. As CTV stained cells divide, their fluorescence 
emission decreases due to splitting of the cytoplasm, producing a set of uniformly decreasing 
fluorescence peaks. The individual peaks therefore allow identification of cellular division events. 
          The results, presented in figure 24, clearly show that the new culture method enables efficient 
CTL proliferation over 96 hours, with up to 10 cellular divisions seen. Further analysis determined 
an average of 63.62% of CTLs reach the final 2 divisions. The current culture method reaches an 
average of 62.02% of CTLS within the final 2 divisions. The comparable results, shown in figure 
25, denote the two methods of CTL culture equally proficient in stimulating CTL proliferation over 
the 96 hours.  The maintained level of proliferation, coupled with the high survival rate, of CTLs 
using the new culture method that does not require the addition of exogenous IL-2, should provide 
increased opportunities to further investigate tumour mediated immune suppression in a more 
physiological manner.  
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Figure 23: Gating strategy for the identification of CL4 CTLs 
CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell media 
and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from the source, 
resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 1mL T cell media 
and pulsed with 5uL KdHA for 1hr. Naive CL4+/- splenocytes were harvested, washed twice in RPMI and 
counted. CL4+/- splenocytes were resuspended at 5x105 cells/mL in T cell media. CL4-/- splenocytes were 
washed 3 times in RPMI, counted and resuspended to 5x106 cells/mL in T cell media. 1mL of both CL4-/-  and 
CL4 +/- solutions were co-cultured in 8 individual centre wells of a 24 well plate, and left to culture for 96 
hours. 250uL cell samples were centrifuged(1400rpm, 5min) and supernatant discarded. Cells were washed 
twice using FACS buffer. 1uL CD8+ stain(APC) and Vβ8.1 stain(FITC) were diluted 1uL in 100uL FACs 
buffer. Samples were centrifuged, supernatant discarded, and resuspended in 50uL diluted stain for 30 minutes 
at 4oC. PI was diluted 1uL:400uL in FACs buffer. Samples were washed twice and resuspended in 200uL 
PI suspension. Lymphocytes were determined based on cell size and granularity(FSC-H/SSC-H). Single cells 
were detected from the lymphocyte population using FSC-H/FSC-A. CD8+ cells were isolated, by an increase 
in APC fluorescence. CD8+ cells were analysed for their Vβ8.1 expression, indicated by increased FITC 
fluorescence emission. Alive cells were determined by the lack of Zmb NIR/PI emission. 87.6% of CL4 CTLs 







 Vβ8.1 (FITC) 
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Figure 24: New culture method induces high levels of both CTL survival and 
proliferation  
CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell 
media and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from 
the source, resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 
1mL T cell media and pulsed with 5uL KdHA for 1hr. Naive CL4 splenocytes were harvested, counted and 
washed twice in PBS. CTV stain was diluted 1uL in 1000uL PBS. 1uL CTV was used per 4x106 cells. 
Splenocytes were centrifuged, supernatant discarded and resuspended in diluted CTV stain. CTV Staining 
was completed at 37oC for 15 minutes, followed by a 5x quench in 0.5% protein rich media and an 
additional 15 minute, dark incubation at room temperature. When complete, cells were washed 3 times in 
RPMI, re-counted and resuspended at 5x105 cells/mL in T cell media. CL4-/- splenocytes were washed 3 
times in RPMI, counted and resuspended to 5x106 cells/mL in T cell media. 1mL of both cell solutions  
were co-cultured together in wells of a 24 well plate and cultured for 96 hours. Following culture, 250uL 
cells was extracted from each well and transferred into FACs tubes. Samples were extracellularly stained 
for both CD8(APC) and Thy1.1(FITC), using the protocol described in  methods. PI was diluted 
1uL:400uL FACs buffer. Samples were washed twice in PBS and resuspended in 200ul PI solution, as 
described in methods. Samples were run on the Novocyte flow cytometer. Analysis utilised a gating 
strategy, shown in figure 19, to identify alive CL4 CTLs. CTV emission was analysed and percentage of 
cells in the last two divisions calculated. High levels of proliferation were seen with an average of 62.02% of 
cells reaching the last two divisions.(n=3) 
<————— CTV <————— CTV 
UNIVERSITY OF BRISTOL  112  
Figure 25: Comparable proliferation of new culture method and IL-2 supplemented 
CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell 
media and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from 
the source, resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 
1mL T cell media and pulsed with 5uL KdHA for 1hr. Naive CL4+/- splenocytes were harvested, counted 
and washed twice in PBS. CTV stain was diluted 1uL in 1000uL PBS. 1uL CTV was used per 4x106 cells. 
Splenocytes were centrifuged, supernatant discarded and resuspended in diluted CTV stain. CTV Staining 
was completed at 37oC for 15 minutes, followed by a 5x quench in 0.5% protein rich media and an 
additional 15 minute, dark incubation at room temperature. When complete, cells were washed 3 times in 
RPMI and re-counted. 4x106 CL4+/- splenocytes were extracted from the total resuspended at 5x105 
cells/mL in T cell media. CL4-/- splenocytes were washed 3 times in RPMI, counted and resuspended to 
5x106 cells/mL in T cell media. 1mL of both CL4-/-  and CL4 +/- solutions were co-cultured in 8 individual 
centre wells of a 24 well plate, and left to culture for 96 hours. The remaining naive CL4+/- splenocytes 
were primed overnight using a mixed lymphocyte reaction with KdHA, as described in methods. 5x106 
primed splenocytes per condition were harvested, washed and resuspended in 2ml IL-2 media with their 
corresponding conditions. The cellular suspensions were plated into separate wells of a 24 well plate and 
cultured for an additional 72 hours. Following culture, 1mL cells was extracted from each well and 
transferred into FACs tubes. Samples were extracellularly stained for both CD8(APC) and Thy1.1(FITC), 
using the protocol described in  methods. PI was diluted 1uL:400uL FACs buffer. Samples were washed 
twice in PBS and resuspended in 200ul PI solution, as described in methods. Samples were run on the 
Novocyte flow cytometer. Analysis utilised a gating strategy, shown in figure 19, to identify alive CL4 
CTLs. CTV emission was analysed and percentage of cells in the last two divisions calculated. No 
significant difference(p=0.7002) in the percentage of CL4+/- CTLs reaching the last two divisions was seen 
when comparing the newly developed and IL-2 supplemented culture methods.(n=2) 
New 
Old 
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3.3.4 Characterisation of CTLs following new culture. 
For the use of the new CTL culture method to become comprehensive it was first optimised and 
tested to determine the purity of the surviving population. The current culture method used results 
in an alive population consisting of ~94.6% CL4 lymphocytes. Such a high yield of CL4 CD8+ T 
cells enables their isolation via Flow cytometry sorting for the alive population. Being able to extract 
specific numbers of CL4 CD8+ T cells solely through gating on live cells, prevents the need for 
potentially effector compromising fluorescent staining. Staining for specific molecules such as CD8 
or CD3 is possible however the effects of the fluorescent antibodies are poorly understood, as well as 
the process being time consuming. It is therefore beneficial to result in a high purity of solely CL4 
CD8+ T Cells following culture. As both the current and new culture methods induce stimulation 
through priming with the HA peptide, the only population of primed cells should be CL4 CD8+ T 
cells as they are the sole group of cells with a TCR specific for  HA. However endogenously 
presented peptides may also be capable of inducing alternative cellular stimulation. 
         To assess the purity of the population following the new culture method, CTLs were cultured 
for 96 hours and stained for Thymocyte antigen 1(Thy1.1) and CD8 using fluorescent antibodies. 
Thy1.1(CD90) is a cell surface protein expressed solely on thymocytes, allowing the immediate 
detection of the lymphocyte population. Once lymphocytes are isolated, the CD8 stain is capable of 
distinguishing CTLs specifically through their co-signaling receptor. Using the previously shown 
gating strategy for live cells, the stained new culture sample was then measured using a NovoCyte 
flow cytometry system and analysed using FlowJo software, results presented in figure 26. 
          The population of stained cells was compared against an unstained sample, ensuring that 
there was a distinct increase in fluorescence and therefore binding of fluorescently labelled 
antibodies to both Thy1.1 and CD8 molecules. The results demonstrate 86% of the remaining alive 
cells to be Thy1.1+. Once gating on Thy1.1+ cells, the population is seen to be 93.3% CD8+. The 
results therefore show the remaining population to have a high yield of CL4 CD8+ T cells therefore 
allowing the potential for gating solely on live cells in future experiments. In addition, Thy1.1 may 
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be used to isolate cells in sorting using flow cytometry, as its binding to antibodies has been 
demonstrated to exhibit no effects to CTL effector function. Sorting on Thy1.1+ cells would 
therefore allow extraction of a ~93% pure population of CL4 CTLs, for further experimentation. 
     
   
Figure 26: Identification of a high yield of CL4 CD8+ Cells in the surviving population 
CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell media 
and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from the source, 
resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 1mL T cell media 
and pulsed with 5uL KdHA for 1hr. Naive CL4 splenocytes were harvested, counted and washed twice in 
RPMI. When complete, cells were resuspended at 5x105 cells/mL in T cell media. CL4-/- splenocytes were 
washed 3 times in RPMI, counted and resuspended to 5x106 cells/mL in T cell media. 1mL of both cell 
solutions  were co-cultured together in wells of a 24 well plate and cultured for 96 hours. Following culture, 
250uL cells was extracted from each well and transferred into FACs tubes. Samples were live/dead stained 
using Zmb NIR, using the previously described method. Once stained, cells were washed twice and 
extracellularly stained for both CD8(APC) and Thy1.1(FITC), using the protocol described in methods. Results 
show 86% of the remaining alive population of cells to be Thy1.1+. 93.3% of the Thy1.1+ cells, were also seen 
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    Following priming, T cells typically develop into three main categories, T central memory(TEM), 
T effector memory(TCM), and T effectors cells(196). By identifying extracellular molecular 
expression patterning, it is capable to determine the majority population phenotype. In order to 
determine the differentiated type of cells present over the course of the newly developed culture 
method, a time course characterisation was completed.  
         The time course entailed 6 days of extracellular staining targeting: CD44, CD62L, CD69, and 
PD-1. CD44 is a glycoprotein indicative of lymphocyte activation. CD44 can be used to determine 
activated cells as it is not highly expressed in naive T cells. CD62L is a cell adhesion molecule used 
by CTLs to home to the lymph nodes and is therefore lost upon naive T cell priming, however it is 
also characteristic of central memory CTLs and therefore is noted to be unregulated again in 
differentiated CTLs. When seen in combination with CD44-, CD62L+ indicates naive T cells, 
however CD62L+ CD44+ cells are recognised as central memory T cells. Upon loss of 
CD62L(CD62L-) but maintenance of CD44+, cells are deemed effector/effector memory cells. 
CD69+ expression is a distinguishing early T cell activation marker, noted to initially increase 
shortly after TCR interaction, before slowly decreasing overextended culture, and is therefore 
indicative of T cell activation. PD-1 is a vital immune checkpoint receptor involved in immune-
regulation. Activation of the PD-1 receptor by its corresponding ligand(PD-L1) promotes self-
tolerance and immune regulation, suppressing T cell function. PD-1 is therefore not present on 
naive T cells but instead up regulation following expression and differentiation.  
         Thy1.1 and CD8 were primarily stained to ensure the analysed population was solely CL4 
CD8+ T cells. Samples were stained for the 4 molecules, for 6 consecutive days following initial co-
culture. Following daily staining the samples were fixed in 1% PFA, and all run on a Fortesa flow 
cytometer system. Results shown in figure 27.  
         Results show a sharp increase CD69 expression as soon as day 1, suggesting high levels of 
naive T cell activation and therefore successful priming. The level of CD69 is noted to peak on day 
2, before beginning to descend until day 6 where it again increases, this could imply a re-stimulation 
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of a memory population within the culture. Furthermore, day 1 sees a large increase in PD-1 
expression further supporting successful priming of naive T cells into CTLs. The level of PD-1 is 
sustained throughout the rest of the assay, demonstrating an active mature CTL population. A 
gradual increasing expression of CD44 over the first 2 days of culture is seen, depicting the 
activation of CTLs and loss of naive T cells. In contrast, CD62L is seen to sharply drop on day 1, 
further indicating the activation of naive T cells. However, CD62L expression is then seen to rise 
until Day 3 where it begins to again decrease. This may be advocating the differentiation of a 
central memory population of T cells on day 3. Central memory T cells are often identified as 
CD44+ CD62L+, in contrast to Effector/effector memory T cells which are commonly determined 
by their loss of CD62 expression. The molecular profile of the  population on Day 3 suggests a high 
number of central memory T cells, primarily by the high level of both CD44 and CD62L. However, 
this population is seen to further differentiate from day 4 onwards where the gradual loss of CD62L 
suggests the formation of an increasingly effector/effector memory population. 
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Figure 27: A time course of activation and differentiation markers 
CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell media 
and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from the source, 
resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 1mL T cell media 
and pulsed with 5uL KdHA for 1hr. Naive CL4 splenocytes were harvested, counted and washed twice in 
RPMI. When complete, cells were resuspended at 5x105 cells/mL in T cell media. CL4-/- splenocytes were 
washed 3 times in RPMI, counted and resuspended to 5x106 cells/mL in T cell media. 1mL of both cell 
solutions  were co-cultured together in wells of a 24 well plate and cultured for 144 hours. At time of priming 
and every 24 hours throughout the culture culture, 250uL cells was extracted from one well and transferred 
into FACs tubes. Samples were live/dead stained using Zmb NIR, using the previously described method. 
Once stained, cells were washed twice and extracellularly stained for CD44(PerCP-Cy5.5), CD62L(PE), 
CD69(BV605), and PD-1(BV786) using the protocol described in methods. Samples were fixed in 200ul 1% 
PFA and run within 1 week.  
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3.3.5 Are CTLs able to effectively eliminate cancer cells when cultured in 
the absence of IL-2? 
Cytotoxic T Cells play a key role in preventing cancer development via immunosurveillance. 
Supplementary exogenous IL-2 added to culture media increases the survival and cytotoxic 
capabilities of CTLs making them extremely effective killers. However, the high concentrations of 
supplementary IL-2 proves un-physiological and therefore not representative of in vivo studies. 
Previous studies have suggested the role of IL-2 in the prevention of suppression following treatment 
via PGE2. To overcome the limitation of in vitro IL-2 supplemented CTL studies the newly 
developed CTL culture method utilises no additional IL-2, instead uses solely antigen presenting 
cells and CL4 splenocytes, deducing a more physiological method of priming. 
         In order to determine whether the CTLs are able to eliminate cancer cells when cultured in 
the absence of IL-2, imaging-based kill assays were completed. CTLs were cultured for 96 hours 
using the novel culture method previously described and therefore requiring no exogenous IL-2 
other than a result of autocrine/paracrine production. Renca cells, previously transfected with the 
mCherry plasmid(Renca mCherry), emit a red cytoplasmic fluorescence allowing their detection by 
the IncuCyte incubated microscope. MCherry Renca cells were plated into a glass bottomed 384 
well plate and incubated until adherence to the plate occurred. Once the mCherry cells had 
adhered the new cultured CTLs were harvested and sorted for live cells using fluorescence-activated 
cell sorting(FACs). Sorting ensured that equal numbers of live CTLs would be co-cultured. The 
CTLs were able to be sorted solely on live cells as over 85% of the remaining alive cells following 96 
Results show on day 0 before priming, no naïve CTLs express CD44, CD69 or PD-1. In contrast, CD62L 
is expressed by almost 100% of naïve CTLs. Following priming on day one CD44, CD69 and PD-1 all 
increase dramatically to 61%, 70% and 69% respectively. Simultaneous, CD62L decreased to 43%. 
CD44 and CD69 both peaked population expression at 97% and 98% respecifully, on Day 2, followed by 
a continuous steep decrease over the remaining 4 days. PD-1 also peaked on day two at 98%, where levels 
maintained a shallow decrease for the remaining 4 days. CD62L began to rise following day 1 until day 3 
where it peaked at 84%. From day 3 CD62L decreased over the remaining assay.(n=2) 
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hours of culture were CL4 CD8+ cells, demonstrated previously. Once sorted, equal numbers of 
CTLs were added onto of the wells containing adhered mCherry Renca cells at a 1:1 ratio. The 
plate was then incubated for 18 hours in an IncuCyte live cell analysis system(Essenbioscience). 
Upon completion of the assay, total surface area of mCherry cells(uM2/well) were calculated and 
averaged across 4 repeats. Resulting data was normalised and converted into rolling averages to 
enhance the overall trend. Decreases in the surface area of mCherry cells was due to cell death and 
was indicative of cytolysis via CTLs. Un-pulsed Renca cells were used as a control to ensure the 
cytolysis seen was specific towards cells presenting the HA antigen and therefore completed by CL4 
CTLs. In addition, wells of solely Renca cells were run in order to consider the natural increase in 
surface area over 17 hours due to Renca cell proliferation. 
         Results, seen in figure 28, show a significant decrease in the level of cytolysis exerted by CL4 
CTLs primed in the absence of IL-2. Significant cytolysis is seen by CL4 CTL cells cultured in the 
absence of IL-2. Yet, the steep decreasing gradient depicting IL-2 CL4 CTL cytolysis, demonstrates 
a dramatically enhanced cytotoxic ability. Further gradient comparisons, shown in figure 29, clearly 
show the decreased effector function of CTLs primed in the absence of IL-2. However, the 
increased ability of IL-2 CL4 CTLs is not necessarily physiological, and may been unrealistically 
effective. Further investigations must be completed to determine the correct physiological rate of 
CTL cytolysis. Overall effective cytolysis was witnessed in the newly cultured CTLs, therefore future 
experiments into the suppressive effects of PGE2 on CTL effector function were able to utilise the 
new culture method circumventing the necessity for increased IL-2 supplementation.  













Figure 28 : Imaging based kill assay to compare the cytolytic effect of CTLs when 
culture +/- supplementary IL-2 
CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell 
media and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from 
the source, resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 
1mL T cell media and pulsed with 5uL KdHA for 1hr. Naive CL4+/-splenocytes were harvested, counted 
and washed 3 times in RPMI. 4x106 CL4+/- splenocytes were extracted from the total resuspended at 5x105 
cells/mL in T cell media. CL4-/- splenocytes were washed 3 times in RPMI, counted and resuspended to 
5x106 cells/mL in T cell media. 1mL of both CL4-/-  and CL4 +/- solutions were co-cultured in 8 individual 
centre wells of a 24 well plate, and left to culture for 96 hours. The remaining naive CL4+/- splenocytes 
were primed overnight using a mixed lymphocyte reaction with KdHA, as described in methods. 5x106 
primed splenocytes per condition were harvested, washed and resuspended in 2ml IL-2 media with their 
corresponding conditions. The cellular suspensions were plated into separate wells of a 24 well plate and 
cultured for an additional 72 hours. 60-80% confluent Renca mCherry cells were detached from a T25 
flask using 500uL Trypsin-EDTA. Detached cells were quenched in 4mL complete media, collected into a 
15mL falcon tube and centrifuged. Renca mCherry cells were resuspended in 1mL complete media and 
counted. Additional complete media was added until 1x106 cells/mL was achieved. 2uL KdHA was added 
to the suspension, and incubated for 60 minutes, at 37oC. Cells were centrifuged, supernatant discarded and 
washed twice using 10mL RPMI. Once washed, Renca mCherry cells were re-counted, and resuspended 
to 3x105 cells/mL in Fluorobrite media. 50uL Renca mCherry cells were plated in individual wells of a 
glass bottomed 384 well plate, and incubated until cellular adherence, at 37oC. 4 repeats per condition were 
plated. All cultured CTLs were harvested into separate 15mL falcon tubes corresponding to their culture 
conditions. All CTLs were washed in PBS, and resuspended in 1mL conditioned imaging buffer. 1.5mL 
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Figure 29: Comparative rates of CTL induced target cytolysis.  
The gradient of each kill assay time curve was calculated by division of the change in surface area by 
time. The gradient of the increase in surface area demonstrated by the Renca only control, was 
detracted from the resulting cytolytic gradients to account for the full change in surface are and 
therefore cytolysis over the time course. The results gradients were plotted on a bar chart to represent 
the rate of cytolysis. A T test  confirmed a significant difference in the rate of cytolysis between CL4 
cultured using the newly developed culture method and IL-2 supplemented culture. 
CTLs were sorted using FACs for 60,000 alive cells per condition into their corresponding eppendorf, 
taking into account an un-pulsed control group. Sorted CTLs were centrifuged, 4000xg 4minutes, using a 
microfuge, and supernatant carefully extracted ensuring no disturbance to the cellular pellet. All CTLs 
were resuspended to 3x105 cells/mL in Fluorobrite media. 50uL CTLs were added to corresponding target 
wells containing adhered Renca mCherry, immediately before the plate was placed in the IncuCyte 
imaging system for 18 hours. Total target cell surface area (um2/well) was measuring using red 
fluorescence masking, over the duration of the assay. The mean of 4 repeats was calculated per timepoint 
for each condition. Results were normalised, and rolling averages produce. A row of Renca only controls 
were used to demonstrate cell growth over the duration of the assay. The decrease in target cell surface 
area was indicative of target cell death via CTL cytolysis. The results show a significant increase in the rate 
of cytolysis induce by IL-2 supplemented CL4 (red) compared to the CL4 cultured using the newly 
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3.3.6 Does PGE2 suppress CTL proliferation when cultured in the 
absence of IL-2? 
The previous study demonstrated that following 72 hour culture in the absence of Il-2, 1uM PGE2 
significantly suppressed the level of proliferation seen, indicating the role of PGE2 in tumour 
mediated immune suppression. The previously used culture method the population of CD8+ T cells 
within the control group, in the absence of supplementary IL-2, was not able to  be efficiently 
utilised for further investigations into the suppressive effects of PGE2, due to both timing and 
limited resources. However, the newly developed method of priming enables high levels of surviving 
CL4 CD8+ T cells following 96 hours in culture. In order to confirm that the previous 1uM PGE2 
induced suppression witnessed, was not solely relevant when used in combination with the previous 
culture methods, additional proliferation assays were complete to determine the  suppressive effect 
of 1uM PGE2.  
         CTV stained CL4 splenocytes were primed and cultured for 96 hours in the presence of 1uM 
PGE2. Once complete the cells were Live/Dead stained, and stained for Thy1.1+ and CD8+ 
surface molecules to enable identification of CL4 CD8+ T cells. The level of proliferation was 
determined by examining the percentage of cells that reached the final two division through the 
culture.  
         Results, seen in figure 30, show a significant reduction in the proliferation of CL4 CD8+ T 
cells following the addition of 1uM PGE2. 48% of PGE2 treated CTLs were seen to reach the final 
two proliferative events, compared to 78% of the untreated control. Parametric T tests confirmed 
the suppressive effect seen to be significant. The suppressive effect of 1uM pGE2 in the absence of 
additional IL-2 is therefore not restricted to the type of T cell priming. The combined investigations 
thereby support currently literature demonstrating  a suppression of proliferation, in CTLs priming 
using irradiated Renca cells  in the presence of 1uM PGE2.  
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Figure 30: Effect of PGE2 on CL4 CTL proliferation 
 CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell media 
and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from the source, 
resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 1mL T cell media 
and pulsed with 5uL KdHA for 1hr. Naive CL4 splenocytes were harvested, counted and washed twice in 
PBS. CTV stain was diluted 1uL in 1000uL PBS. 1uL CTV was used per 4x106 cells. Splenocytes were 
centrifuged, supernatant discarded and resuspended in diluted CTV stain. CTV Staining was completed at 
37oC for 15 minutes, followed by a 5x quench in 0.5% protein rich media and an additional 15 minute, dark 
incubation at room temperature. When complete, cells were washed 3 times in RPMI, re-counted and 
resuspended at 5x105 cells/mL in T cell media. CL4-/- splenocytes were washed 3 times in RPMI, counted 
and resuspended to 5x106 cells/mL in T cell media. 1mL of both cell solutions were co-cultured together in 
wells of a 24 well plate. Wells were either treated with 1uM PGE2 or a vehicle control and cultured for 96 
hours. Following culture, 250uL cells was extracted from each well and transferred into individual FACs 
tubes. Samples were live/dead stained using Zmb NIR, using the previously described method. Once stained, 
cells were washed twice and extracellularly stained for both CD8(APC) and Thy1.1(FITC), using the protocol 
described in methods. Samples were run on a Novocyte flow cytometry system, gated strategy in figure 18. 
CTV fluorescence was used to determine the number of cellular division and the percentages of cells reaching 
the last two divisions were calculated. The results show a significant reduction(n=1, p<0.0045) in the 
percentage of CL4 CTLs reaching the last two divisions when treated with 1uM PGE2. 
CL4 
1uM PGE2 CL4 
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3.3.7 Does PGE2 suppress CTL cytolytic function when cultured in the 
absence of IL-2? 
PGE2 has been demonstrated to exert an immunosuppressive effect on the proliferation of CTLs 
when incorporated into culture. The suppression seen has been demonstrated to be independent on 
the method of priming, both direct priming via tumour cells and cross presentation via APCs are 
seen to be suppressed upon the addition of 1uM PGE2. However, the suppression of proliferation at 
1uM PGE2 is only witnessed when no supplementary IL-2 is added to the culture. The addition of 
IL-2 in culture media has been seen to inhibit suppression and increase the concentration of PGE2 
required to exhibit any suppressive effects.  
         When CTLs are cultured in high levels of IL-2, previously described, the addition of 1uM 
PGE2 is not seen to significantly inhibit CTL cytolysis. To determine whether the lack of effect of 
1uM pGE2 previously seen were true of due to high levels of IL-2 in the culture media, further kill 
assays were completed using both: CTLs primed using the previous method of culturing without 
supplementation of IL-2, in addition to CTLs primed using the new culture method(+/- 1uM 
PGE2). 
         In order to confirm the effects of PGE2 on CTL cytolysis in the absence of additional IL-2, the 
well-established and controlled incucyte imaging-based killed assay was completed. Using an 
imaging-based kill assay allowed for the identification of any confounding factors that may alter the 
conclusion of results, ensuring the affects occurring were correct. IncuCyte kill assays were set up, as 
previously described, using Renca mCherry cells as targets. CTLs were primed using either the 
Wuelfing lab culture method without the protocoled addition of IL-2, or using the newly developed 
culture method. Either 1uM PGE2 or a vehicle control was added at the time of priming. Results 
were acquired in the form of rate of change in surface area. The total surface area of cytoplasmic 
red florescence of mCherry cells per well was calculated using IncuCyte Zoom analysis. Once 
recorded the resulting data was normalised and rolling means calculated to represent the overall 
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directory, shown in figure 31. Gradients of each condition were calculated over representative time 
points and compared to demonstrate the level of cytolytic function, as seen in figure 32.  
         The results show a significant reduction in the rate of cytolysis exhibited by CTLs when 
cultured in 1uM PGE2, in the absence of additional IL-2. 1uM PGE2 is seen to completely inhibit 
the ability of CTLs to eliminate mCherry renca cells. No decrease in surface area is witnessed when 
1uM PGE2 treated CTLs are co-cultured with HA presenting mCherry cells, clearly demonstrating 
significant suppression of cytolytic function. This is confirmed through analysis of the rate of 
cytolysis as depicted by gradient of the slope. A negative gradient is noted in the results, presented as 
0, deeming complete inhibition of cytolysis. 
 
  










1uM PGE2 CL4 
CL4 
Renca Only 
(+/- 1uM PGE2) 
Figure 31: Imaging based kill assay to compare the suppressive effect of 1uM PGE2 
on CTLs cytotoxic function.  
CL4-/- splenocytes were harvested and washed twice in RPMI. Cells were resuspended in 30mL T cell media 
and transferred into a 50mL Falcon tube. Cells were irradiated for 2500 seconds, 30cm away from the source, 
resulting in 3000 Rads. Once complete, splenocytes were washed twice and resuspended in 1mL T cell media 
and pulsed with 5uL KdHA for 1hr. Naive CL4+/-splenocytes were harvested, counted and washed 3 times in 
RPMI. Cells were resuspended at 5x105 cells/mL in T cell media. CL4-/- splenocytes were washed 3 times in 
RPMI, counted and resuspended to 5x106 cells/mL in T cell media. 1mL of both CL4-/-  and CL4 +/- solutions 
were co-cultured in 8 individual centre wells of a 24 well plate. Select wells were treated with 1uM PGE2 or a 
vehicle control and cultured for 96 hours. 60-80% confluent Renca mCherry cells were detached from a T25 
flask using 1mL Trypsin-EDTA. Detached cells were quenched in 4mL complete media, collected into a 
15mL falcon tube and centrifuged. Renca mCherry cells were resuspended in 1mL complete media and 
counted. Additional complete media was added until 1x106 cells/mL was achieved. 2uL KdHA was added to 
the suspension, and incubated for 60 minutes, at 37oC. Cells were centrifuged, supernatant discarded and 
washed twice using 10mL RPMI. Once washed, Renca mCherry cells were re-counted, and resuspended to 
3x105 cells/mL in Fluorobrite media. 50uL Renca mCherry cells were plated in individual wells of a glass 
bottomed 384 well plate, and incubated until cellular adherence, at 37oC. 4 repeats per condition were plated. 
All cultured CTLs were harvested into separate 15mL falcon tubes corresponding to their culture conditions. 
All CTLs were washed in PBS, and resuspended in 1mL conditioned imaging buffer. 1.5mL eppendorf were 
prepared containing 200uL 2X conditioned imaging buffer, for each experimental condition. CTLs were 
sorted using FACs for 60,000 alive cells per condition into their corresponding eppendorf, taking into account 
an un-pulsed control group. Sorted CTLs were centrifuged, 4000xg 4minutes, using a microfuge, and 
supernatant carefully extracted ensuring no disturbance to the cellular pellet. All CTLs were resuspended to 
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Figure 32: Effect of PGE2 on CTL induced target cytolysis.  
The gradient of each kill assay time curve was calculated by division of the change in surface area by time. 
The gradient of the increase in surface area demonstrated by the renca only control, was detracted from the 
resulting cytolytic gradients to account for the full change in surface are and therefore cytolysis over the time 
course. The results gradients were plotted on a bar chart to represent the rate of cytolysis. A T test confirmed 
a significant reduction in the rate of cytolysis following culture in the presence of 1uM PGE2. 
50uL CTLs were added to corresponding target wells containing adhered Renca mCherry, immediately 
before the plate was placed in the IncuCyte imaging system for 18 hours. Total target cell surface 
area(um2/well) was measuring using red fluorescence masking, over the duration of the assay. The mean of 4 
repeats was calculated per timepoint for each condition. Results were normalised, and rolling averages 
produce. A row of Renca only controls were used to demonstrate cell growth over the duration of the assay. 
The decrease in target cell surface area was indicative of target cell death via CTL cytolysis. The results show 
a significant increase in the rate of cytolysis induce by IL-2 supplemented CL4(red) compared to the CL4 
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3.3.8 Discussion 
The newly developed method for priming and culturing T cells abolishes the need for 
supplementary IL-2. The addition of high levels of IL-2 in the previous culture method is 
unphysiological and has been proven to largely inhibit the level of suppression seen in CTLs when 
exposed to PGE2. Previous studies using the culture method for adoptive transfer models in both 
mice and tumour spheroids, have witnessed extreme levels of suppression in both synapse 
maintenance and cytolysis(135). However, the CL4 CTL controls have been consistently cultured in 
a replenished media containing high levels of IL-2 compared to the adoptively transfer samples that 
have not only entered a solution with much lower levels of IL-2 but also the additional investigated 
suppressive mediators within the tumour microenvironment. In contrast, the in vitro studies 
reported in the previous chapter, unexpectedly saw little/no suppression when cultured with varied 
levels of PGE2 contrasting previous studies which have demonstrated 1uM PGE2 to be sufficient in 
order to suppress both the proliferation and IFN-y production when priming naive T cells(91). This 
effect was not originally witnessed using the previous culture method, only showing significant 
suppression when a 10-fold higher concentration of PGE2(10uM) was used, in addition to no 
significant suppression of cytolysis being witnessed. The lack of suppression was believed to 
primarily been due to the high level of IL-2 in the culture media. The newly developed method for 
priming and culturing T cells abolishes the need for supplementary IL-2, making a much more 
physiologically relevant way of priming and culturing CTLs.  
         The new culture method has shown to be extremely simplistic and manageable, preventing 
the need for bi-daily media changes over the weekend. In addition, the high percentage of CL4 
CD8+ T cells by 96 hours, allows for efficient fluorescence-activated cell sorting of CL4 CTLs 
merely on gating for cells expressing Thy1.1+ or stringent gating on live cells. Being able to isolate a 
pure CL4 CD8+ population by gating solely on live cells or even Thy1.1+ is essential for the 
efficient use of CL4 CTLs in kill assays, as staining for molecules such as CD8 or TCR has the 
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potential to block or stimulate the molecules potentially inducing aberrant effects, therefore affecting 
the accuracy of the results.  
         Further characterisation of the cell surface molecules: CD44, CD62L, CD69 and PD-1, 
clearly demonstrated successful activation of naive T cells throughout the cell culture. Population 
molecular profiles showed successful, physiologically relevant activation and differentiation of T 
cells following the new IL-2 abrogated culture method. By day 3 it was noted that a population of 
central memory T cells had developed, only to further differentiate into effector and effector 
memory T cells over the following consecutive days. The formation of an effector/effector memory 
population seen on day 4 indicates it to be the preferred earliest time for CTL use in kill assays, as it 
is effector/effector memory cells that shall best induce a cytolytic effect. Day 6 would be an ideal 
time to use CTLs in a kill assay because of the highest percentage of effector cells, however by day 6 
lower levels of surviving cells was noticed, therefore further optimisation should be completed in 
order to fully maximise the potential of the new culture method. 
         IL-2 heavily induces T cell differentiation and proliferation, hence its use in both cytokine 
therapy and expanding T Cell populations for adoptive T cell transfer(197). The previous culture 
method demonstrated the use of IL-2, with much higher levels of proliferation being seen in CD8+ 
T cells primed using a single spleen mixed lymphocyte reaction upon the addition IL-2. However, 
the new culture method was seen to be capable of inducing equally comparable levels of 
proliferation over 96 hours without the need for supplementary IL-2, further demonstrating a more 
physiological and effective method of priming naive T cells. In addition, when testing the effect of 
1uM PGE2 of the priming of CTLs using the new culture method, suppression was seen.        
         An additional function of IL-2 is to encourage the production of both IFN-y and the key 
molecules used in CTL effector function, perforin and granzymes(195). IL-2 signalling induces 
multiple intracellular signalling pathways including the activation of mTORC1 signalling, in turn 
encouraging the production of pro inflammatory molecules. The production of both IFN-y and the 
key molecules used in CTL effector function, perforin and granzymes has been noticeably increased 
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following IL-2 culture(195). Increased IL-2 is also heavily associated with differentiation of effector 
CTLs abolishing the population of memory CTLs. The increase in pro-inflammatory mediator 
production following IL-2 exposure is noted when comparing the cytolytic ability of CTLs cultured 
using the previous method of culture to that of the new. CTLs cultured in absence of IL-2 
demonstrated a strong cytolytic ability against tumour cells, however CTLs cultured in IL-2 showed 
dramatically enhanced killing ability, eliminating tumour cells at a much higher rate. The increased 
rate of killing could also be due to an increased population of memory T cells in the CTL 
population of cells in absence of IL-2.  
         However, this is merely speculation as CTLs cultured using the old, IL-2 supplemented, 
culture method have not yet been characterised. Therefore, for further investigation into to differing 
cytotoxic abilities of the CTLs resulting from differing culture methods(+/- IL-2) further in depth 
comparable characterisation should be completed. 
         Investigations into the effect of PGE2 on CTLs were completed using the newly developed 
CTL culture to acquire more physiological and representative results of potentially suppressive 
mechanisms within the tumour microenvironment. Previous investigations showed that 1uM PGE2 
was sufficient to suppress the proliferation of CTLs, however that the effect was only noted in the 
absence of supplementary IL-2. Repeated proliferation assays using the new culture method further 
confirmed this finding, showing a reduced capacity of proliferation in CTLs culture with 1um 
PGE2. The results further supported the study and previous findings, suggesting that PGE2 could 
have a role in the suppression of CTL proliferation following metastasis of tumour cells into tumour 
draining lymph nodes. Following metastasis of tumour cells into the lymph nodes, directly activated 
tumour specific CTLs would then home to the tumour in order to eliminate cancer cells. Previous 
studies into the effector function of CTLs primed in the presence of PGE2, showed no significant 
findings however this was believed to be due to the high levels of additional IL-2. The new culture 
method enabled investigation into the effect of PGE2 in the absence of supplemented IL-2. Results  
showed a complete inhibition in cytolysis of tumour cells by CTLs primed and cultured in 1uM 
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PGE2. This clearly demonstrates not only, that IL-2 has the ability to circumvent suppression seen 
by PGE2, but that 1uM PGE2 may be an important mechanism utilised and unregulated by cancer 
cells to suppress the cytotoxic function of CTLs and therefore contribute to tumour development.   
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3.4 Characterisation of new cancer cell lines 
3.4.1 Introduction 
In vitro cancer studies provide a useful tool for investigations into understanding the intricate 
interactions between cancer development and progression and the immune system. Multiple well-
established cancer cell lines have been developed and optimised for use in studies, one prime 
example being the murine renal carcinoma model, Renca. Replicative immortality, coupled with 
advanced long-term liquid nitrogen storage, enables the extended use of many cancer cells lines for 
many years, enabling a multitude of experiments and research to be undertaken. However, cancer 
is recognised as not a single but instead a group of over 200 different diseases due to the 
multifaceted phenotypic and genetic alterations seen in varying cancer types. The vast variation in 
cancer types is one of the reasons developments in treatments and prognoses proves so difficult. For 
translational research to occur, studies must investigate multiple cancer types to determine whether 
effects witnessed are phenotypic of a broad class of cancers or merely the single cell line being 
investigated. Therefore, the development of two new murine cancer cell line models was initiated. 
         4T1 and CT26 are two new cancer cell lines in the Morgan lab. 4T1 is a cancer cell line 
originating from the mammary gland tissue of a mouse(181). Used primarily as model for breast 
cancer, the 4T1 cell line is epithelial and has been reported to metastasis within murine 
models(181). 4T1 cells are extremely proliferative, dividing at very high rates, and results in cellular 
extrusion and apoptosis following 100% confluence in culture. In vivo tumours are made up of a 
mixture of multiple cell lines at different ratios depending on the type and origin. Therefore, in 
addition to the new epithelial 4T1 cell line, a fibroblastic cell line derived from a murine model 
colorectal carcinoma was developed, named CT26. Enabling the completion of future studies on a 
variety of cancer cell types and origins will allow for the identification of additional cancer-induced 
immune effects, whilst determining whether they are cancer cell specific or translational(180).  
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3.4.2 Aims 
I. To characterise the cell surface molecular patterning 
II. To determine whether 4T1 and CT26 cells are capable of priming naïve CL4 T cells. 
III. To determine whether CL4 CTLs are able to eliminate 4T1 and CT26 
IV. To transfect the 4T1 and CT26 cell lines to express the HA peptide. 
 
3.4.3 Characterisation of cell lines 
In order to utilise new cancer cell lines in research it must be determined which key cell surface 
molecules they express, particularly for immunological studies. For cancer cells to interact with 
cytotoxic T cells they must be capable of both being recognised and providing secondary co-
stimulation(87). The interactions between CTLs and cancer cells is increasingly complex.  
CD8+ T cells are primed and activated through two main signals. The first is recognition of a 
specific antigen bound to class 1 MHC complex. However ultimately the cancer cell co-signalling 
receptor expression determines the fate of the CD8+ T cell. A wide variety of co-signalling 
receptors, both stimulatory and inhibitory, have been identified to affect CTL function and 
activation. In order to effectively use the new 4T1 and CT26 cancer cell lines, their cell surface 
molecular expression patterning was first characterised, in attempt to identify key classical 
immunological receptors. 
         To characterise the cell surface molecular expression of both the 4T1 and CT26 cell lines, 
cells were stained using fluorochrome conjugated antibodies, each specific for a cell surface 
receptor. The chosen cell surface molecules stained for were:  MHC1, MHC2, CD80, CD86, 
CD40, ICAM-1, PD-1, and Galectin-9. Samples of each cell line were stained with single stains 
enabling the detection of the population expression of individual specific cell surface molecules, 
depicted by a positive fluorescence population shift. Comparisons between unstained cells and sings 
stained samples allowed for detection of individual molecule expression on the cell surface. All 
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antibodies were titrated, for optimal use and ensuring accurate results. Both accutase and Trypsin 
were tested and compared when detaching the cells from culture preceding staining, to ensure no 
molecules were undetected due to cleavage by trypsin.   
          MHC1 is expressed on almost all nucleated cells of the body. It is used to present fragments of 
degraded intracellular peptides, enabling detection of viral infection or transformation by the 
immune system. MHC1 is the main signaling complex in CTL interaction. The specific TCR binds 
to MHC1 complexes to both stimulate priming and proliferation, as well as emitting their cytotoxic 
effector function. In order to utilise a tumour cell line for immunological studies, it is therefore 
essential that they express MHC1 to allow interactions with CTLs. However, cancer cells have been 
reported to down regulate MHC1 complex in attempt to evade detection by the immune 
system(198).  
         MHC2 is primarily expressed on professional antigen presenting cells of the immune system. 
Phagocytotic cells such as Dendritic cells are most commonly associated with MHC2 as they 
phagocytose antigenic peptides in order to present them, via MHC2, to additional immune cells 
within the lymphatic system. Therefore, MHC2 is not expected to be expressed on the cell surface 
of epithelial or fibroblast cancer cells. 
         For successful T cell stimulation, CTLs must receive two independent signals. First, the TCR 
must recognise and interact with an MHC1 bound antigen. The second signal must come from a 
co-stimulatory molecule. Traditionally CD80 and CD86 were recognised and the two primary CTL 
co-signaling molecules(87). Binding to CD28, the presence of one or both molecules enables 
sufficient T cell signaling inducing proliferation and effector function. More recently the role of 
ICAM-1 has also been highlighted. Typically regarded for its role in leukocyte extravasion, ICAM-1 
is also capable of inducing secondary stimulatory signals to CTLs(92). Furthermore, CD40 is a co-
stimulatory molecule, however it is typically only present on professional antigen presenting cells. 
For a successful immunogenic tumour model at least one co-stimulatory molecule must be 
expressed on the cell surface to allow for effective CTL interactions. 
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         Upon activation CTLs have been demonstrated to up regulate the Programmed death 
receptor-1(PD-1) expression on their cell surface(199). PD-1 is a regulatory protein, involved in 
eliminating exhausted CTLs in addition to preventing autoimmune disease by inducing self-
tolerance through the inhibition and apoptosis of CTLs. PD-1 is activated through interaction with 
its ligand(PD-L1). Studies have reported cancer cells to utilise this immune-regulatory process in 
attempt to evade elimination by the immune system(199). Lymphocytes have been noted to have an 
increased expression of the PD-1 receptor following tumour infiltration, increasing their potential 
interaction and therefore suppression and cell death(200). Further studies have seen tumour cells 
over express PD-L1, further driving the potential of PD-1 dependent apoptosis.  
         Recent studies have noted cancer cells to up regulate an additional molecule capable of 
modulating T cell responses, named Galectin-9. Galectin-9 is a carbohydrate binding protein, 
expressed on both epithelial and endothelial cells in addition to a variety of immune cells, including 
B and T cells.  Immune modulation via, galectin-9, is due to its ability to act as a stimulatory ligand 
for the Tim-3 receptor expressed by T cells. Tim-3 is an immune checkpoint and therefore co-
inhibitory receptor of T cell function. Primarily involved in T cell homeostasis, and prevention of 
autoimmune disease, Tim-3 expression is noted in exhausted CTLs following prolonged antigen 
exposure. However increased activation of Tim-3, through the up regulation of Galectin-9 has been 
reported to be utilised by cancer cells as an evasive mechanism(201). Therefore, it is important to 
determine whether expression of both PD-L1 and Gal-9 is apparent on both new cell lines before 
immunological studies are completed.   
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Figure 33: Cell line expression of key co-signalling molecules. 
60-80% confluent Renca mCherry cells were detached from a T75 flask using 1mL Trypsin-EDTA. 
Detached cells were quenched in 4mL complete media, collected into a 15mL falcon tube and centrifuged. 
Renca mCherry cells were resuspended in 1mL complete media and counted. Additional complete 
media was added until 5x105 cells/mL was achieved. 9 x 1mL samples were extracted into 
individual FACs tubes and washed twice in PBS. Samples were live/dead stained using Zmb NIR, 
using the previously described method. Once stained, one FACs tube was fixed to be used as a Zmb 
only control. Remaining samples were washed twice and each extracellularly stained, using the 
protocol described in methods, for a single molecule: MHC1(Pacific blue), MHC2(APC), 
CD80(BV650), CD86(BV605), CD40(PE), ICAM-1(FITC), PD-L1(BV786) and Galectin-9(BV421).  
MHC1 MHC2 CD80 CD86 
CD40 ICAM-1 PD-L1 Gal-9 
CT26 
MHC1 MHC2 CD80 CD86 
CD40 ICAM-1 PD-L1 Gal-9 
4T1 
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Results shown in figure 30 show a clear population shift increasing in fluorescence following MHC1 
staining. The shift in population signifies high levels of expression of MHC1 on the cell surface. 
Both 4T1 and CT26 cell lines demonstrated MHC1 expression and therefore hold the potential to 
interact with TCRs. The presence of MHC1 is vital for immunological studies, therefore its 
presence on both cell lines is vital to allow them to further be developed for tumour models. As 
expected, when stained for MHC2 expression, the results show no population shift, indicating no 
MHC2 expression on either 4T1 or CT26 cell lines. CT26 shows a large population shift when 
stained for CD80, depicting a high level of expression. No shift is seen for either CD86 or ICAM-1. 
However, the apparent presence of CD80 should be sufficient to induce CTL proliferation and 
effector function, deeming CD26 a potential novel tumour cell line model. In contrast, little/no 
convincing shifts are seen in 4T1 expression of co-stimulatory markers. Antibodies were titrated, to 
ensure the correct dilution was utilised. In addition, both accutase and trypsin were tested as means 
of cell detachment, to ensure that the lack of receptors was not due to cleavage via trypsin.  The lack 
of co-stimulation molecules on 4T1 may present as an issue for its use in immune studies, therefore 
additional investigation must be undertaken, such as confluence dependent molecule expression. 
          The single stain flow cytometry results confirm the expression of PD-L1 on both 4T1 and 
CT26 cell lines, however no expression of Galectin-9. The expression of PD-L1 holds interesting 
prospects for future investigations into tumour:immune cell interactions, as well as potential 
investigations into the variation of PD-L1 expression due to different conditions and culture 
methods such as 3D spheroid cultures. Having PD-L1 expression further increases the interest in 
developing both 4T1 and CT26 cell lines into established tumour model for future use. 
 
Samples were fixed in 200ul 1% PFA and run within 1 week. Both CT26 and 4T1 cells were shown 
to express Class 1 MHC complexes, shown by a right-ward population shifts in fluorescence emission. 4T1 
cells were shown to not express any of the targeted co-stimulatory molecules(CD80, CD86, ICAM-1) 
however does express PD-L1. CT26 cells were seen to express CD80, in addition to PD-L1. Neither cell 
lines expressed MHC2, CD40, CD86, ICAM-1 or Galectin-9.(n=6) 
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3.4.4 Are 4T1 and CT26 cells able to prime CL4 CD8+ T Cells? 
Both 4T1 and CT26 cell lines have been reported to metastasis within murine models(180-181). 
The ability of metastasis enables migration of cancer cells into the tumour draining lymph nodes 
therefore giving the potential of direct presentation by the cancer cells to naive T cells.  In order for 
cancer cells to prime naive T cells they must be able to provide 2 distinct stimulatory signals(87). 
The first signal is provided through the presentation of a recognisable antigen by a Class 1 MHC 
complex. All nucleated cells express major histocompatibility complexes; however, many cancers 
have been reported to down regulate MHC1 expression as an immune evasion mechanism(198).  
          CT26 and 4T1 characterisation results show that both cell lines express high levels of MHC1 
on their cell surface, enabling them to present the HA peptide following peptide loading. The 
second signal required for full activation of naive CTLs is provided via co-signalling receptors, most 
commonly CD80/CD86 on APCs, but also ICAM-1. A second stimulatory signal is essential for 
effective priming. CT26 cells were shown to express high levels of CD80. The expression of both 
MHC1 and CD80 by CT26 cells should be sufficient for the priming on naive CTLs once HA 
peptide loaded. In contrast, 4T1 cells were not shown to express CD80, CD86 or ICAM-1. The 
lack of expression of the named co-stimulatory receptors suggests that 4T1 may not be able to 
effectively prime naive T Cells. However additional co-stimulatory receptors, such as CD226, were 
not tested for therefore they still may be capable of inducing CTL proliferation(87). To determine 
whether CT26 and 4T1 cells are capable of priming naive T cells, flow cytometry proliferation 
assays were completed.  
         To demonstrate T cell proliferation naive CL4 splenocytes were stain using Cell Trace 
Violet(CTV) and co-cultured with irradiated 4T1 and CT26 cell lines. When cells undergo 
proliferation, they divide into two daughter cells including their cytoplasm. The division of a cell 
splits the level CTV stain into two producing a population of cells with lower levels of CTV and 
therefore lower levels of fluorescent emission. Decreases in emission enable the detection of whether 
a cell has undergone division, and therefore can be used to determine whether the cancer cells are 
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able to effectively prime naive T Cells. CT26 and 4T1 cell lines were irradiated to prevent their 
growth throughout the culture before being peptide loaded to present the HA antigen. Once loaded 
both the CTV stained naive CL4 splenocytes and the cell lines were plated in a 96 well plate at a 
1:1 ratio. Assays were completed for both 72 and 120 hours to optimise the potential proliferation 
seen. Following incubation cultures were prepared with PI stain solution to enable detection of 
live/dead cells and run on the Novocyte flow cytometry system. 
          Results, depicted in figure 34, show that 4T1 cells are unable to induce CL4 CTL 
proliferation at both 72hrs and 120hrs. By 72 hours 48.5% of CL4 CTLs were still alive, however a 
single sustained CTV level demonstrated that no division had occurred. By 120 hours, all of the co-
cultured CTLs were seen to be dead by the complete uptake of PI dye. Along with the total sample 
death, no proliferation had been witnessed over the extended culture period, thereby confirming 
that 4T1 cells were unable to induce CL4 CTL proliferation.  
         In contrast, by 72 hours CT26 92.6% of CL4 CTLs were alive, and were seen to have 
undergone one division event, indicating that CT26 were able to induce proliferation of CL4 CTLs. 
Following 120 hours of co-culture all of the CTLs had died, likely caused by the lack of nutrients in 
culture media as the larger CT26 cells require much higher levels of metabolites diminishing the 
supplies available for CTLs. No additional division events had occurred over the 120 hour period 
suggesting that lack of nutrients preceded any further potential proliferation.  
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Figure 34: CTL priming via direct presentation from 4T1 and CT26 cancer cell 
lines 
4T1 cells are not capable of inducing CD8+ T cell proliferation.  60-80% confluent 4T1 and CT26 cells 
were detached from T25 flasks using 500uL Trypsin-EDTA. Detached cells were quenched in 4mL 
complete media, collected into separate 15mL falcon tube and centrifuged. The cell lines were resuspended 
in 10mL complete media and transferred into 50mL falcon tubes. Cells were irradiated for 9680 seconds, 
33cm away from the source, resulting in 9600 Rads. Once complete, cells were washed twice, resuspended 
in 1mL complete media and counted. Cells were further diluted with complete media to make 
1x106cells/mL. Naive CL4 splenocytes were harvested, counted and washed twice in PBS. Cells were 
centrifuged(1400rpm, 5min), resuspended in 600uL MACs buffer in addition to 50uL anti-CD8 MACs 
beads, and incubated for 30 minutes at 4oC. An LS column was placed in a midiMACs magnet, above an 
open 50mL falcon tube, and wetted using MACs buffer. Once incubation was complete, cells were washed 
twice in MACs buffer, and resuspended in 5ml. The solution was applied to the LS separation column. 
Once the sample had passed, the LS column was washed with 5mL MACs buffer. LS column was 
removed from the midiMACs magnet and 5mL MACs buffer added. A sterile plunger was forcefully 
pushed expelling solution through the column into a 50ml falcon tube, resulting in a CD8+ rich 
population of cells. Upon collection the CD8+ cells were washed using T cell media, counted and 
resuspended at 1x106 cells/mL in T cell media. CTV stain was diluted 1uL in 1000uL PBS. 1uL CTV was 
used per 4x106 cells. Splenocytes were centrifuged, supernatant discarded and resuspended in diluted CTV 
stain. CTV Staining was completed at 37oC for 15 minutes, followed by a 5x quench in 0.5% protein rich 
media and an additional 15 minute, dark incubation at room temperature. When complete, cells were 
washed 3 times in RPMI, re-counted and resuspended at 5x105 cells/mL in complete media. 100uL of 
either 4T1 or CT26 cells and CL4 CTLs were co-cultured together in individual wells of a 96 well plate 
and cultured for 72 or 120 hours. Following culture wells were vigorously resuspended, 200uL samples 
were extracted from each well and transferred into corresponding wells in a new 96 well plate. The new 
plate was centrifuged(1400rpm, 5 mins) and supernatant discarded. PI was diluted 1uL:400uL FACs 
buffer. Samples were washed twice in PBS and resuspended in 200ul PI solution, as described in methods. 
Samples were run on the Novocyte flow cytometer. Analysis utilised a gating strategy, shown in figure 19, 
to identify alive CL4 CTLs. Analysis of CTV emission determined 4T1 cells were not able to prime CL4 
CTLs within 72 or 120 hours. In contrast, results show CT26 cells were able to prime the CTLs, inducing 
one proliferation event. In both cell line cultures, alive CL4 CTLs were present at 72 hours however by 
120 hours all CL4 CTLs had died.(n=3) 
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3.4.5 Are CL4 CD8+ T cells able to eliminate 4T1 and CT26 cells?  
In order to investigate the suppression of cytotoxicity seen in tumour infiltrating lymphocytes and 
therefore the suppressive mechanisms conjured by the tumour microenvironment, CTLs must first 
be able to be recognised and eliminate the cell lines.  
         To determine the cytotoxic effect of CL4 CTLs on both CT26 and 4T1 cells, kill assays were 
completed. The well-established Renca HA cells were used as a comparative control as previous 
experiments have demonstrated CTLs exert a consisted level of cytolysis when they are targeted. 
Target cells were stained with Cell Trace Violet to allow their detection and plated in a 96 well 
plate.  CTLs were then counted and added onto the target cells at a 1:1 ratio. Co-cultures were 
incubated for 17 hours before being centrifuged and resuspended in accutase. Accutase detached 
the remaining adhered cells from the wells to enable PI staining. Resuspension in PI stain solution 
allowed immediate detection of live/dead cells when run on the Novocyte flow cytometer system, 
results shown in figure 35. 
         With the use of the well-established Renca HA cell line as a control, results shown clearly 
demonstrate CTLs are able to effectively eliminate both 4T1 and CT26. Comparable levels of 
specific cytotoxicity was noted when comparing  4T1(35.19%) and Renca cells(40.05%) (p=0.8951). 
However, a one way anova revealed a significant difference(p<0.0001) between the groups. Further 
comparisons deemed the significant results due to the increased level of specific cytotoxicity of 
CT26 cells. The increase in cytotoxicity was seen to be significantly higher than seen in both 
4T1(p<0.0001) and Renca cells(p<0.0001). 
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Figure 35: Comparative cell line cytolysis 
Naive CL4 splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. PGE2 conditions(0.1uM PGE2/1uM PGE2/10uM PGE2) were added into 
separate wells at time of priming. 5x106 primed splenocytes per condition were harvested, washed and 
resuspended in 2ml IL-2 media with their corresponding conditions. The cellular suspensions were plated 
into separate wells of a 24 well plate and cultured for 96 hours. 60-80% confluent Renca HA cells were 
detached from a T25 flask using 1mL Trypsin-EDTA. Detached cells were quenched in 4mL complete 
media, collected into a 15mL falcon tube and centrifuged. Renca HA cells were resuspended in 1mL 
complete media and counted. Additional complete media was added until 1x106 cells/mL was achieved. 
2uL KdHA was added to the suspension, and incubated for 60 minutes, at 37oC. Once complete cells were 
centrifuged(1200rpm, 3min), supernatant discarded and the cells washed twice in PBS. CTV stain was 
diluted 1uL in 1000uL PBS. 1uL CTV was used per 1x106 cancer cells. Renca HA cells were counted, 
centrifuged, supernatant discarded and resuspended in diluted CTV stain. CTV Staining was completed at 
37oC for 15 minutes, followed by a 5x quench in 0.5% protein rich media and an additional 15 minute, 
dark incubation at room temperature. When complete, cells were washed twice in complete media, re-
counted and resuspended to 1x106 cells/mL in complete media.  All cultured CTLs were harvested into 
separate 15mL falcon tubes corresponding to their culture conditions. All CTLs were washed in RPMI, 
and counted. CTLs were further washed and resuspended to 1x106 cells/mL in complete media. 100ul of 
both cancer cells and CTLs were co-cultured in repeated wells of a 96 well plate. 4 repeats were plated per 
condition, in addition to 4 wells of Renca HA only and 4 wells for a positive killed control. 
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3.4.6 Discussion 
Cancer is described as a collection of over 200 individual diseases characterised by their aberrant 
growth and accelerated proliferation. All cancers share a collection of phenotypic characteristics, 
deemed the “hallmarks of cancer”(2). One more recently discovered hall mark is the escape and 
evasion of the immune system(23). However, there are extensive mechanisms behind which cancer 
cells evade the immune system, many of which vary depending on the type of cancer. Many up 
regulate the expression of immunosuppressive ligands such as PD-L1, whereas others increase 
intracellular proteins, e.g. COX-2,  thereby increasing the local concentration of PGE2(200, 186). 
Therefore, in order to complete translational research multiple tumour types must be investigated to 
determine whether any effects seen are global or specific to a single cancer type. 
         The study completed, developed and investigated the immunological properties of two new 
cancer cell lines in order for their future use. 4T1 and CT26 cancer cells were extensively cultured 
and properties investigated to determine whether they would be useful in future immunological 
studies. 4T1 cells are of epithelial origin from a murine mammary carcinoma. Whereas the CT26 
cell line is fibroblastic from a colorectal carcinoma. Both cell lines were very simple to culture, 
The plate was incubated at 37oC for 17 hours. When complete, media from the positive control wells was 
carefully extracted ensuring not to disturb the adherent cells. 150ul accutase was added to the positive 
control wells and incubated for 10 minutes at room temperature. Positive control wells were resuspended 
and collected into a 1.5mL eppendorf. The eppendorf was heated to 90oC for 10 minutes in a heat plate. 
The remaining plate was centrifuged at 1400rpm 5 mins, and supernatant discarded. PI was diluted 
1uL:400uL in accutase. 150uL PI solution was added to each remaining well, incubated for 10 minutes at 
room temperature and run within the hour. PI was added to the heated cell accutase at a 1uL:400uL ratio. 
150uL kill positive cells were pipetted into a new row of wells in the 96 well plate. All wells were 
resuspended and run on the Novocyte. Gating strategy seen in figure 19 was used to identify target cells 
including their live/dead populations. Percentage of dead target cells was determined and specific 
cytotoxicity calculated using the formula, noted in methods. A one-way Anova demonstrated a significant 
difference(n=3, p<0.0001) of cytolysis between the cell lines. Individual comparisons show no significant 
difference between the percentage of CL4 CTL specific cytotoxicity against 4T1 and Renca cell 
lines(p=0.8951). CT26 showed a substantial increase in CTL specific cytolysis compared to both 
Renca(p<0.0001) and 4T1(p<0.0001). 
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however, grew at very different rates. 4T1 cells grew extremely quickly yet experienced cell death if 
100% confluence was exceeded. In contrast, CT26 cells did not grow as quickly yet once 100% 
confluence was reached, cells would grow onto of each other creating dense fibroblastic mesh. Both 
cells have been reported to metastasis extensively, and therefore have great potential for in vivo 
murine studies.  
         Characterisation of the cell lines provided basic descriptions of key cell surface molecules on 
the differing cell lines. As both expressing MHC1, they are capable of presenting intracellular 
peptides to CTLs, giving them potential in immunological studies. However, for complete 
interaction with CTLs co-signalling molecules must also be apparent. CT26 express high levels of 
CD80, making it a very good model for interactions with CD8+ T cells. Proliferation assays further 
supported CT26 as a good candidate for immune studies as CTL proliferation was seen upon co-
culture of HA pulsed CT26 cells with naive T cells. In contrast 4T1 cells did not notably express 
any tested co-stimulatory molecules. There are multiple additional co-signalling molecules that were 
not tested for therefore further investigations must be completed before disregarding the 4T1 cell 
line as a model for immunological studies. However, no proliferation was seen when HA pulsed 
4T1 cells were co-cultured with naive T cells, deeming the model in comparable with the current 
Renca model when studying immune reactions. In spite of its comparability, 4T1 cells have been 
reported to extensively metastasis in murine models, providing the potential for alternative immune 
studies to be completed. Modern techniques of inducing foreign protein expression into cells, such 
as lipofection and CrispR-Cas9, have great potential to induce co-stimulatory signal expression in 
4T1 cells, providing an increasingly sophisticated model. The introduction of individual co-
stimulatory receptor expression would allow the investigation and comparison of immune 
interactions with different co-signalling receptors and their effectiveness/suppression, thereby 
enabling further controlled research models. 
        Kill assays demonstrated comparable results of cancer cell elimination to the currently used 
Renca model. Pulsed 4T1 cells were eliminated at indistinguishable levels to Renca HA cells, 
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whereas the CT26 cell line exhibited higher levels of cytolysis. The high level of cytolysis is likely 
due to the increased level of CD80 expression. CD80 is able to efficiently activate CTLs enabling 
their effective cytolytic action and elimination of cancer cells. In addition, it was be noted that 4T1 
cells may express a higher level of PD-L1. Increased PD-L1 expression can induce increased levels 
of CTL cell death upon interaction, therefore decreasing the level of cytolysis witnessed. 
         In conclusion both cell lines have great promise for use in immunological studies. The CT26 
line provides an interesting comparison to the currently used Renca model, due to its expression of 
classical co-stimulatory receptor CD80 compared to Renca’s ICAM-1 signalling mechanism. In 
addition, its fibroblastic cell morphology enables further research into the contributing effects of 
different cell types in tumour induced immunosuppression. In contrast 4T1 cells provide an 
interesting model of in vivo metastasis, and immune evasion. Due to their relatively low expression 
of classical co-signalling molecules, the introduction of alternative co-signalling molecules would 
enable extremely controlled immune experiments into the contribution of alternative co-signalling 
molecules in immune stimulation and suppression.  However, to utilise the full potential of both cell 
lines with the CL4 model, they must be transfected to express the KdHA peptide to enable CL4 in 
vivo studies, and abolish the need for peptide loading. Furthermore, the producing of mCherry 
emitting 4T1 and CT26 cell lines would enable their use in the optimised IncuCyte imaging based 
kill assay, giving further understanding into their elimination by CL4 CTLs. 
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4. Future work 
4.1 Investigating PGE2 induced immunosuppression 
Overall results from the project confirm that PGE2 is capable of suppressing both the proliferation 
and the cytolytic effector function of cytotoxic T cells. However, one key limitation noted 
throughout the project was the circumvention of suppression seen when high levels of IL-2 were 
used to supplement the culture media. CTLs cultured in IL-2 showed little/no effect when cultured 
in levels of PGE2(1uM) that had previously been reported to induce significant suppression(91). 10-
fold higher levels of PGE2 were needed to witness significant suppression that matches the 
literature. The results of the project would imply that the addition of IL-2 in CTL culture has 
inhibited suppression that may be noted in more physiological systems, resulting in false negative 
results. In addition, IL-2 cultured CTLs have been used as a comparative control with exceedingly 
high cytolytic function, thereby potentially witnessing false positive results. The new developed 
method of culturing T cells acts as a more physiological control; however, this must be confirmed. 
Future research must be completed into determining and optimising the most physiologically 
relevant culture method. Kill assay comparisons between mature effector/effector memory CL4 
CTLs and the ex vivo cultured CTLs should be examined to decipher the most accurate method of 
culture. In addition, the previous Wuelfing CTL culture method should be characterised over a 
time course to determine the precise differentiation of the population of CTLs being produced. 
Furthermore, the newly developed culture method is needed to be fully optimised, to enable a high 
yield of effector/effector memory cells coupled with an increased survival rate, for utilisation in kill 
assays. Once fully optimised, more physiologically primed CTLs should also be used in imaging 
studies to fully assess T cell signalling, polarisation and the suppressed phenotype seen. 
         Additional studies into the suppression induced by PGE2 should also be completed. The noted 
addition of TG4-155, partially resolving suppression can be explained by the interaction of PGE2 
with alternative EP receptors, namely EP4, however cannot be confirmed. Further experiments 
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should be completed, utilising secondary EP blockers, as well as the identification of specific EP 
receptor expression on the CTL cell surface. Understanding the EP receptor dynamics would allow 
for a more in-depth understanding on the suppressive effects exerted by PGE2 within the tumour 
microenvironment.  
         In vivo studies of PGE2 would not only circumvent the immediate need for a physiologically 
relevant CTL culture method but would also allow investigations into the role of PGE2 in the 
tumour microenvironment as a whole. Development and inoculation of a murine model with a 
COX-2 k/o cancer cell line would allow detection of the contribution of PGE2 in the induction of 
the suppressed phenotype seen in tumour infiltrating lymphocytes.  
 
4.2 Development of new cancer cell lines 
The newly developed cancer cell lines show great promise for future immunological studies. In 
order to fully maximise their potential transfection of the KdHA protein should be completed to 
allow for both: in vivo investigations, as well in vitro CL4 studies without the need for loading. 
Cytoplasmic staining of cells for use in Incucyte kill assays has been attempted however the process 
of staining using chemicals such as CFSE proves to affect the cells, making them less adherent and 
not in optimal state, therefore adding an additional unreliable variable to the results. Therefore, 
once the cells are eble to endogenously present the HA peptide, an additional transfection for 
mCherry cytoplasmic fluorescence would be extremely useful as it would enable their use in 
IncuCyte imaging-based kill assays. 
 
5. Conclusion 
This study aimed to determine the effect of PGE2 on CTL function as a possible mechanism of 
tumour mediated immune-suppression. Overall the study confirms that PGE2 does induce 
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significant suppression of CTL proliferation and cytotoxic function, and therefore could play a role 
in inducing suppressed TIL function. However, the effect of PGE2 was shown to be entirely 
dependant on the culture conditions of CTLs. Increased IL-2 supplementation of CTL culture 
abolished any noted suppression, requiring a 10-fold increase in PGE2 concentration before 
suppression was seen.   Utilising a new culture method allowed identification of significant 
suppression by 1uM PGE2, supporting current literature, whilst maintaining effective levels of 
proliferation and cytolysis in untreated control. PGE2 was did not demonstrate any effect on the 
immunological synapse, suggesting an alternative mode of action, however this may be down to 
culture method and should therefore be retested utilising the new culture method. Two new cell 
lines , 4T1 and CT26, show great promise in future comparative immunological studies, due to 
their contrasting co-signalling molecule expression, yet maintained levels of elimination via CTLs.   
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6. Appendix 
A B 
Figure: Transfection of 4T1 and CT26 cell lines 
The CL4 mouse model enables immunological studies through the use of a monoclonal population of CD8+ 
T cells, uniformly expressing a TCR specific for the haemagglutinin(HA) antigen from the influenza 
virus(A/PR/8/H1N1). Utilising a monoclonal population of CTLs allows for the investigation of specific T 
cell interactions with any cells expressing the HA antigen and co-signaling receptors, including cancer cells. 
To optimise the experimental use of 4T1 and CT26 cell lines in the CL4 model, including murine inoculation 
and tumour formation, they must endogenously present the HA antigen, allowing for recognition and 
interaction by CL4 CD8+ T cells. The currently used Renca cell line was previously transfected to express the 
HA peptide, as well a multiple other characteristic such as the over expression of ICAM-1. Previous 
transfection was completed via plasmid lipofection. A frozen glycerol stock of the, previously used, HA coding 
p-IRES vector was located in the Morgan lab -80c freezer. 
         In attempt to isolate the vector, the glycerol stock was thawed and plated on Ampicillin supplemented 
agar and allowed to grow. Solitary colonies were isolated, ensuring origination from a single cell, used to 
inoculate bacteria growth media and left overnight in a shaking incubator to permit maximal growth. 
Following culture, the bacterial cells were re-isolated. A centrifuge mini prep(Qiagen) was completed to 
extract and elute the vector. Once isolated, the vector was both digested and linearized before being run 
through gel electrophoresis to confirm the correct vector was present. Restriction Enzymes NDE1 and STU 
were use in attempt to cut out the multiple cloning sites, as seen in figure 24, and therefore potential location 
of the HA peptide. Empty p-IRES vectors, also from frozen glycerol stocks, were used as controls. 
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3ul NDE1 and STU were added to 3ul of eluted plasmid DNA and incubated for 1hr at 37c. A control of 3ul 
of the undigested of DNA was diluted in ddH20.  Agarose powder and ddH2O was mixed and solution gently 
warmed until fully dissolved. Clear solution was poured into a gel template and wells created using a pronged 
comb. Once solid, the gel was placed onto an electrophoresis unit and submerged in 1% TAE. All samples 
were mixed with loading dye and pipetted into their corresponding wells, at the negative end of unit. 1Kb 
molecular weight ladders were loaded either sides of the samples to enable the calculation of their sizes. 
Electrical current was tippled and gel run for 1 hour. Upon completion the gel was removed from the unit 
and photographed using a Transilluminator for imaging and analysis. Results show an aberrant number and 
size of DNA segments, determining the plasmid not to be pIRES-HA. 
         Analysis of the gel electrophoresis results indicate no presence of the HA peptide within the vector. 
Furthermore, upon further investigation, the results indicate that the DNA seen was not the expected vector. 
Both the control empty p-IRES and p-IRES-HA showed no associated of banding following digestion or 
linearisation. 1Kb ladders were used to calculate the length of DNA, however  both the size and number of 
noted fragments did not correlate to the expected p-IRES vectors. Measures were taken to ensure this was not 
due to contamination. Further investigations lead to the completion of external DNA sequencing, which 
confirmed that the DNA acquired was not the desired plasmid, sequence shown in appendix. Novel HA 
expressing vectors have since been designed and purchased to ensure lipofection, if successful, resulting in 
expression of the correct HA peptide, enabling endogenous recognition via CL4 CTLs. Until the new vector 
arrives and is lipofected, investigations shall rely on peptide pulsing to induce CTL responses, which has 
proven successful. 
































Figure 37 Plasmid Sequencing:  
Midi-prep isolated plasmids were sent for external DNA sequencing. Sequencing was completed 
by Eurofins genomics, and results electronically returned. Results demonstrated no presence of 
the HA peptide within the plasmids. In addition no IRES component was noted, deeming the 
plasmid incorrectly identified.  
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Figure 36: Genotyping CL4+ mice. 
Blood extracted through the tail vein of each mouse was diluted using 2mL FACS buffer. Samples were 
centrifuged(1400rpm, 5min) and supernatant discarded. Cells were resuspended in 1mL Ack Lysis buffer 
for 3 minutes. Cells were washed twice using FACS buffer. 1uL CD8+ stain(APC) and Vβ8.1 stain(FITC) 
were diluted 1uL in 100uL FACs buffer. Samples were centrifuged, supernatant discarded, and 
resuspended in 50uL diluted stain for 30 minutes at 4oC. Samples were washed twice and resuspended in 
200uL FACs buffer. Lymphocytes were determined based on cell size and granularity(FSC-H/SSC-H). 
Single cells were detected from the lymphocyte population using FSC-H/FSC-A. CD8+ cells were 
isolated, by an increase in APC fluorescence. CD8+ cells were analysed for their Vβ8.1 expression, 
indicated by increased FITC fluorescence emission. Genotyping identified CL4+/- mice by over 90% of the 
CD8+ population being Vβ8.1+. 
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Figure 35: Killing assay - Target cell titration. 
Naive CL4 splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with KdHA, 
as described in methods. The cellular suspensions were plated into separate wells of a 24 well plate and 
cultured for 96 hours. 60-80% confluent Renca HA cells were detached from a T25 flask using 1mL Trypsin-
EDTA. Detached cells were quenched in 4mL complete media, collected into a 15mL falcon tube and 
centrifuged. Renca HA cells were resuspended in 1mL complete media and counted. Additional complete 
media was added until 1x106 cells/mL was achieved. 2uL KdHA was added to the suspension, and incubated 
for 60 minutes, at 37oC. Once complete cells were centrifuged(1200rpm, 3min), supernatant discarded and the 
cells washed twice in PBS. CTV stain was diluted 1uL in 1000uL PBS. 1uL CTV was used per 1x106 cancer 
cells. Renca HA cells were counted, centrifuged, supernatant discarded and resuspended in diluted CTV stain. 
CTV Staining was completed at 37oC for 15 minutes, followed by a 5x quench in 0.5% protein rich media and 
an additional 15 minute, dark incubation at room temperature. When complete, cells were washed twice in 
complete media, re-counted and resuspended to 1x106 cells/mL in complete media.  All cultured CTLs were 
harvested into a 15mL falcon tube, washed in RPMI, and counted. CTLs were further washed and 
resuspended to 1x106 cells/mL in complete media. Different ratios of cancer cell:CTL were co were co-
cultured in repeated wells of a 96 well plate. 3 repeats were plated per condition, in addition to 3 wells of 
Renca HA only and 3 wells for a positive killed control. The plate was incubated at 37oC for 17 hours. When 
complete, media from the positive control wells was carefully extracted ensuring not to disturb the adherent 
cells. 150ul accutase was added to the positive control wells and incubated for 10 minutes at room 
temperature. Positive control wells were resuspended and collected into a 1.5mL eppendorf. The eppendorf 
was heated to 90oC for 10 minutes in a heat plate. The remaining plate was centrifuged at 1400rpm 5 mins, 
and supernatant discarded. PI was diluted 1uL:400uL in accutase. 150uL PI solution was added to each 
remaining well, incubated for 10 minutes at room temperature and run within the hour. PI was added to the 
heated cell accutase at a 1uL:400uL ratio. 150uL kill positive cells were pipetted into a new row of wells in the 
96 well plate. All wells were resuspended and run on the Novocyte. Gating strategy seen in figure 16 was used 
to identify target cells including their live/dead populations. Percentage of dead target cells was determined 
and specific cytotoxicity calculated using the formula, noted in methods.(n=2) 
 
A. Target cell titrations determined that a 1:1 CTL to Target cell ratios gave the cleanest separation whilst 
maintaining a sizeable alive target cell population enabling easy detection of both live and dead populations 
and therefore specific cytotoxicity calculations. 
 
B. Killer cell titrations determined 1:1 CTL to target cell ratio to be the most efficient. A 5:1 ratio 
showed slightly increased, but not significant, levels of killing but required notably higher numbers of 
CTLs. A 1:1 ratio maintained high levels of killing without the need for excessive CTLs and was 
therefore used throughout the project. 
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Figure 38: Killing assay of CL4 cultured using he previous culture method in 
absence of IL-2. 
Naive CL4 splenocytes were harvested and primed overnight using a mixed lymphocyte reaction with 
KdHA, as described in methods. PGE2 conditions(0uM PGE2/1uM PGE2) were added into separate wells 
at time of priming. 5x106 primed splenocytes per condition were harvested, washed and resuspended in 
2ml T cell media with their corresponding conditions. The cellular suspensions were plated into separate 
wells of a 24 well plate and cultured for 48 hours. 60-80% confluent Renca mCherry cells were detached 
from a T25 flask using 500uL Trypsin-EDTA. Detached cells were quenched in 4mL complete media, 
collected into a 15mL falcon tube and centrifuged. Renca mCherry cells were resuspended in 1mL 
complete media and counted. Additional complete media was added until 1x106 cells/mL was 
achieved. 2uL KdHA was added to the suspension, and incubated for 60 minutes, at 37oC. Cells 
were centrifuged, supernatant discarded and washed twice using 10mL RPMI. Once washed, 
Renca mCherry cells were re-counted, and resuspended to 3x105 cells/mL in Fluorobrite media. 
50uL Renca mCherry cells were plated in individual wells of a glass bottomed 384 well plate, and 
incubated until cellular adherence, at 37oC. 4 repeats per condition were plated. All cultured CTLs 
were harvested into separate 15mL falcon tubes corresponding to their culture conditions. All CTLs were 
washed in PBS, and resuspended in 1mL conditioned imaging buffer. 1.5mL eppendorf were prepared 
containing 200uL 2X conditioned imaging buffer, for each experimental condition.CTLs were sorted 
using FACs for 60,000 alive cells per condition into their corresponding eppendorf, taking into 
account an un-pulsed control group. Sorted CTLs were centrifuged, 4000xg 4minutes, using a 
microfuge, and supernatant carefully extracted ensuring no disturbance to the cellular pellet. All 
CTLs were resuspended to 3x105 cells/mL in 2X conditioned Fluorobrite media. 50uL CTLs 
were added to corresponding target wells containing adhered Renca mCherry, immediately 
before the plate was placed in the IncuCyte imaging system for 18 hours. Total target cell surface 
area(um2/well) was measuring using red fluorescence masking, over the duration of the assay. The 
mean of 4 repeats was calculated per timepoint for each condition. Results were normalised, and 
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A Renca only control(Yellow) was used to demonstrate cell growth over the duration of the assay. 
The decrease in target cell surface area was indicative of target cell death via CTL cytolysis. CTLs 
treated with 1uM PGE2(Green) saw a reduction in cytotoxicity compared to untreated CL4(Red). 
The addition of 1uM TG4-155 to 1uM PGE2 treated samples(Orange) saw a partial reversal of 
the suppression seen, increasing cytolysis to comparable levels as the untreated control.(n=1) 
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